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CHAPTER 1.1.  GENERAL INTRODUCTION
Pneumococcal disease: still a worldwide problem 
Despite the availability of effective pneumococcal vaccines, the respiratory pathogen 
Streptococcus pneumoniae (the pneumococcus) is still a major cause of death 
amongst the elderly and the leading cause of child mortality. The pneumococcus 
can colonize the nasopharynx and from there can spread to the adjacent cavities, 
the lungs, the bloodstream or the brain, causing respectively otitis media/sinusitis, 
pneumonia, bacteremia or meningitis. Each year, an estimated 735.000 children die 
of pneumococcal disease, with approximately 90% of these deaths occurring in 
low-income countries. This number, which already excludes pneumococcal deaths 
linked with HIV-positivity, corresponds to 11% of all deaths in children aged 1-59 
months worldwide 1, 2. Even though this number is already high, pneumococcal 
disease incidence is probably still underestimated due to the low sensitivity of 
diagnostic tests and limited access to care and/or diagnostics in these countries 2.
Vaccination: can we do better?
Effective pneumococcal vaccines have been on the market for several years now. 
Although a 23-valent polysaccharide vaccine (PPSV23) was already licensed in the 
1980s, this vaccine is not effective in young children due to its inability to mount a 
T-cell dependent response 3. Consequently, pneumococcal conjugate vaccines 
(PCVs) have been developed that induce a very strong T-cell dependent antibody 
response to the polysaccharide structures that cover the outside of the bacterium. 
Currently there are 97 different serotypes circulating in the world population, which 
each produce a biochemically distinct polysaccharide capsule. PCVs only target a 
limited number of these serotypes 4 and the selection of the respective vaccine poly-
saccharides was based on epidemiological data describing serotype-dependent 
invasiveness and prevalence in the Western world 5. 
Countries that have introduced PCVs in their national immunization program have 
seen a great reduction in the number of pneumococcal-related deaths. This reduction 
is seen not only in children, but also in the elderly population, pointing to the induction 
of herd immunity 6-8. Unfortunately, since PCVs are among the most expensive 
vaccines on the market, several countries are unable to introduce these vaccines. 
This is especially the case for middle-income countries, who are not eligible to receive 
ﬁnancial support from the Global Alliance for Vaccines and Immunization (GAVI) 9, 10. 
The introduction of PCV-7, targeting seven different pneumococcal serotypes, 
strongly reduced the incidence of vaccine-type invasive pneumococcal disease 
(IPD). Of concern, this decrease was accompanied by an increase in IPD caused by 
non-PCV serotypes 11, 12. Because of the limited coverage of serotypes, additional 
polysaccharides were added, resulting in 10-valent (PCV-10) and 13-valent (PCV-13) 
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vaccines. Although these vaccines provide additional protection, there are still many 
serotypes that are not yet covered 13. Moreover, conjugation of polysaccharides to a 
protein-carrier is a difﬁcult and costly process and it has been very challenging to 
induce a good and balanced immune response against all of the serotypes in the 
vaccines 14.
Although PCVs are thus highly effective against pneumococcal disease caused by 
vaccine serotypes, the overall carriage rates of S. pneumoniae have not gone down 
persistently 15 and disease incidence caused by non-vaccine serotypes is increasing. 
In this context, pneumococcal antibiotic resistance is also an increasingly important 
health issue. Between 15-26% of pneumococcal infections are reported to be multi- 
drug resistant, i.e. resistant to more than three classes of antibiotics 16, 17. Although 
most infections caused by resistant pneumococci can still be treated with penicillin 
provided that the dosage is high enough 18, treatment of meningitis can already be 
difﬁcult for even intermediately resistant strains due to the limited penetration of 
penicillin through the blood-brain barrier 19, 20. Novel treatment options, as well as fast 
and accurate detection of the causative agent of infection together with its antibiotic 
resistance proﬁle, are therefore also becoming increasingly important in staying 
ahead in the battle with the pneumococcus. 
The different faces of pneumococcal disease
The ﬁrst step towards pneumococcal disease is colonization of the nasopharynx. 
Carriage rate, duration and density differ signiﬁcantly based on age, pneumococcal 
serotype and immune status. Approximately 50-70% of all children are colonized at 
any given time by S. pneumoniae, typically in the absence of clinical symptoms 21. 
Pneumococcal carriage in adults without children lies around 7%, versus 34% for 
adults with children 22. Most at risk of developing pneumococcal disease are children 
under 5 years of age, the elderly and immune compromised individuals such as 
patients with HIV infection or sickle cell disease 23.
S. pneumoniae is one of the major causes of middle ear infection, or otitis media 
(OM) and the predominant cause of acute otitis media, which is deﬁned by rapid 
onset of local and systemic symptoms 24. OM affects up to 80% of children under the 
age of 3, can lead to permanent hearing loss and can also appear in a chronic or 
recurrent form 25. 
Pneumococcal colonization can also lead to community acquired pneumonia (CAP). 
An estimated 13.9 million cases of pneumococcal pneumonia occur amongst 
children <5 years old worldwide yearly, accounting for 36% of all child pneumonia 
cases 2. Amongst adults, the estimated proportion of CAP attributable to the 
pneumococcus is 27% 26, 27. 
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Approximately a quarter of all pneumococcal pneumonia cases are thought to result 
in bacteremia 26. In severe cases, sepsis may occur, which is characterized by a 
systemic inﬂammatory response and (multi) organ failure as a consequence of 
insufﬁcient blood ﬂow. This accordingly can lead to septic shock, which is 
characterized by low blood pressure that does not improve after intravenous ﬂuids 
have been given 28. Mortality rates can be as high as 30% for sepsis, 50% for severe 
sepsis and 80% for septic shock, even in high-income countries following direct and 
adequate treatment 29. It is thought that more than 1:1000 individuals in the developing 
world develop sepsis each year, and that between a third and half of them progress 
to severe sepsis 29. From the bloodstream, the bacterium can cross the blood-brain 
barrier and blood-cerebrospinal ﬂuid barrier, resulting in inﬂammation of the 
meninges, the protective membranes covering the brain and spinal cord 30. The case 
fatality rate for meningitis ranges from 30% up to more than 50% in low-income 
countries 31, 32.
Pneumococcal diagnostics
Culture-based methods: still the gold standard
Even though several molecular techniques have in recent years become available to 
detect S. pneumoniae, the gold standard for diagnosis of IPD is still the culture-based 
method. The diagnosis of pneumococcal community-acquired pneumonia (CAP) 
and other lower respiratory tract infections are made by culturing of respiratory 
secretions such as sputum, bronchoalveolar lavage (BAL), or pleural ﬂuid. Diagnosis 
of pneumococcal bacteremia and sepsis, meningitis or otitis media are diagnosed 
through culturing of respectively blood, cerebral spinal ﬂuid (CSF) and middle ear 
ﬂuid, or by direct microscopic analysis of Gram stained smears of clinical material 24, 
33-35. After culturing on sheep blood agar or chocolate agar plates, identiﬁcation can 
be achieved by observation of the morphological appearance and four main 
phenotypic characteristics: ?-hemolysis of blood agar, catalase negativity, optochin 
susceptibility and bile solubility. However, since resistance to optochin has been 
reported, identiﬁcation can no longer rely solely on optochin susceptibility 36. 
Culture-based detection has several shortcomings. For instance, the presence of 
other colonizing microorganisms in the nasopharynx can interfere with culturing for 
detection of the causative agent of CAP 33. For the diagnosis of pneumococcal 
bacteremia and sepsis, a major problem is the fact that blood cultures generally take 
between 24-48 hours to become positive. Antibiotic treatment is therefore normally 
initiated before the results of blood cultures are known. Additionally, 55 - 65 % of 
blood cultures remain negative in septic shock cases 37, 38. The low sensitivity of blood 
cultures might in part be caused by the use of antibiotics prior to specimen collection, 
and in the case of S. pneumoniae infections, possibly by the release of pneumococcal 
autolysin, resulting in cell death 39, 40. 
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Molecular detection techniques
There are several alternative strategies to diagnose invasive pneumococcal disease. 
Pneumococcal C-polysaccharides (teichoic acid, found in the cell wall and common 
to all serotypes) 41can be detected in urine samples, using a rapid immune chromato-
graphic test (Binax-Now)42. This test, when applied to urine samples, has a good 
speciﬁcity (>90%), but a relatively low sensitivity (70-80%), with a signiﬁcant 
proportion of patients with positive blood or sputum culture results having a negative 
Binax-Now test result 34. Moreover, pneumococcal carriage can produce false 
positive results, which make the test less suitable for the detection of IPD in population 
groups with high carriage rates, like children 43, 44. 
Recently, several methods have been developed that use matrix-assisted laser 
desorption ionization–time of ﬂight mass spectrometry (MALDI-TOF MS) to identify 
microorganisms by analyzing the cellular proteome and comparing this to a 
database 45-47. Several of these platforms have already been approved for clinical use 
and are being used in China, the USA and Europe 48, 49. MALDI-TOF can be used 
without a culturing step on body ﬂuid samples other than plasma, since approximately 
5 × 103 colony forming units (CFU) is needed for reliable MALDI-TOF analysis, while 
1 × 105 CFU/ml in body ﬂuids (other than plasma) is generally regarded as the 
minimum bacterial count with clinical signiﬁcance of infection 50. Even though several 
studies have indicated that the use of these mass spectrometry platforms for the 
detection of blood stream infections, also surpasses the conventional diagnostics in 
speed and accuracy 51, 52, these studies were all performed using blood culture 
broths. Since bacterial numbers in the blood of sepsis patients can be as low as 10 
colony forming units (CFU) per ml of blood 53, 54, the sensitivity of MALDI-TOF would 
still need to be optimized in order to detect bacteria in blood without a culturing step. 
In addition, several real-time PCR assays are now available that detect pneumococcal 
DNA. Real-time PCR based detection can provide results within a few hours without 
the need to culture, and can theoretically detect as little as one genome copy of DNA. 
Moreover, the bacterium does not need to be alive to be detected, as opposed to 
culture-based methods, which may be an advantage when antibiotic treatment has 
already started. It has been shown that at least one third of culture- negative clinical 
samples that were analyzed by 16S rDNA PCR analysis tested positive for 
pneumococcal DNA, suggesting signiﬁcant underdetection of pneumococcal 
infections when relying on culture-based methods alone 55. However, even though 
qPCR seems to be a promising method to detect pneumococcal infections within a 
shorter time span and with greater sensitivity, it will still require extensive clinical 
validation and standardization, especially for those cases that are negative for 
culturing and positive for qPCR and vice versa.
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Establishment of pneumococcal colonization
Stable colonization of the nasopharynx requires initial adherence to the mucosal 
surface, preventing bacteria from being swept away by mucociliary clearance 56, 57. 
The epithelial layer consists of ciliated and non-ciliated epithelial cells, mucus-secreting 
cells such as goblet cells, and antigen-sampling M-cells 57, 58. Covering the epithelial 
surface is a gel-like layer of mucus 57. The ﬁrst step in colonization is passage through 
this mucosal layer. The pneumococcus expresses a thick negatively charged 
polysaccharide capsule, which, by repelling the anionic mucus, facilitates easy 
passage to the epithelial surface 59. Secretion of the pneumococcal pore-forming 
toxin pneumolysin results in inhibition of ciliary beating 60. Upon initial contact with the 
epithelial layer, a weak attachment is thought to be formed between bacterial 
lectin-like proteins and host surface carbohydrates 61. The secretion of several exo-
glycosidases (NanB and NanC) then results in cleavage of sialic acid from mucin, 
glycolipids, glycoproteins and oligosaccharides that are attached to the epithelial cell 
surface. This likely aids the exposure of underlying host glycoconjugate receptors 
62-64. The interaction with host cell surface proteins accordingly results in more stable 
adherence 61. Streptococcus pneumoniae has a wide repertoire of adherence factors, 
such as PavA, PspC and PsaA, which has been extensively reviewed by others 65-67. 
Even though the polysaccharide capsule is an essential virulence factor that is 
required for protection against phagocytosis and complement-mediated killing 67-69, 
it also reduces the ability of pneumococcal cell-surface associated proteins to 
engage their cognate host receptors on the epithelial cell surface 65. The formation of 
long pili that are able to extend beyond the pneumococcal capsule likely aids the 
accessibility of the surface adhesion factors and has been shown to play a role in 
adhesion and colonization 70, 71. Rapid reduction of encapsulation is also thought to 
be an important factor in the ability to colonize 72. It has recently been shown that the 
polysaccharide capsule can actually be shed when the pneumococcus is in close 
proximity of the epithelial cell surface, thus allowing better binding 73. 
In addition to adhesion, acquiring nutrients for replication is another important factor 
for establishment of stable colonization. The most important source of nutrients for S. 
pneumoniae are carbohydrates, followed by sialic acids, hyaluronic acids, 
disaccharides, iron, zinc and manganese, all of which can be obtained from the 
mammalian host, although their availability can be scarce and is limited to speciﬁc 
microenvironments within the host (reviewed by 56).
The transition from colonization to disease
In most cases, colonization does not lead to the development of invasive disease. 
The transition from colonization to invasion is likely a gradual transition. For instance, 
‘invading’ pneumococci have been observed deeper in the epithelial surface of the 
nasopharynx of healthy mice colonized with S. pneumoniae, indicating that crossing 
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of the barrier is an intrinsic element of asymptomatic colonization 74. There are various 
risk factors for development of pneumococcal disease, such as a preceding viral 
infection (such as the inﬂuenza virus, which will be further discussed in chapter 2), 
COPD and exposure to tobacco smoke, all of which have one thing in common: 
inﬂammation of the respiratory epithelium (for a review of all known risk factors see 23). 
Both pneumococcal surface proteins and receptors on the respiratory epithelium can 
change their expression in the presence of local inﬂammation. Inﬂammatory 
mediators can, for example, increase the afﬁnity of pneumococcal cell wall choline 
to the epithelial platelet activating factor receptor (PAFr). Binding to this receptor 
also induces internalization of the pneumococcus, which can result in transcellular 
migration 75, 76. Similarly, the afﬁnity of pneumococcal choline binding protein A 
(CbpA) to epithelial sialic acid is increased in an inﬂammatory environment, while 
direct interaction of CbpA with the polymeric Ig receptor results in increased migration 
through the mucosal barrier 77, 78. Once the pneumococcus is present in the 
bloodstream, it can produce a thick polysaccharide capsule, which serves as an 
effective protection mechanism against complement deposition and phagocytosis 67. 
Immune recognition and clearance 
Recognition by pattern recognition receptors
A key element in the clearance of S. pneumoniae from the respiratory tract is early 
recognition of colonizing pneumococci by the innate immune system. Pattern 
recognition receptors (PRRs) that are present on epithelial cells and local phagocytes 
such as macrophages and dendritic cells play a key role in this process. PRRs 
recognize conserved non-self molecular motifs, typically referred to as pathogen- 
associated molecular patterns (PAMPs). Many classes of PRRs exist; including the 
membrane bound Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), the 
cytoplasmic receptors NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs), 
and the secreted PRRs such as complement receptors and mannan-binding lectin. 
As with any complex pathogen, many different (classes of) PRRs are involved in the 
recognition of S. pneumoniae. The Toll-like receptors are the most well-studied 
PRRs for S. pneumoniae. For instance, the surface PRR Toll-like receptor 2 (TLR2) 
recognizes pneumococcal lipoteichoic acid 79, 80, while the pneumococcal pore- 
forming toxin pneumolysin is recognized by Toll-like receptor 4 (TLR4)81. Although 
S. pneumoniae is typically an extracellular pathogen, intracellular PRRs have also 
been shown to play a role. For instance, the endosomal Toll-like receptor 9 (TRL9) 
was found to recognize pneumococcal DNA 82. In addition, the intracellular PRR 
 nucleotide-binding oligomerization domain 2 (Nod2) recognizes pneumococcal 
peptidoglycan fragments, a process that was shown to be dependent on the secretion 
of pneumolysin 83. Additionally, the C-type lectin SIGN-R1, which is present on macro - 
phages, recognizes sugar residues on pneumococcal capsular polysaccharides 84. 
Another macrophage receptor that recognizes S. pneumoniae is the scavenger 
receptor MARCO, which is able to mediate binding and internalization of pneumococci 
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in vitro 85. Furthermore, the platelet-activating factor receptor (PAFR) recognizes 
pneumococcal phosphorylcholines. The recognition of S. pneumoniae by PRRs and 
the subsequent signaling pathways have been reviewed in detail by others 23, 86, 87. 
Early production of soluble mediators
The activation of PRRs, but also the colonization-induced damage of the epithelial 
layer, results in the induction of inﬂammation, including soluble inﬂammatory 
mediators such as TNF?, IL-6, IFN?/?, IL-1?, CXCL-1.and MCP-1 23, 86, 87. The production 
of these cytokines and chemokines helps recruit and activate other cells of the 
immune system. Following pneumococcal infection, the respiratory epithelium also 
starts producing antimicrobial compounds such as lysozyme, defensins and 
cathelicidins. While cationic antimicrobial components (CAMPs), such as ?-defensins 
and the cathelicidin LL-37 have the ability to directly kill invading microorganisms 88, 
the capsule of certain pneumococcal serotypes can prevent this. Puriﬁed anionic 
pneumococcal capsule, such as capsule of serotype 3, but not non-anionic capsule 
such as that of serotype 1, has been shown to protect S. pneumoniae from 
CAMP-mediated killing, presumably by scavenging of unbound peptides 89. Shedding 
of the pneumococcal capsule was found to be initiated by exposure of S. pneumoniae 
to CAMPs 73. Capsular shedding may thus might have multiple functions, i.e. direct 
protection of pneumococci against CAMP-mediated killing as well as improving 
interaction of pneumococcal adherence factors with host receptors to facilitate further 
adhesion to the respiratory epithelium. Human lysozyme, was found to be ineffective 
in inducing lysis of the pneumococcal cell wall. The pneumococcal enzymes 
peptidoglycan N-acetylglucosamine deacetylase PgdA and the O-acetyltransferase 
Adr are able to modify pneumococcal peptidoglycans, resulting in resistance against 
lysozyme 90, 91. In addition, the pneumococcal surface protein A (PspA) can bind 
lactoferrin, thereby preventing lactoferrin from absorbing free iron ions, which are an 
essential substrate for bacterial growth 92. 
Clearance by the early cellular response
The induction of a local inﬂammatory response results in the recruitment and differ-
entiation of phagocytes, including neutrophils and macrophages. Murine studies 
have demonstrated that there is an early inﬂux of neutrophils. These neutrophils likely 
play a role in containing the infection, however, their presence does not result in 
complete clearance of colonization 93. Within the respiratory tract, resident alveolar 
macrophages form the ﬁrst line of defense during the initial stages of infection and 
are thought to play mainly a role in clearing the infection before clinical symptoms 
appear 94. Macrophages can recognize opsonized pneumococci through complement 
and Fc? receptors, but can also recognize non-opsonized pneumococci (e.g. through 
PRRs like MARCO or SIGN-R1) 95. They have several functions: generating an 
inﬂammatory response, killing of phagocytosed bacteria, and antigen presentation. 
Macrophages are able to kill bacteria in their phagolysozome using reactive oxygen 
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species (ROS), nitric oxide (NO) or reactive nitrogen species (RNS). However, the 
pneumococcus has developed many strategies to evade the effects of these 
mechanisms (reviewed by 95). Pneumococcal killing can also occur through 
macrophage apoptosis. Murine studies have shown that macrophage apoptosis has 
been implicated in enhancing pneumococcal clearance and reducing invasion from 
the lungs to the bloodstream 96, 97. In addition to clearance, macrophages and 
dendritic cells are also important for initiating the subsequent adaptive response.  
The humoral immune response 
In response to pneumococcal colonization, systemic and mucosal antibodies are 
produced by B cells against both pneumococcal protein antigens as well as the 
polysaccharide capsule 98, which are important for protection against subsequent 
infections. Vaccination with PCVs, which induces capsule-speciﬁc IgG, IgM and IgA, 
has demonstrated that these antibodies can play an important role in protection 
against pneumococcal colonization 99, 100. Mainly IgG1 and IgG2 are induced in 
response to PCVs, with higher IgG1 concentrations in infants and more IgG2 in adults 
101. Interestingly, in the elderly, who are at higher risk of pneumococcal disease, 
natural anti-cps IgG and IgM antibody levels, as well as the opsonic functionality of 
the antibodies decline with age 100. 
Even though IgA1 antibodies represent the most abundant immunoglobulin subclass 
present on the airway mucosa, it is not clear if they play an important role in protection 
against pneumococcal colonization. S. pneumoniae is able to expresses an IgA1 
protease which cleaves the hinge region of the ?-chain of IgA1 102, 103. However, the 
efﬁcacy of this IgA1 protease in vivo in humans has not been demonstrated, and it is 
also not clear if all pneumococcal strains have an equally efﬁcient IgA1 protease.
Antibodies can help protect against pneumococcal colonization through several different 
mechanisms 104. First of all, antibodies can neutralize pathogens by blocking speciﬁc 
surface-expressed factors or neutralizing secreted bacterial factors. Secondly, they 
can opsonize the pneumococcus, followed by uptake and killing by phagocytes such 
as macrophages, DCs and neutrophils. Through this mechanism PCV-induced 
antibodies are able to clear pneumococci from the bloodstream, preventing invasive 
disease. Another often overlooked aspect of antibodies is that they can also activate 
Fc? receptors, which in turn can affect the inﬂammatory response 105, 106. Recent 
studies have also shown that mucosal protection is mediated by the agglutinating 
potential of pneumococcus-speciﬁc Immunoglobulin G (IgG), and that this also 
contributes to PCV-induced herd immunity 103, 107. The induction of opsonizing capsule 
speciﬁc IgG antibodies is a widely accepted correlate of protection for PCV-induced 
prevention of disease 100. While many other potential correlates of protection have 
been identiﬁed through e.g. murine studies, these have not yet been formally validated 
in human studies. 
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PCV-induced responses have been shown to protect not only against invasive 
disease, but also against colonization due to active transport of IgG to the mucosal 
surface via the neonatal Fc receptor 108, 109. A signiﬁcant part of the PCV-induced 
protection against invasive disease is therefore likely the result of the prevention of the 
ﬁrst stage of infection, i.e. initial binding to the respiratory epithelial cells. Protection 
against colonization and disease is also induced by natural episodes of pneumococcal 
infection. This naturally acquired immunity does not only generate immune memory 
to the capsule, but also against a range of pneumococcal proteins 98, 110. In recent 
years, several protein-based vaccine candidates have been developed 7, 111, which 
might have the potential to provide superior coverage against the wide range of 
pneumococcal strains. 
Cellular immunity to S. pneumoniae
While PCV-induced immunity is mainly mediated through antibodies, infection- 
induced protection to S. pneumoniae is thought to also depend on the induction of 
a local CD4+ IL-17+ response 112, 113. Even though plasma antibody responses are 
induced in response to intranasal immunization by live pneumococcal colonization, 
antibody-deﬁcient mice were still protected against re-colonization, suggesting that 
antibody-independent acquired immunity also contributes to protection. In addition, 
mice lacking T lymphocytes and MHCII-deﬁcient mice (lacking CD4+ T cell responses) 
were unable to clear colonization 112. Moreover, the presence of IL-17 has shown to be 
responsible for accelerated clearance of pneumococci 114, while human colonization 
of the nasopharynx has also shown to result in an increase in antigen-speciﬁc CD4+ 
IL-17 producing cells (T helper 17 cells, hereafter referred to as Th17 cells) 115. Even 
though these results point to an important role for the IL-17 response in clearance of 
S. pneumoniae, antibodies might still play an important role in the prevention of a 
subsequent colonization event. 
For the differentiation of naïve CD4+ T cells towards a Th17 phenotype, three signals are 
needed: the activation of the T cell receptor (TCR) through engagement with its 
cognate antigen in complex with MHC-II on the surface of antigen-presenting cells 
(APCs), activation of a T cell co-stimulatory receptor by CD80 or CD86 on the APC, 
and the activation of speciﬁc cytokine receptors on the T cell (Figure 1). Several 
cytokines have been shown to be involved in the differentiation of naïve CD4+ cells 
into Th17 cells, amongst which TGF-?, IL-21, IL-23, IL-1?, TNF?, and IL-6 116, 117. 
The chemokine IL-17A that is secreted by Th17 cells, accordingly activates epithelial 
cell responses and leads to the activation and recruitment of effector cells such 
as neutrophils and macrophages, resulting in phagocytosis and killing of S. 
pneumoniae 112, 114, 115. Th17 helper cells have also been demonstrated to have the 
capacity to act as effective B cell helpers, inducing B cell differentiation and isotype 
class switching to IgG2a and IgG3 subtypes 118. It is therefore likely that they are also 
involved in the generation of the subsequent antibody response. 
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While it seems clear that Th17 responses play a role in protection against pneumo - 
coccal infection, there are contradictory reports concerning the role of the T helper 1 
cytokine IFN-?. Results from experiments using IFN-? deﬁcient mice suggested that 
IFN-? does not play a signiﬁcant role in protection against S. pneumoniae 114, 119. 
Conversely, several other murine studies have reported a beneﬁcial role for IFN-? in 
pneumococcal clearance 120-122. It thus remains unclear what role Th1-type responses 
play in pneumococcal clearance. A study by Olliver and coworkers, using a coculture 
model of human monocytes and CD4+ T cells, showed that both Th1 and Th17 helper 
cytokines were triggered by pneumococcal peptidoglycan, while the balance 
between the two immune effector cytokines was dependent on bacterial viability with 
live pneumococci triggering a Th1-biased response and heat-killed pneumococci 
triggering a Th17-biased response 123. The biological consequences of these observations 
remain unclear.
Although not frequently studied, another player of the cellular immune system that 
has been reported to play a role in pneumococcal infection are natural killer 
T cells (NKT cells). These T lymphocytes, with characteristics of NK cells, have been 
reported to recognize pneumococcal capsular polysaccharide antigens presented 
Figure 1. Th17 differentiation. Recognition of S. pneumoniae by TLRs and/ or Fc? receptors 
on the surface of APCs and subsequent phagocytosis results in the secretion of cytokines (1), 
activation of co-stimulatory molecules such as CD80 (2) and antigen presentation by MHCII 
molecules (3). These three signals result in activation of cytokine receptors, CD28 and the TCR 
on CD4+ T cells, which can result in differentiation towards a Th17 phenotype.
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by CD1d-expressing DCs, after which direct NKT-B cell interaction resulted in 
prolonged antibody responses through the induction of isotype class switching and 
memory 124. In addition, NKT cells have also been shown to play a role in promoting 
trafﬁcking of neutrophils to the site of pneumococcal infection 125. 
Moreover, natural kill cells (NK cells), which represent roughly 10% of all lympho cytes 
in healthy lungs 126, have recently also been reported to play a role in pneumococcal 
infection. Depletion of NK cells in mice suggested that NK cells contribute to increased 
mortality following pneumococcal pneumonia 127. More in depth research will be 
needed to identify the exact function of NK cells in pneumococcal clearance.  
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CHAPTER 1.2.  AIMS AND OUTLINE OF THESIS
Infections with Streptococcus pneumoniae still cause an enormous global burden of 
disease and mortality, despite the availability of effective vaccines. Due to their high 
costs, PCVs are still not universally implemented in national immunization schemes 
across the world. In addition, none of the currently licensed vaccines provides 
protection against all serotypes, resulting in serotype replacement by non-vaccine 
serotypes in vaccinated populations. Although there are efforts to further increase the 
number of serotypes in PCVs, it is unlikely that complete coverage will be achieved 
against all clinically relevant serotypes. 
In order to develop novel vaccines that are affordable and provide protection against 
the majority of pneumococcal strains, it is important to understand the mechanisms 
by which asymptomatic pneumococcal colonization progresses to disease and 
which immune factors are important for protection. Therefore, the overall aim of this 
thesis was to study the mechanisms involved in immune recognition and clearance 
of S. pneumoniae, where we focused on two subquestions:
· Which mechanisms are important in exacerbation of disease due to inﬂuenza A 
virus coinfections? 
· What is the role of antibodies and IL-17 in protection and clearance of pneumococcal 
infections? 
In addition to this, another aim of this PhD study was to participate in the development 
of a platform for the detection of the causative agents of sepsis, where we focused on 
the detection of S. pneumoniae. 
Exacerbation of disease due to influenza A virus coinfections 
Viral co-infections, in particular with inﬂuenza virus, are a well known risk factor for the 
development of pneumococcal disease. In chapter 2, we review the current literature 
on the interactions between inﬂuenza virus, the pneumococcus and the host immune 
system. Immune response pathways to inﬂuenza virus and pneumococcal infections 
are discussed and we explore the potential impact that the sequence of infection may 
have on the outcome. In chapter 3 we study the interaction of inﬂuenza virus with 
sialic acids on epithelial cells and how this affects the subsequent development of 
pneumococcal otitis media.
The role of antibodies and IL-17 in protection and clearance of 
pneumococcal infections 
In chapter 4, we examine the role of antibodies and IL-17 in the protection against 
inﬂuenza-virus induced pneumococcal otitis media. The effect of mucosal vaccination 
on protection against IAV-induced pneumococcal OM in mice was studied using the 
model antigen pneumococcal surface protein A (PspA) in combination with the 
benchmark mucosal adjuvant CTB. In this model, we speciﬁcally focus on the role of 
antibodies and IL-17 in protection.
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Under certain conditions asymptomatic nasopharyngeal colonization can also 
progress to the lower respiratory tract, causing pneumonia. In adults and elderly, 
two age groups that in most countries are not directly protected by vaccination, 
pneumococcal pneumonia likely frequently occurs in the presence of pre-existing 
immunity, including antibodies against S. pneumoniae and memory T cells. At presence, 
little is known about the role of e.g. antibodies on the subsequent immune response 
and clearance. Using an in vitro model of human PBMCs and alveolar macrophages, 
in chapter 5 we study the effect of speciﬁc IgG on the subsequent cellular response 
and bacterial clearance by alveolar macrophages. Antibodies can have many distinct 
functions in the protection against pneumococcal infections. Recent studies have 
shown that mucosal IgG can block early pneumococcal attachment to the respiratory 
epithelium through the formation of bacterial aggregates. These aggregates are removed 
by cilial beating, thus preventing establishment of colonization. In chapter 6, we sought  to 
develop a novel ﬂow-cytometry-based high-throughput method that allows quantitation 
of the agglutinating potential of anti-pneumococcal antibodies. 
Detection of the causative agent of sepsis: real-time PCR detection of  
S. pneumoniae  
In chapter 7, we focus on improving the detection of pneumococcal infection, and 
speciﬁcally bacteremia and sepsis. The mortality rate of sepsis increases rapidly with 
each hour of delay in the initiation of antimicrobial therapy. At this moment, the gold 
standard for the detection of the causative agent of sepsis is still blood culture, which 
generally takes between 24-48 hours to become positive. We therefore aimed to 
develop a novel quantitative PCR assay with increased sensitivity for the detection of 
S. pneumoniae. This study was part of a larger project to develop a novel multiplex 
bedside test for the accurate and fast detection of the causative agents of sepsis and 
their antimicrobial resistances.
Finally, in chapter 8 the results and conclusions of the preceding chapters are 
summarized and discussed, future perspectives are presented and new ideas for 
future studies are proposed. 
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 23
23
Introduction and aims
1
REFERENCES
1. WHO, Vol. 20172012).
2. O’Brien, K.L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 
years: global estimates. Lancet 374, 893-902 (2009).
3. Centers for Disease Control and Prevention  1-182010).
4. Geno, K.A. et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 
28, 871-899 (2015).
5. Bogaert, D., Hermans, P.W., Adrian, P.V., Rumke, H.C. & de Groot, R. Pneumococcal vaccines: an update 
on current strategies. Vaccine 22, 2209-2220 (2004).
6. Whitney, C.G. et al. Decline in invasive pneumococcal disease after the introduction of protein-polysac-
charide conjugate vaccine. N Engl J Med 348, 1737-1746 (2003).
7. Daniels, C.C., Rogers, P.D. & Shelton, C.M. A review of pneumococcal vaccines: current polysaccharide 
vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther 21, 27-35 (2016).
8. Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P. & George, R.C. Herd immunity and serotype 
replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an 
observational cohort study. Lancet Infect Dis 11, 760-768 (2011).
9. MSF  (Médecins Sans Frontières, MSF Access Campaign; 2015).
10. Kulpeng, W. et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection 
at what price in the Thai context? Vaccine 31, 2839-2847 (2013).
11. Singleton, R.J. et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska 
native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. Jama 297, 
1784-1792 (2007).
12. Munoz-Almagro, C. et al. Emergence of invasive pneumococcal disease caused by nonvaccine 
serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46, 174-182 (2008).
13. Lund, E. Laboratory diagnosis of Pneumococcus infections. Bull World Health Organ 23, 5-13 (1960).
14. Selman, S., Hayes, D., Perin, L.A. & Hayes, W.S. Pneumococcal conjugate vaccine for young children. 
Manag Care 9, 49-52, 54, 56-47 passim (2000).
15. Spijkerman, J. et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage 
of S. pneumoniae, S. aureus, H. inﬂuenzae and M. catarrhalis. PLoS One 7, e39730 (2012).
16. Draghi, D.C., Jones, M.E., Sahm, D.F. & Tillotson, G.S. Geographically-based evaluation of multidrug 
resistance trends among Streptococcus pneumoniae in the USA: ﬁndings of the FAST surveillance 
initiative (2003-2004). Int J Antimicrob Agents 28, 525-531 (2006).
17. Whitney, C.G. et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the 
United States. N Engl J Med 343, 1917-1924 (2000).
18. Friedland, I.R. & Klugman, K.P. Antibiotic-resistant pneumococcal disease in South African children. Am 
J Dis Child 146, 920-923 (1992).
19. Gouveia, E.L. et al. Clinical outcome of pneumococcal meningitis during the emergence of pencillin-re-
sistant Streptococcus pneumoniae: an observational study. BMC Infect Dis 11, 323 (2011).
20. Andes, D. & Craig, W.A. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus 
pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42, 2375-2379 
(1998).
21. Bosch, A.A. et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th 
year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 34, 
531-539 (2016).
22. Wyllie, A.L. et al. Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; 
little evidence for pneumococcal circulation independent from the reservoir in children. Sci Rep 6, 34888 
(2016).
23. van der Poll, T. & Opal, S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. 
Lancet 374, 1543-1556 (2009).
24. Ngo, C.C., Massa, H.M., Thornton, R.B. & Cripps, A.W. Predominant bacteria detected from the middle 
ear ﬂuid of children experiencing otitis media: a systematic review. PLoS One 11, e0150949 (2016).
25. Cripps, A.W., Otczyk, D.C. & Kyd, J.M. Bacterial otitis media: a vaccine preventable disease? Vaccine 23, 
2304-2310 (2005).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 24
24
Chapter 1
26. Said, M.A. et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review 
and meta-analysis of diagnostic techniques. PLoS One 8, e60273 (2013).
27. Fine, M.J. et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta- 
analysis. Jama 275, 134-141 (1996).
28. Singer, M. et al. The third international consensus deﬁnitions for sepsis and septic shock (Sepsis-3). 
Jama 315, 801-810 (2016).
29. Jawad, I., Luksic, I. & Rafnsson, S.B. Assessing available information on the burden of sepsis: global 
estimates of incidence, prevalence and mortality. J Glob Health 2, 010404 (2012).
30. Gratz, N.L., L.N.; Tuomanen, E. Pneumococcal invasion: development of bacteremia and meningitis, in 
Streptococcus pneumoniae: molecular mechanisms of host pathogen interactions. (eds. J. Brown, S. 
Hammerschmidt & C. Orihuela) 435-446 (Elsevier, USA; 2015).
31. Feikin, D.R. et al. Serotype-speciﬁc changes in invasive pneumococcal disease after pneumococcal 
conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 10, e1001517 
(2013).
32. WHO Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 30, 4717-4718 (2012).
33. Blaschke, A.J. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis 52 
Suppl 4, S331-337 (2011).
34. Werno, A.M. & Murdoch, D.R. Medical microbiology: laboratory diagnosis of invasive pneumococcal 
disease. Clin Infect Dis 46, 926-932 (2008).
35. Geiseler, P.J., Nelson, K.E., Levin, S., Reddi, K.T. & Moses, V.K. Community-acquired purulent meningitis: 
a review of 1,316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 2, 725-745 (1980).
36. Kellogg, J.A., Bankert, D.A., Elder, C.J., Gibbs, J.L. & Smith, M.C. Identiﬁcation of Streptococcus 
pneumoniae revisited. J Clin Microbiol 39, 3373-3375 (2001).
37. Kumar, A. et al. Initiation of inappropriate antimicrobial therapy results in a ﬁvefold reduction of survival in 
human septic shock. Chest 136, 1237-1248 (2009).
38. Heffner, A.C., Horton, J.M., Marchick, M.R. & Jones, A.E. Etiology of illness in patients with severe sepsis 
admitted to the hospital from the emergency department. Clin Infect Dis 50, 814-820 (2010).
39. Resti, M. et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive 
pneumococcal disease by culture or molecular methods: a prospective, observational study of children 
and adolescents with proven pneumococcal infection. Clin Ther 31, 1266-1273 (2009).
40. Cvitkovic Spik, V. et al. Improvement of pneumococcal pneumonia diagnostics by the use of rt-PCR on 
plasma and respiratory samples. Scand J Infect Dis 45, 731-737 (2013).
41. Poxton, I.R., Tarelli, E. & Baddiley, J. The structure of C-polysaccharide from the walls of Streptococcus 
pneumoniae. Biochem J 175, 1033-1042 (1978).
42. Gutierrez, F. et al. Evaluation of the immunochromatographic Binax NOW assay for detection of 
Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in 
Spain. Clin Infect Dis 36, 286-292 (2003).
43. Dominguez, J. et al. Usefulness of urinary antigen detection by an immunochromatographic test for 
diagnosis of pneumococcal pneumonia in children. J Clin Microbiol 41, 2161-2163 (2003).
44. Dowell, S.F., Garman, R.L., Liu, G., Levine, O.S. & Yang, Y.H. Evaluation of Binax NOW, an assay for the 
detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect 
Dis 32, 824-825 (2001).
45. Seng, P. et al. Ongoing revolution in bacteriology: routine identiﬁcation of bacteria by matrix-assisted 
laser desorption ionization time-of-ﬂight mass spectrometry. Clin Infect Dis 49, 543-551 (2009).
46. Singhal, N., Kumar, M., Kanaujia, P.K. & Virdi, J.S. MALDI-TOF mass spectrometry: an emerging 
technology for microbial identiﬁcation and diagnosis. Front Microbiol 6 (2015).
47. Emonet, S., Shah, H.N., Cherkaoui, A. & Schrenzel, J. Application and use of various mass spectrometry 
methods in clinical microbiology. Clin Microbiol Infect 16, 1604-1613 (2010).
48. Patel, R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem 61, 100-111 (2015).
49. Luo, Y. et al. Performance of the VITEK MS matrix-assisted laser desorption ionization-time of ﬂight mass 
spectrometry system for rapid bacterial identiﬁcation in two diagnostic centres in China. J Med Microbiol 
64, 18-24 (2015).
50. Hsieh, S.Y. et al. Highly efﬁcient classiﬁcation and identiﬁcation of human pathogenic bacteria by 
MALDI-TOF MS. Mol Cell Proteomics 7, 448-456 (2008).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 25
25
Introduction and aims
1
51. Tadros, M. & Petrich, A. Evaluation of MALDI-TOF mass spectrometry and Sepsityper Kit™ for the direct 
identiﬁcation of organisms from sterile body ﬂuids in a Canadian pediatric hospital. Can J Infect Dis Med 
Microbiol 24, 191-194 (2013).
52. La Scola, B. & Raoult, D. Direct identiﬁcation of bacteria in positive blood culture bottles by matrix-assisted 
laser desorption ionisation time-of-ﬂight mass spectrometry. PLoS One 4, e8041 (2009).
53. Loonen, A.J.M. et al. Comparison of pathogen DNA isolation methods from large volumes of whole 
blood to improve molecular diagnosis of bloodstream infections. PLoS One 8, e72349 (2013).
54. Boardman, A.K., Campbell, J., Wirz, H., Sharon, A. & Sauer-Budge, A.F. Rapid microbial sample 
preparation from blood using a novel concentration device. PLoS One 10, e0116837 (2015).
55. Harris, K.A., Turner, P., Green, E.A. & Hartley, J.C. Duplex real-time PCR assay for detection of 
Streptococcus pneumoniae in clinical samples and determination of penicillin susceptibility. J Clin 
Microbiol 46, 2751-2758 (2008).
56. Siegel, S.J. & Weiser, J.N. Mechanisms of bacterial colonization of the respiratory tract. Annu Rev 
Microbiol 69, 425-444 (2015).
57. Fahy, J.V. & Dickey, B.F. Airway Mucus Function and Dysfunction. N Engl J Med 363, 2233-2247 (2010).
58. Kim, D.Y. et al. The airway antigen sampling system: respiratory M cells as an alternative gateway for 
inhaled antigens. J Immunol 186, 4253-4262 (2011).
59. Nelson, A.L. et al. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. 
Infect Immun 75, 83-90 (2007).
60. Feldman, C. et al. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium 
in vitro. Microb Pathog 9, 275-284 (1990).
61. Voss, S., Gamez, G. & Hammerschmidt, S. Impact of pneumococcal microbial surface components 
recognizing adhesive matrix molecules on colonization. Mol Oral Microbiol 27, 246-256 (2012).
62. Xu, G. et al. Three Streptococcus pneumoniae sialidases: three different products. J Am Chem Soc 133, 
1718-1721 (2011).
63. Tong, H.H., Blue, L.E., James, M.A. & DeMaria, T.F. Evaluation of the virulence of a Streptococcus 
pneumoniae neuraminidase-deﬁcient mutant in nasopharyngeal colonization and development of otitis 
media in the chinchilla model. Infect Immun 68, 921-924 (2000).
64. Tong, H.H., Liu, X., Chen, Y., James, M. & Demaria, T. Effect of neuraminidase on receptor-mediated 
adherence of Streptococcus pneumoniae to chinchilla tracheal epithelium. Acta Otolaryngol 122, 
413-419 (2002).
65. Hammerschmidt, S. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 9, 12-20 
(2006).
66. Mitchell, A.M. & Mitchell, T.J. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol 
Infect 16, 411-418 (2010).
67. Kadioglu, A., Weiser, J.N., Paton, J.C. & Andrew, P.W. The role of Streptococcus pneumoniae virulence 
factors in host respiratory colonization and disease. Nature Reviews Microbiology 6, 288-301 (2008).
68. Magee, A.D. & Yother, J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect 
Immun 69, 3755-3761 (2001).
69. Shainheit, M.G., Mule, M. & Camilli, A. The core promoter of the capsule operon of Streptococcus 
pneumoniae is necessary for colonization and invasive disease. Infect Immun 82, 694-705 (2014).
70. Barocchi, M.A. et al. A pneumococcal pilus inﬂuences virulence and host inﬂammatory responses. Proc 
Natl Acad Sci U S A 103, 2857-2862 (2006).
71. Nelson, A.L. et al. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol 66, 
329-340 (2007).
72. Hammerschmidt, S. et al. Illustration of pneumococcal polysaccharide capsule during adherence and 
invasion of epithelial cells. Infect Immun 73, 4653-4667 (2005).
73. Kietzman, C.C., Gao, G., Mann, B., Myers, L. & Tuomanen, E.I. Dynamic capsule restructuring by the 
main pneumococcal autolysin LytA in response to the epithelium. Nat Commun 7, 10859 (2016).
74. Briles, D.E., Novak, L., Hotomi, M., van Ginkel, F.W. & King, J. Nasal colonization with Streptococcus 
pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73, 6945-6951 
(2005).
75. Cundell, D.R., Gerard, N.P., Gerard, C., Idanpaan-Heikkila, I. & Tuomanen, E.I. Streptococcus pneumoniae 
anchor to activated human cells by the receptor for platelet-activating factor. Nature 377, 435-438 (1995).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 26
26
Chapter 1
76. McCullers, J.A. & Rehg, J.E. Lethal synergism between inﬂuenza virus and Streptococcus pneumoniae: 
characterization of a mouse model and the role of platelet-activating factor receptor. Journal of Infectious 
Diseases 186, 341 (2002).
77. Rosenow, C. et al. Contribution of novel choline-binding proteins to adherence, colonization and 
immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25, 819-829 (1997).
78. Kaetzel, C.S. Polymeric Ig receptor: defender of the fort or Trojan horse? Curr Biol 11, R35-38 (2001).
79. van Rossum, A.M., Lysenko, E.S. & Weiser, J.N. Host and bacterial factors contributing to the clearance 
of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 73, 7718-7726 (2005).
80. Yoshimura, A. et al. Cutting edge: recognition of Gram-positive bacterial cell wall components by the 
innate immune system occurs via Toll-like receptor 2. J Immunol 163, 1-5 (1999).
81. Malley, R. et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal 
infection. Proc Natl Acad Sci U S A 100, 1966-1971 (2003).
82. Albiger, B. et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal 
infection. Cell Microbiol 9, 633-644 (2007).
83. Davis, K.M., Nakamura, S. & Weiser, J.N. Nod2 sensing of lysozyme-digested peptidoglycan promotes 
macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest 121, 
3666-3676 (2011).
84. Kang, Y.S. et al. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Strepto -
coccus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci U S A 101, 215-220 (2004).
85. Arredouani, M. et al. The scavenger receptor MARCO is required for lung defense against pneumococcal 
pneumonia and inhaled particles. J Exp Med 200, 267-272 (2004).
86. Koppe, U., Suttorp, N. & Opitz, B. Recognition of Streptococcus pneumoniae by the innate immune 
system. Cell Microbiol 14, 460-466 (2012).
87. Paterson, G.K. & Mitchell, T.J. Innate immunity and the pneumococcus. Microbiology 152, 285-293 
(2006).
88. Schaller-Bals, S., Schulze, A. & Bals, R. Increased levels of antimicrobial peptides in tracheal aspirates 
of newborn infants during infection. Am J Respir Crit Care Med 165, 992-995 (2002).
89. Llobet, E., Tomas, J.M. & Bengoechea, J.A. Capsule polysaccharide is a bacterial decoy for antimicrobial 
peptides. Microbiology 154, 3877-3886 (2008).
90. Vollmer, W. & Tomasz, A. The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase 
in Streptococcus pneumoniae. J Biol Chem 275, 20496-20501 (2000).
91. Crisostomo, M.I. et al. Attenuation of penicillin resistance in a peptidoglycan O-acetyl transferase mutant 
of Streptococcus pneumoniae. Mol Microbiol 61, 1497-1509 (2006).
92. Hammerschmidt, S., Bethe, G., Remane, P.H. & Chhatwal, G.S. Identiﬁcation of pneumococcal surface 
protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect Immun 67, 1683-1687 
(1999).
93. Matthias, K.A., Roche, A.M., Standish, A.J., Shchepetov, M. & Weiser, J.N. Neutrophil-toxin interactions 
promote antigen delivery and mucosal clearance of Streptococcus pneumoniae. J Immunol 180, 
6246-6254 (2008).
94. Dockrell, D.H. et al. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a 
resolving model of pulmonary infection. J Immunol 171, 5380-5388 (2003).
95. Dockrell, D.H. & Brown, J.S. Streptococcus pneumoniae interactions with macrophages and mechanisms 
of immune evasion, in Streptococcus pneumoniae: molecular mechanisms of host pathogen interactions. 
(eds. J. Brown, S. Hammerschmidt & C. Orihuela) 401-422 (Elsevier, USA; 2015).
96. Bewley, M.A. et al. A cardinal role for cathepsin d in co-ordinating the host-mediated apoptosis of 
macrophages and killing of pneumococci. PLoS Pathog 7, e1001262 (2011).
97. Marriott, H.M. et al. Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment 
to apoptosis during bacterial clearance. J Clin Invest 115, 359-368 (2005).
98. Ferreira, D.M. et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals 
the protective efﬁcacy of carriage in healthy adults. Am J Respir Crit Care Med 187, 855-864 (2013).
99. Simell, B. et al. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers 
immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol 
19, 1618-1623 (2012).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 27
27
Introduction and aims
1
100. Adler, H., Ferreira, D.M., Gordon, S.B. & Rylance, J. Pneumococcal capsular polysaccharide immunity in 
the elderly. Clin Vaccine Immunol 24 (2017).
101. Lottenbach, K.R. et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass 
antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 67, 4935-4938 (1999).
102. Kilian, M., Mestecky, J. & Schrohenloher, R.E. Pathogenic species of the genus Haemophilus and 
Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun 26, 143-149 (1979).
103. Roche, A.M., Richard, A.L., Rahkola, J.T., Janoff, E.N. & Weiser, J.N. Antibody blocks acquisition of 
bacterial colonization through agglutination. Mucosal Immunol 8, 176-185 (2015).
104. Weiser, J.N. & Nahm, M.N. Immunity to extracellular bacteria, in Fundamental Immunology. (ed. W.E. 
Paul) 1182–1203 (Lippincott Williams & Wilkins, Philadelphia, PA, USA; 2008).
105. den Dunnen, J. et al. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs 
and FcgammaRIIa in human dendritic cells. Blood 120, 112-121 (2012).
106. Vogelpoel, L.T. et al. FcgammaRIIa cross-talk with TLRs, IL-1R, and IFNgammaR selectively modulates 
cytokine production in human myeloid cells. Immunobiology 220, 193-199 (2015).
107. Mitsi, E. et al. Agglutination by anti-capsular polysaccharide antibody is associated with protection 
against experimental human pneumococcal carriage. Unpublished (2016).
108. Dagan, R. et al. Serum serotype-speciﬁc pneumococcal anticapsular immunoglobulin g concentrations 
after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal 
acquisition of pneumococcus. J Infect Dis 192, 367-376 (2005).
109. Klugman, K.P. Efﬁcacy of pneumococcal conjugate vaccines and their effect on carriage and 
antimicrobial resistance. Lancet Infect Dis 1, 85-91 (2001).
110. Cobey, S. & Lipsitch, M. Niche and neutral effects of acquired immunity permit coexistence of 
pneumococcal serotypes. Science 335, 1376-1380 (2012).
111. Olafsdottir, T.A., Lingnau, K., Nagy, E. & Jonsdottir, I. Novel protein-based pneumococcal vaccines 
administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal 
disease in neonatal mice. Infect Immun 80, 461-468 (2012).
112. Malley, R. et al. CD4(+) T cells mediate antibody-independent acquired immunity to pneumococcal 
colonization. Proc Natl Acad Sci U S A 102, 4848-4853 (2005).
113. Zhang, Z., Clarke, T.B. & Weiser, J.N. Cellular effectors mediating Th17-dependent clearance of 
pneumococcal colonization in mice. J Clin Invest 119, 1899-1909 (2009).
114. Lu, Y.J. et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4 
(2008).
115. Wright, A.K. et al. Experimental human pneumococcal carriage augments IL-17A-dependent T-cell 
defence of the lung. PLoS Pathog 9, e1003274 (2013).
116. Volpe, E. et al. A critical function for transforming growth factor-beta, interleukin 23 and proinﬂammatory 
cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9, 650-657 (2008).
117. Wilson, N.J. et al. Development, cytokine proﬁle and function of human interleukin 17-producing helper 
T cells. Nat Immunol 8, 950-957 (2007).
118. Mitsdoerffer, M. et al. Proinﬂammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad 
Sci U S A 107, 14292-14297 (2010).
119. Rijneveld, A.W. et al. The role of interferon-gamma in murine pneumococcal pneumonia. J Infect Dis 185, 
91-97 (2002).
120. Elhaik-Goldman, S. et al. The natural cytotoxicity receptor 1 contribution to early clearance of 
Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS One 6, e23472 (2011).
121. Rubins, J.B. & Pomeroy, C. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal 
pneumonia. Infect Immun 65, 2975-2977 (1997).
122. Nakamatsu, M. et al. Role of interferon-gamma in Valpha14+ natural killer T cell-mediated host defense 
against Streptococcus pneumoniae infection in murine lungs. Microbes Infect 9, 364-374 (2007).
123. Olliver, M., Hiew, J., Mellroth, P., Henriques-Normark, B. & Bergman, P. Human monocytes promote Th1 
and Th17 responses to Streptococcus pneumoniae. Infect Immun 79, 4210-4217 (2011).
124. Bai, L. et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and 
long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A 110, 
16097-16102 (2013).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 28
28
Chapter 1
125. Kawakami, K. et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection 
against Streptococcus pneumoniae infection. Eur J Immunol 33, 3322-3330 (2003).
126. Shi, F.D., Ljunggren, H.G., La Cava, A. & Van Kaer, L. Organ-speciﬁc features of natural killer cells. Nat 
Rev Immunol 11, 658-671 (2011).
127. Christaki, E. et al. NK and NKT cell depletion alters the outcome of experimental pneumococcal 
pneumonia: relationship with regulation of interferon-gamma production. J Immunol Res 2015, 532717 
(2015).
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 29
29
Introduction and aims
1
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 30
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 31
Interactions between Streptococcus 
pneumoniae and influenza virus:  
a mutually beneficial relationship?
Kirsty R. Short*, Marrit N. Habets*, Peter W.M. Hermans & Dimitri A. Diavatopoulos
*these authors contributed equally
Future Microbiol. 2012, 7(5); 609-24
2
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 32
32
Chapter 2
ABSTRACT
Historically, most research on infectious diseases has focused on infections with 
single pathogens. However, infections with pathogens often occur in the context of 
pre-existing viral and bacterial infections. Clinically, this is of particular relevance for 
co-infections with Streptococcus pneumoniae and inﬂuenza virus, which together are 
an important cause of global morbidity and mortality. In recent years new evidence 
has emerged regarding the underlying mechanisms of inﬂuenza-virus induced 
susceptibility to secondary pneumococcal infections, in particular regarding the 
sustained suppression of innate recognition of S. pneumoniae. Conversely, it is also 
increasingly being recognized that there is not a unidirectional effect of the virus on 
S. pneumoniae, but that asymptomatic pneumococcal carriage may also affect 
subsequent inﬂuenza virus infection and the clinical outcome. Here, we will review 
both aspects of pneumococcal-inﬂuenza virus infection, with a particular focus on 
the age-related differences in pneumococcal colonization rates and invasive 
pneumococcal disease. 
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INTRODUCTION
Respiratory tract infections caused by bacterial and viral pathogens are one of the 
biggest health problems to human populations worldwide. They are the number one 
cause of death in low income countries, accounting for 6.1% of deaths worldwide, 
which is almost double the percentage of deaths attributed to HIV/AIDS 1. Respiratory 
disease can develop when bacterial or viral pathogens invade the mucosal surface 
of the respiratory tract and cause damage. Clinical evidence suggests that infection 
with particular combinations of pathogens results in exacerbated infection and a 
more severe clinical outcome compared to infection with either pathogen alone 2, 3. 
This is particularly true for combined infections with inﬂuenza virus and the bacterium 
Streptococcus pneumoniae (the pneumococcus), two major human pathogens that 
collectively are responsible for a signiﬁcant proportion of all infection-related deaths 
worldwide 4, 5.
S. pneumoniae colonization and disease
S. pneumoniae is a Gram-positive bacterium that transiently colonises the mucosal 
surfaces of the upper respiratory tract. Upon entry into the nasopharynx, it traverses the 
mucus barrier and subsequently attaches to the apical surface of the respiratory tract 
epithelium6. This ability to cross the mucus layer and attach to the underlying epithelium 
marks an important difference with the normal microbiota, which is normally segregated 
from the mucosal epithelium7. During human life, all individuals are sequentially 
colonised with S. pneumoniae. For the vast majority of colonised individuals, this event is 
completely asymptomatic. The duration and frequency of pneumococcal colonization is 
dependent upon many factors (e.g. 8-13), although typically there is a clear demarcation 
between colonization dynamics in pre-school children and older individuals. Depending 
on geographical and socio-economic conditions, up to 8 out of 10 healthy pre-school 
children are colonised with S. pneumoniae at any given time 14, 15. In contrast, pneumococcal 
colonization rates are signiﬁcantly lower in older individuals (approximately 10%) 16. 
Although the exact immunological correlates of protection against pneumococcal (re)
colonization remain the subject of debate, both antibodies and cellular immunity have 
been suggested to play an important role 8, 17-19.
Nasopharyngeal colonization, whilst asymptomatic, marks the ﬁrst step in the 
development of pneumococcal disease 11, 20. This transition from colonization to 
disease occurs when the bacterium overcomes the mucosal immune defences in the 
nasopharynx and disseminates to the middle ear cavity (causing otitis media), the 
lower respiratory tract (causing pneumonia), the blood (causing sepsis) and/or the 
meninges (causing meningitis). There are numerous host, environmental and 
microbial factors that deﬁne an individual’s susceptibility to develop pneumococcal 
disease 21-25. However, one of the best characterised susceptibility factors is a recent 
or concurrent infection with a respiratory virus, in particular with inﬂuenza virus. 
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Influenza virus 
Inﬂuenza viruses (types A, B and C) are negative sense RNA viruses of the Family 
Orthomyxoviridae. In humans, the most common cause of respiratory illness is 
inﬂuenza A virus (IAV). Whilst there is increasing evidence regarding the clinical 
importance of inﬂuenza B virus 26, 27, the majority of research on viral-bacterial 
co-infections has focused on IAV, and hence IAV will be the focus of this review. 
Typically, IAV is most pathogenic in the young, elderly and immunocompromised. IAV 
can be categorised into subtypes based on antigenic differences in the surface 
glycoproteins hemagglutinin (HA) and neuraminidase (NA). The HA of inﬂuenza virus 
binds to terminal sialic acid residues on cell surface glycoproteins and glycolipids, 
facilitating internalisation of the virus.In contrast to the HA, the NA of inﬂuenza virus 
cleaves terminal host sialic acid residues to facilitate the release of newly synthesised 
viral particles. Each year, antigenic changes (or ‘drift’) in the HA and NA result in 
seasonal outbreaks of IAV. When there is a dramatic change in the HA and/or NA, e.g. 
due to a recombination event between avian and human strains or direct infection of 
humans with an avian strain, global pandemics can result.
Pneumococcal-influenza virus co-infections
The IAV pandemics of the 20th century (1918; 1957 & 1968) clearly demonstrated that 
infection with IAV facilitates the progression of S. pneumoniae from a commensal 
organism to a potentially fatal pathogen 28-32. In all three pandemics most fatalities 
were not due to primary viral infection. Instead, the majority of individuals are thought 
to have succumbed to a secondary bacterial infection, predominately caused by the 
pneumococcus 28-32. Recent evidence suggests that a similar trend occurred during 
the 2009 H1N1 pandemic. For example, in the U.S.A 13% of post-mortem lung 
samples from patients with fatal pandemic 2009 H1N1 showed a concurrent infection 
with S. pneumoniae 33. In Japan and Argentina, an even stronger association was 
found, where approximately 50% of the severe cases tested positive for S. pneumoniae 
34, 35. Clinical evidence also suggests that an increased incidence of pneumococcal 
disease occurs during seasonal outbreaks of IAV. For example, American children 
hospitalised with severe pneumococcal pneumonia were signiﬁcantly more likely 
than control subjects to have experienced an inﬂuenza virus like illness in the weeks 
preceding their hospital admission 36. Thus, inﬂuenza-pneumococcal co-infections 
remain an area of continual clinical relevance. 
In light of the major public health burden that pneumococcal-inﬂuenza virus 
co-infections represent, extensive research has been performed to explain the role of 
IAV in pneumococcal disease. One of the ﬁrst proposed mechanisms is the viral 
destruction of the respiratory epithelium, enabling S. pneumoniae to adhere to newly 
exposed elements in the basement membrane 37, 38. Since then, the number of 
different mechanisms has been signiﬁcantly expanded to include modulation of 
neutrophil function by IAV, increased bacterial adherence due to virus-induced 
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changes in adherence receptors and alterations in innate signalling and cytokine/
chemokine responses. These mechanisms have been extensively and elegantly 
reviewed elsewhere (e.g. 39). Here, we will only review key studies from the last four 
years which provide important mechanistic insights into the role of IAV in 
pneumococcal disease, in order to provide an up-to-date summary of the growing 
wealth of literature in this area. 
The second aim of this review departs from traditional perspectives on inﬂuen-
za-pneumococcal co-infections. The relationship between these two pathogens has 
often been described as ‘synergistic’. That is to say that co-infection is mutually 
beneﬁcial for both pathogens. As described above, the ability of IAV to facilitate 
pneumococcal disease has been well documented. However, this research largely 
remains ‘uni-directional’ and there is a paucity of research regarding the effect of the 
pneumococcus on viral infection. This review will thus critically analyse the available 
evidence in regards to the effects of pneumococcal colonization/infection on the 
pathogenesis of IAV. Finally, we discuss the key clinical approaches that should be 
taken into account in light of the complex and bi-directional nature of inﬂuenza-pneu-
mococcal co-infections. 
NOVEL INSIGHTS INTO INFLUENZA VIRUS-INDUCED 
PNEUMOCOCCAL DISEASE
In recent years there have been numerous studies providing novel mechanistic 
insights into the interactions between IAV and the pneumococcus (see Figure 1). 
Here we will critically discuss these studies and the additional insights that they 
provide to understanding pneumococcal-inﬂuenza virus co-infections. 
Neutrophil induced immunopathology
IAV-induced polymorphonuclear neutrophil (PMN) dysfunction is considered a key 
component of viral-bacterial co-infections; as neutrophils are an important cell type 
in controlling pneumococcal infections 40, 41. However, whilst PMNs do contribute to 
the protection against pneumococcal disease, their exact role remains unclear. 
Experiments in which PMNs were depleted show that mice colonised with S. 
pneumoniae do not necessarily develop invasive disease 42. Moreover, there is now 
evidence that the increased mortality observed during co-infections is associated 
with a neutrophilic inﬂux into the lungs. Karlström and colleagues 43 show that during 
co-infection, treatment with antibiotics induced pneumococcal lysis, which in turn 
causes an inﬂux of neutrophils into the lungs of IAV-infected mice. This results in 
excessive lung damage and mortality, an effect that could be prohibited by 
suppression of the neutrophil inﬂux 43. Importantly, Karlström and colleagues did not 
assess the functionality of the pulmonary neutrophils. It thus remains possible that 
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disease is exacerbated not only by the recruitment of neutrophils, but also due to viral 
repression of the recruited neutrophils to kill S. pneumoniae.
We have recently made similar observations in regards to the development of inﬂuen-
za-pneumococcal otitis media 44. Using a novel infant mouse model of disease we 
have shown that IAV facilitated the development of pneumococcal otitis media. 
Interestingly, we also demonstrated that infection with IAV alone induces a neutrophilic 
inﬁltrate in the middle ear cavity. In a co-infection, almost all pneumococci in the 
Figure 1. Model of inﬂuenza virus-induced susceptibility to pneumococcal infection. 
A. Following entry into epithelial cells, viral replication decreases mucociliary velocity, thereby 
adversely affecting clearance of S. pneumoniae from the mucus. B. Inﬂuenza virus infection 
results in the IL-12 and TNF-? dependent production of IFN-? by T cells, as well as endogenous 
IFN-? production by APCs. IFN-? downregulates the scavenger receptor MARCO, expressed 
by alveolar macrophages, which leads to inhibition of bacterial phagocytosis. C. In response to 
inﬂuenza virus infection, DCs as well as other cell types show increased apoptosis. Apoptotic 
immune cells increase their surface expression of CD200, which can subsequently bind to 
CD200R expressed on myeloid DCs and macrophages. Engagement of CD200R results in the 
sustained desensitization to bacterial stimuli. D. The production of type I interferons by epithelial 
cells and innate immune cells also inhibits the recruitment of PMNs and macrophages from the 
periphery through the IL-23-IL-17 axis. E. PMN inﬂux is also reduced by the release of cortico-
steroids.
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middle ear co-localize with this inﬂammatory cell inﬁltrate. It is therefore tempting to 
speculate that IAV-induced neutrophilia in the middle ear, together with viral 
attenuation of PMN functionality, facilitates pneumococcal outgrowth. 
Together, these data indicate that neutrophils may play both protective and damaging 
roles in the response to pneumococcal infections. In addition to the previously 
established role of PMNs in opsonophagocytosis and killing of S. pneumoniae, novel 
aspects of PMN function, such as the formation of neutrophil extracellular traps 45 and 
their role in priming the adaptive immune system 46 may also contribute to the 
pathogenesis of S. pneumoniae. Further research into the balance of these responses 
and how inﬂuenza virus modulates this is needed to improve our understanding of 
these complex and dynamic interactions.
Pulmonary macrophage dysfunction
Several studies have also identiﬁed an important role for macrophages in controlling 
both pneumococcal colonization and disease 47, 48. However, upon co-infection with 
IAV macrophages display decreased binding and phagocytosis of S. pneumoniae 49, 
due to the production of interferon-? (IFN-?) by activated T cells. IFN-? downregulates 
the alveolar macrophage scavenger receptor MARCO, resulting in a dramatic 
decrease in the antibacterial functionality of macrophages. Consistent with these 
data, Ludewick and colleagues 50 show that a prior infection with IAV, but not with 
human metapneumovirus (hMPV) facilitates a secondary infection with S. 
pneumoniae. Importantly, whilst no observed differences are observed in macrophage 
or neutrophil recruitment in co-infected mice, IFN-? is detected in the bronchoalveo-
lar lavages of IAV, and not hMPV, infected mice. Moreover, there is a strong correlation 
in the kinetics of IFN-? production and bacterial outgrowth, suggesting that 
IAV-induced IFN-? may indeed facilitate secondary pneumococcal pneumonia. 
The ability of IAV to modulate innate sensing of bacteria is not limited to the scavenger 
receptor MARCO. IAV also causes prolonged desensitization of alveolar macrophages 
to bacterial Toll-like receptor (TLR) ligands such as ﬂagellin (TLR5), LPS (TLR4) and 
LTA (TLR2) 51. This desensitization effect lasts for several months, due to the longevity 
of resident airway macrophages. ‘Desensitized’ macrophages have reduced 
chemokine production, NF-?B activation and consequently recruit less neutrophils to 
the site of infection. This altered macrophage function means that upon secondary 
infection with S. pneumoniae, mice quickly succumb to disease 51. Interestingly, 
IAV-induced apoptosis of leukocytes results in increased surface expression of the 
inhibitory signal molecule CD200 52. The interaction of CD200 with its cognate 
receptor CD200R, which is highly expressed on myeloid cells such as macrophages 
and dendritic cells, results in reduced responsiveness of CD200R+ cells to S. 
pneumoniae. This may also (partially) explain the decreased responsiveness of APCs 
as described above 51. 
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IAV induced macrophage dysfunction may also be applicable to co-infections in 
humans, as peripheral blood mononuclear cells of children with a severe inﬂuenza 
virus infection show diminished responses to TLR ligands, compared to children with 
a moderate inﬂuenza virus infection and non-infected controls 53. Thus, IAV is able to 
cause prolonged effects on the innate response to pneumococcal infections, 
potentially by inducing long-lasting changes in circulating monocytes or in tissue 
macrophages. Evidence for the latter was reported by Chen and colleagues 54, who 
investigated the effect of viral infection on macrophage differentiation. Although 
macrophages are highly plastid and can change their phenotype depending on the 
local environment, they have traditionally been divided into two classes: pro-inﬂam-
matory macrophages and alternatively activated macrophages (AAM). The ‘classical’ 
pro-inﬂammatory macrophages are associated with the early host defense against 
microbial infections. In contrast, AAM demonstrate poor bactericidal activity and are 
more associated with maintenance of tissue homeostasis, tissue remodeling, wound 
healing and dampening of inﬂammatory responses 55, 56. Chen et al. showed that 
pulmonary AAM are elevated in the lungs of mice at day 7-14 post-inﬂuenza virus 
infection 54. Although formal proof that this effect contributes to susceptibility to 
pneumococcal infection is still missing, it is likely that these changes also affect the 
early response to pneumococcal infections.
In summary, strong evidence is emerging that macrophages play a crucial role in 
determining the immune response to S. pneumoniae. Further research is needed to 
clarify how viral infection modulates the detection of S. pneumoniae and subsequent 
innate signaling of macrophages. 
Dendritic cells
In contrast to the growing wealth of literature on the role of macrophages in inﬂuen-
za-pneumococcal co-infections, few studies have addressed the role of dendritic 
cells (DCs) in secondary bacterial disease. This may reﬂect, in part, the disconnect 
between studies on murine DCs and what is known regarding human DCs. In order 
to provide a clinically relevant model, Wu et al. used human monocyte derived 
dendritic cells to study the effects of IAV-pneumococcal co-infection on DC function 
57. Following viral infection, a reduced IL-10 response to heat-killed S. pneumoniae 
was recorded along with a synergistic stimulation of TNF-?, IFN-? and IL-12. However, 
no synergistic effect was observed in terms of DC apoptosis or activation. At present, 
the functional consequences of these observations in vivo remain unclear, and it 
should be noted that the innate response against live or heat-killed S. pneumoniae 
can differ signiﬁcantly, as recently described by Olliver et al. 58. Nevertheless, given 
the important role of DCs in shaping the adaptive immune response against both 
viruses and bacteria, this remains a crucial area for future research. 
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 39
39
Interactions between Streptococcus pneumoniae and influenza virus: a mutually beneficial relationship?
2
Impaired NK cell response
Natural killer (NK) cells are widely known to play an essential role in host defense 
during the early stages of viral infection via killing of infected cells and the production 
of cytokines. These cells do not only have anti-viral effects, but also play a role in 
the host defense against extracellular bacterial pathogens 59. These effects may be 
either direct or through the activation of other cell types such as macrophages 60, 61. 
For example, in a murine model of secondary Staphylococcal pneumonia, IAV 
decreased the production of TNF-? by NK cells, which in turn repressed the 
phagocytosis of S. aureus by alveolar macrophages 62. Although it is tempting to 
speculate that similar effects play a role during post-IAV susceptibility to pneumococcal 
infections, neither IL-10 nor IFN-? were found to be upregulated in the lungs of 
S.aureus – IAV co-infected mice, both of which have previously been implicated in 
viral-induced predisposition to pneumococcal disease 49, 63, 64.
Soluble mediators of virus-induced bacterial disease
In addition to affecting a variety of different leukocytes, infection with IAV can also 
trigger the production of numerous soluble mediates, including type I IFNs and 
 glucocorticoids (GCs). The presence of both type I IFNs and GCs have important 
consequences for the development of secondary bacterial disease. 
Type I IFNs consist of two subgroups, IFN-? and IFN-?, both of which signal through 
a shared receptor (IFNAR) 65, 66. They are produced by almost every cell in the body 
and constitute an important component of the antiviral response. For example, type I 
IFNs trigger the production of antiviral factors such as 2?-5? oligoadenylate (2–5A) 
synthetases, Mx proteins and the RNA activated protein kinase 67. Accordingly, IFNAR-/- 
mice succumb to viral infections whilst their wild-type countertypes do not 66. Studies 
using lymphocytic choriomeningitis virus (LCMV) and Listeria monocytogenes showed 
that post-viral susceptibility to bacterial infection was mediated by this viral induction of 
type I IFNs 68. The production of type I IFNs resulted in neutrophil apoptosis, leukopenia 
and as a result, increased bacterial outgrowth 68. It was hypothesised that a similar 
mechanism occurred during co-infection with S. pneumoniae and IAV 69. However, 
subsequent studies showed that not only did IAV not induce leukopenia, but when 
leukopenia was artiﬁcially induced there was no increase in susceptibility to 
pneumococcal disease 69. Instead, studies using IFNAR-/- mice showed that IAV-induced 
type I IFNs facilitate pneumococcal disease by impairing the production of CXCL1 
and CXCL2, thereby reducing neutrophil chemotaxis to the site of infection. Accordingly, 
the pulmonary administration of exogenous CXCL1 and CXCL2 facilitated neutrophil 
chemotaxis and protected mice from secondary pneumococcal pneumonia 70. 
Virus-induced type I IFNs may also play a role in increased pneumococcal 
colonization upon IAV infection. Co-infection with IAV and pneumococci results in a 
synergistic stimulation of type I IFNs in the upper respiratory tract of mice. The 
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presence of type I IFNs in the nasopharynx inhibits the production of CCL2, a 
chemokine responsible for the recruitment of monocytes/macrophages to clear the 
colonizing pneumococci 47. Alternatively, IAV-induced type I IFNs may facilitate 
pneumococcal colonization by affecting Th17 T cells, a central component of the 
response against S. pneumonia in the nasopharynx 18. Speciﬁcally, the production of 
IL-17A by Th17 cells results in the recruitment and activation of neutrophils 71, which 
then helps to clear pneumococci from the upper respiratory tract 8, 72, 73. IAV-induced 
type I IFNs alter this response by inhibiting IL-23 production by DCs, thereby 
decreasing the subsequent Th17 response 74. It should be noted that thus far, the 
latter observation has only been shown in the context of Staphylococcal pneumonia. 
The study of Nakamura and colleagues 47 did not detect signiﬁcant differences in 
IL-17A transcription with or without IAV infection. Nevertheless, IAV-induced type I IFN 
production may offer a mechanistic explanation for clinical observations that 
co-infection with IAV increases pneumococcal colonization as well as disease 75, 76. 
A second group of soluble mediators produced following IAV infection are GCs. GCs 
are produced by the adrenal glands in response to stress through the activation of 
the hypothalamic-pituitary-adrenal axis. They are an important regulator of 
inﬂammation and are released following increased levels of pro-inﬂammatory 
cytokines 77. Mice infected with IAV show strongly elevated levels of serum GC, which 
is independent of the presence of pro-inﬂammatory cytokines. Although GCs were 
found to play a very important role in limiting mucosal damage to the lungs following 
viral infection, their production facilitates secondary infection with the bacterium L. 
monocytogenes by reducing cytokine and chemokine production, resulting in a 
reduced neutrophil inﬁltrate in the liver 78. However, whilst these ﬁndings have 
identiﬁed a novel facet of viral-bacterial interactions, their relevance to secondary 
infections with respiratory bacteria, such as S. pneumoniae, remains to be proven. 
Mucociliary transport 
Many different in vitro studies have shown increased pneumococcal adherence 
following viral infection in both primary and immortalized bronchial cell lines 79, 80. 
However, these models are prone to overlook an important aspect of one of the ﬁrst 
lines of defense: ciliary beating. This feature of the nonspeciﬁc defense against 
respiratory pathogens was recently investigated using a novel murine tracheal explant 
model. Surprisingly, IAV infection was not found to affect the adherence of S. 
pneumoniae, even following tissue damage. In contrast, a reduction of tracheal 
mucociliary velocity was observed following viral infection, resulting in decreased 
clearance of S. pneumoniae 81. These data demonstrate that IAV compromises not 
simply the adaptive immune response, but also one of the most basic ﬁrst line 
defenses against invading bacterial pathogens.
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The role of influenza virus in pneumococcal transmission
A ﬁnal point to note is that we 82 and the group of McCullers 83 have recently 
demonstrated that IAV not only facilitates pneumococcal colonization/disease, but 
also the transmission of pneumococci. In both ferrets and mice infection with IAV 
facilitated the intra- and, in the case of ferrets, inter-cage transmission of S. 
pneumoniae. In mice, IAV facilitated bacterial transmission by acting upon the index 
mice (i.e. those colonised with S. pneumoniae) and the co-housed, naïve contact 
mice. In contrast, in ferrets IAV had the greatest effect on the contact animals. 
Unfortunately, neither of these studies has as of yet identiﬁed the mechanism by 
which IAV was facilitating bacterial transmission, and this remains a crucial area of 
future research. Furthermore, although a recent epidemiological study was unable to 
ﬁnd a relationship between inﬂuenza virus seasonality and the transmission of 
invasive pneumococcal disease 84, further epidemiological research is required to 
assess the effect of IAV infections on pneumococcal carriage in the population. 
A SYNERGISTIC RELATIONSHIP?
Despite the extensive research on the role of inﬂuenza virus in pneumococcal 
disease, few studies have examined the effect of S. pneumoniae on the pathogenesis 
of IAV. There is a growing awareness that the microbial context during which viral 
infections occur are also an important factor that can skew immune homeostasis and 
the outcome of disease. Indeed, the differences that exist between the normal 
nasopharyngeal ﬂora of individuals 85, 86 may help account, at least in part, for some 
of the severe and fatal cases of primary viral pneumonia during the relatively mild 
2009 IAV pandemic 87, 88. Although pneumococcal-inﬂuenza virus co-infections can 
cause synergism of disease, the nature of their relationship is not necessarily 
synergistic itself. It is clear that inﬂuenza virus infection can facilitate bacterial 
outgrowth. Early studies using squirrel monkeys suggested that S. pneumoniae 
increased IAV replication in the lungs of infected animals 89. However, this study was 
performed with a limited number of animals and to the best of our knowledge there 
has been no other direct evidence since showing that S. pneumoniae increases the 
pathogenesis and/or replication of IAV. Much of the evidence for the pneumococcus 
exacerbating infection with IAV requires extrapolation from studies on the interactions 
of other respiratory bacteria and viruses. For example, the Gram-negative bacterium 
Bordetella pertussis exacerbates IAV replication in mice by  modulating the innate 
immune response with its main virulence factor, Pertussis toxin 90. A variety of bacterial 
proteases have also been described to aid IAV infection. Entry of IAV into the host cell 
requires cleavage of the HA by host cell proteases. Both Staphylococcus aureus and 
Aerococcus viridans secrete proteases that, along with host proteases, can cleave 
the viral HA into its active form. Accordingly, mice co-infected with IAV and a S. aureus 
strain lacking the HA-activating protease displayed signiﬁcantly less morbidity and 
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mortality compared to mice infected with IAV and a S. aureus strain positive for the 
protease 91, 92. In addition to direct proteolytic effects on the viral HA by bacterial factors, 
indirect cleavage may also occur through bacterial plasminogen activators such as 
those found in Serratia marcescens. These plasminogen activators generate plasmin 
from plasminogen, which can then cleave the viral HA and facilitate disease 93, 94. Finally, 
the presence of speciﬁc bacterial pathogen associated molecular patterns (PAMPs) 
can increase the susceptibility of a host to speciﬁc viral infections. Speciﬁcally, the 
synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), a component found 
in Gram-positive bacteria, signiﬁcantly increases RSV, HIV-1, measles virus and hMPV 
adhesion to and infection of epithelial cells and leukocytes. This enhanced viral 
adhesion is mediated by the activity of the N-palmitoylate cystein and cationic lysines 
of Pam3CSK4 95. At present, it is unclear if any or all of these mechanisms apply to 
co-infections with IAV and S. pneumoniae. One could envision that whilst S. pneumoniae 
does not possess any known HA cleaving proteases or plasminogen activators, the 
ability of the bacterium to recruit plasminogen to its cell surface 96 could increase the 
local concentration of plasmin and indirectly facilitate increased cleavage of the viral 
HA. However, to our knowledge the only evidence for enhanced viral infection after S. 
pneumoniae exposure comes from an in vitro study where hMPV infection was 
enhanced after polarized bronchial epithelial cells were exposed to S. pneumoniae 97. 
Inhibitory effects of S. pneumoniae on viral replication
In contrast to the lack of evidence documenting increased IAV infection in the 
presence of S.  pneumoniae, there is increasing evidence to suggest that preceding 
colonization with S. pneumoniae actually reduces IAV infection (see Figure 2) 80, 82. 
This concept has been explored as an alternative to the traditional inﬂuenza virus 
vaccine 98, 99. In mice, oral immunisation with bacterial lysate composing of antigens 
derived from Staphylococcus aureus, Streptococcus pyogenes, S. pneumoniae, 
Streptococcus mitis, Klebsiella pneumoniae, Branhamella catarrhalis and Hemophilus 
inﬂuenzae reduces mortality due to inﬂuenza virus infection 98. Similarly, the 
administration of an aerosolized lysate of nontypeable H. inﬂuenza (NTHi) or 
attenuated Bordetella pertussis protected mice against lethal inﬂuenza virus 
pneumonia 100, 101. These data are supported by clinical studies demonstrating that in 
children the administration of a bacterial lysate vaccine signiﬁcantly reduces the 
frequency of respiratory tract infections 99. The observed reduction in viral infection in 
these studies may reﬂect the immunostimulatory effects of speciﬁc PAMPs associated 
with bacteria. Recently, Shinya and colleagues 102 showed that pre-stimulation of 
certain TLRs with bacterial PAMPs (including those found in S. pneumoniae) protected 
mice from infection with IAV. This effect may be explained by multiple mechanisms. 
For instance, PAMPs may induce the production and secretion of cytokines and/or 
chemokines, leading to the recruitment of APCs and effector cells to the site of 
induction. Another potential explanation for this observation is the production of type 
I IFN following stimulation with bacterial ligands. 
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As discussed above, type I IFNs play an important role in post-viral susceptibility to 
pneumococcal disease and colonization. However, there is now a growing body of 
evidence that type I IFNs are not only produced during viral infections, but that they 
are also produced in response to pneumococcal colonization 47, 103, 104. Thus, 
pneumococcal induced type I IFNs may also have important ramiﬁcations for 
Figure 2.  The effect of pneumococcal carriage on the interaction with inﬂuenza virus. 
Pneumococcal carriage rates differ signiﬁcantly between children (~80%) and adults (~10%) 
and may signiﬁcantly affect the microbial context in which infection with inﬂuenza virus occurs. 
A. Adult individuals most likely encounter IAV without prior colonization by S. pneumoniae. In 
this scenario, primary infection with inﬂuenza virus creates a window of susceptibility to 
secondary pneumococcal infection. B. Inﬂuenza viral infection of children is likely preceded by 
pneumococcal colonization. In this scenario, inﬂuenza virus may still exacerbate pneumococcal 
disease. Conversely, stimulation of the immune system by colonising pneumococci may inhibit 
viral replication.
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inﬂuenza virus infections. Unlike the induction of type I IFNs by many viruses, 
pneumococcal type I IFN production is independent of MyD88 103. Instead, type I IFN 
production is dependent upon the pore forming activity of the pneumococcal protein 
pneumolysin (Ply). Ply facilitates the entry of pneumococcal DNA into the cell. This 
DNA then interacts with the cytosolic sensor DAI, resulting the induction of IFN-? 103. 
Individuals colonised with S. pneumoniae who subsequently encounter an inﬂuenza 
virus infection may therefore have sufﬁcient levels of IFN-? and IFN-? in the respiratory 
tract to mitigate IAV infection. Such a scenario may be most relevant to children, who, 
due to their high rate of pneumococcal carriage 10, are likely to be colonised with 
S. pneumoniae prior to contracting IAV 105. Indeed, mice colonised ﬁrst with the 
pneumococcus and then infected with inﬂuenza virus have signiﬁcantly lower viral 
titres in the nasopharynx compared to mice infected with inﬂuenza virus alone 82. 
Similarly, microarray analysis demonstrated that protection against viral pneumonia 
following NTHi lysate treatment, was associated with a signiﬁcant upregulation of 
both type I and type II IFN-associated genes in the lung 100. In contrast to children, 
it is likely that adults (who have a low pneumococcal carriage rate) 10 may ﬁrst 
encounter inﬂuenza virus and then experience a secondary infection with S. pneumonia 
(Figure 2). In such a scenario inhibition of viral replication may not occur. This difference 
in kinetics may explain why in some studies, when inﬂuenza virus was given as 
the primary infection, pneumococcal infection did not inhibit viral replication 80, 106. 
Interestingly, Nakamura and colleagues 47 recently showed that if mice were colonised 
with S. pneumoniae and then infected one day later with inﬂuenza virus, there was no 
signiﬁcant difference in nasopharyngeal viral titres seven days post inﬂuenza virus 
infection. This was despite the signiﬁcantly higher levels of IFN-? detected in 
co-infected mice compared to mice infected with either pathogen alone. However, 
it is possible that the short period between pneumococcal colonization and viral 
infection in this study was not sufﬁcient to induce a partially protective level of type I 
IFNs in the nasal cavity. McCullers and colleagues 80 also did not observe a reduction 
in viral titres when mice had a pre-existing pneumococcal infection. However, it was 
noted that pre-colonization with the pneumococcus did protect mice from the 
morbidity and mortality that normally occurred following inﬂuenza virus infection. 
Consistent with this data, following the 1957 Asian inﬂuenza virus pandemic, patients 
who succumbed to primary viral pneumonia had signiﬁcantly higher viral titres in the 
lungs (20 to 2,000 times)  compared to those who died from a viral-bacterial 
co-infection 107. 
A further piece of evidence to suggest the pneumococcus may inhibit IAV infection 
comes from the recent observation that reducing the normal ﬂora of mice by antibiotic 
treatment signiﬁcantly increases pulmonary viral titres and decreases the adaptive 
immune response to inﬂuenza virus 108. Surprisingly, this phenotype was attributed 
to the loss of Gram-positive bacteria in the gut, rather than the nasal cavity. 
These bacteria were responsible for activating the inﬂammasome, which in turn 
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resulted in DC migration from the lung and T cell priming. In the absence of these 
bacteria there was thus a sub-optimal immune response to inﬂuenza virus and 
increased viral outgrowth. Whilst this may suggest that pneumococcal colonization 
of the nasopharynx is unlikely to affect IAV infection, it is important to note that 
colonising pneumococci traverse the mucous barrier and attach to the apical surface 
of the respiratory tract epithelium 6, 109. When pneumococci reach a certain density, 
autolysis of a bacterial subpopulation occurs 110 and many PAMPs are released, 
including cell wall glycopeptides and pneumolysin. Notably, many of these factors 
have been shown to exert a strong inﬂammatory response, potentially resulting in 
damage to the host 111. Thus, unlike many members of the nasopharyngeal ﬂora, 
Figure 3.  Effect of pneumococcal colonization on infection with inﬂuenza virus. A. During 
colonization, autolysis of S. pneumoniae occurs, resulting in the release of inﬂammatory compounds. 
Bacterial compounds can induce innate signalling on innate immune cells, leading to the 
activation of IL-1? and IL-18. B. IL-18 polarizes T cell responses towards producing IFN-?, which 
is important in the antiviral response to IAV. C. Pneumococcal colonization also induces type I 
interferons through the pore-forming ability of the pneumococcal virulence factor pneumolysin 
(Ply). Upon contact with APCs, pneumococcal DNA is translocated across the membrane into 
the cytosol, where it is recognized by DNA-sensing receptors. This results in the production 
and secretion of IFN-?, which subsequently signals to the IFN-receptor, thereby inducing 
transcription of type I interferon inducible genes.
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colonization with S. pneumoniae is not a ‘passive’ event and there are many 
opportunities for immune recognition and activation. A protective response following 
pneumococcal colonization may not have been observed in the study of Ichinohe and 
colleagues 108 as S. pneumoniae is not present in the murine nasopharyngeal ﬂora. 
Thus, this study has developed an elegant model for bacterial-viral interactions and 
further research remains necessary to determine the relevance of these and other 
studies to the complex interactions between inﬂuenza virus and the pneumococcus 
(see Figure 3). 
CLINICAL PERSPECTIVE
Strategies to reduce secondary pneumococcal disease
The development of secondary invasive pneumococcal disease (IPD) following 
inﬂuenza virus infection remains a major health issue for clinicians. In susceptible 
individuals (such as those in the extremes of age), prevention may provide a long-term 
cost-beneﬁcial solution to reduce secondary IPD. The introduction of a conjugate 
polysaccharide pneumococcal vaccine is highly protective against disease caused 
by vaccine-serotypes, not only in young vaccinated children (98% reduction in 
vaccine-type disease), but also, through herd-immunity, in individuals over 65 years 
old (81% and 92% reduction in vaccine-type disease in the UK and U.S.A., respectively 
112, 113). Although these results are very promising and the recent introduction of a 
13-valent conjugate vaccine will likely further reduce IPD, the observation that 
non-vaccine type IPD increased by 48% in individuals aged 65 years or older is 
alarming. In the young and the elderly, inﬂuenza virus vaccines may also offer an 
attractive alternative in reducing pneumococcal infections 114-116. However, due to the 
limited coverage of current inﬂuenza virus vaccines, yearly revaccinations would be 
required for this approach to succeed. An additional beneﬁt of such a strategy would 
be that it does not only offer protection against pneumococcal disease, but also 
against other secondary bacterial infections such as S. aureus.
Although prevention provides a long-term solution, therapeutic intervention remains 
an important pillar of the current treatment of IPD. Currently licensed treatments 
include antibiotics and certain anti-inﬂammatory agents, most of which have been 
reviewed elsewhere 117. However, recent publications have highlighted a novel aspect 
of the use of antibiotics, in particular regarding how antibiotic treatment affects the 
outcome during co-infections. In the U.S.A., ?-lactams are the primary ﬁrst-line 
therapy for inﬂuenza virus-induced secondary bacterial pneumonia118. In Argentina 
and the U.S.A., ampicillin and ceftriaxone were the most commonly used ?-lactams 
during the 2009 IAV pandemic 119, 120. However, antibiotic treatment of severely ill 
patients does not always improve survival 34, 119, 121-123, and it might even have 
detrimental effects. A study by Karlström and colleagues showed that ampicillin-in-
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duced release of inﬂammatory bacterial compounds caused an inﬂux of neutrophils 
in S. pneumoniae-inﬂuenza virus infected mice, resulting in pulmonary damage 43. 
Concomitant treatment with the macrolide Azithromycin, a known suppressor of 
inﬂammation 124, 125, resulted in less neutrophil recruitment and rescued the mice from 
subsequent mortality. Similarly, two retrospective clinical studies have also shown 
that combined treatment with macrolides and ?-lactams signiﬁcantly reduced 
mortality in adults with bacteremic pneumococcal pneumoniae 126, 127. However, 
it should be noted that the incidence of inﬂuenza virus in these cases was not 
investigated. In summary, therapeutic strategies to prevent an exacerbated inﬂammatory 
response is an important clinical aspect to be considered during viral- bacterial 
co-infections.
Early treatment with the viral NA inhibitor oseltamivir has been shown to reduce 
severe complications and decrease mortality after inﬂuenza virus infection 34. 
Oseltamivir treatment of mice, even when delayed up to ﬁve days after viral infection, 
can reduce mortality to subsequent challenge with S. pneumoniae 128. This could also 
be due to direct antibacterial effects by the drug on S. pneumoniae itself, as oseltamivir 
not only inhibits the viral NA but also the pneumococcal neuraminidase A, an 
important virulence factor of the bacterium 129, 130. However, if results from mice can 
be extrapolated to the clinic and individuals do indeed remain susceptible to bacterial 
infections up to six months after the initial viral infection 51, the efﬁcacy of anti-viral 
drugs may be limited. 
Potential impact of pneumococcal vaccination on influenza  
virus infections
Pneumococcal vaccines have led to signiﬁcantly less invasive pneumococcal 
disease both in children as well as in adults, and studies investigating the effect of 
conjugate vaccines on hospitalizations have shown strong reductions in both 
pneumococcal pneumonia as well as all-cause pneumonia admission rates in young 
children 131. However, one often overlooked aspect of pneumococcal vaccination that 
should be considered is how reduced pneumococcal carriage rates affect viral 
infections, which is particularly relevant in young children. As discussed herein, there 
is strong evidence to suggest that the presence of S. pneumoniae in the nasopharynx 
(i.e. carriage), reduces IAV replication. Should concern therefore be raised that a 
reduction in pneumococcal carriage may result in increased susceptibility to inﬂuenza 
virus infections? Unfortunately, there is currently not sufﬁcient evidence available to 
answer this question. Although the conjugate pneumococcal vaccines protect very 
efﬁciently against pneumococcal disease and decreases carriage rates of the 
corresponding vaccine serotypes, total pneumococcal carriage is not signiﬁcantly 
reduced as the result of a concomitant increase in carriage of non-vaccine serotypes 
(e.g.19). Moreover, the complexity of colonization dynamics is such that if a signiﬁcant 
decline in pneumococcal carriage were to occur, it would likely be accompanied by 
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an increase in colonization rates by other nasopharyngeal bacteria, which are then 
able to occupy the newly vacated niche. The consequences of such an event in terms 
of susceptibility to inﬂuenza virus infection would then need to be evaluated. 
FUTURE PERSPECTIVE
History has taught us that co-infections with S. pneumoniae and IAV can cause 
increased disease severity, which is evident from both seasonal inﬂuenza outbreaks 
as well as from previous inﬂuenza virus pandemics. In order to prevent exacerbated 
disease and mortality, it is important to understand the complex and dynamic 
interactions between the host, S. pneumoniae and inﬂuenza virus that facilitate this 
augmentation of disease. The question whether and when we should treat with anti-
bacterial, antiviral compounds or anti-inﬂammatory (or a combination of these) drugs 
has as of yet not been clearly answered, and should be a focus for future research. 
In the last few years, several novel aspects of inﬂuenza virus-induced susceptibility to 
pneumococcal infections have been reported. In particular the desensitization of 
antigen- presenting cells following inﬂuenza virus infection is of interest, as this may 
explain the post-viral window of susceptibility to S. pneumoniae and other secondary 
bacterial infections. Although a clearer picture is emerging about the underlying 
mechanisms of this phenomenon, future research should also be aimed at developing 
strategies to break this immune paralysis, as this may have huge therapeutic beneﬁts. 
On another note, the conﬂicting role of neutrophils in the development of secondary 
pneumococcal disease is as of yet unresolved. Although it is clear that neutrophils do 
play an important role in the anti-pneumococcal response, it remains unclear if this 
also applies in the context of an inﬂuenza virus infection, which is known to affect the 
PMN response dramatically. Insight into the kinetics and the balance of protective 
and damaging neutrophil response remains an area of future investigation.
Finally, it is important to realize that the bacterial context during which inﬂuenza virus 
infections occur, may also affect the outcome of disease. It is interesting to note that 
secondary invasive pneumococcal disease induced by inﬂuenza virus infections are 
generally thought to be much more problematic for the elderly (who often have 
very low colonization rates) than for children (who are frequently colonized with 
S. pneumoniae). In recent years, the role of the mucosal microbiota in modulating 
and training the immune response to pathogen infections has received much more 
attention. Although the development of next-generation techniques are only just 
starting to shed light on the intra- and inter-individual’s complex dynamics of the 
microbiota, the challenge will be in linking this to changes in one’s susceptibility to 
e.g. inﬂuenza virus infections and the development of disease. Furthermore, the 
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question remains how this information may then be translated into therapeutic 
intervention; should we start monitoring changes in microbiota composition as a 
biomarker for susceptibility? Or should we try to actively restore such a ‘susceptible’ 
microbiota to a ‘healthy’ microbiota through the use of e.g. pre- or pro-biotics? In this 
respect, the discussion whether pneumococcal vaccines should target both the 
development of invasive disease as well as carriage is as of yet unresolved. 
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EXECUTIVE SUMMARY
Inﬂuenza virus-induced susceptibility to S. pneumoniae
??Inﬂuenza virus induces IFN-? production by T cells, which downregulates the 
alveolar macrophage scavenger receptor MARCO, resulting in decreased bacterial 
opsonophagocytosis.
??Infection with IAV reduces chemokine production and NF-?B activation of alveolar 
macrophages, resulting in prolonged desensitization of alveolar macrophages to 
bacterial PAMPs.
??In response to IAV, apoptotic leukocytes show increased surface expression of the 
inhibitory ligand CD200, which signals to CD200R+ innate cells and suppresses 
their immune response.
??IAV-induced type I interferons impair the production of CXCL1/2, thereby reducing 
neutrophil recruitment.
??The production of type I interferons following IAV infection also inhibits CCL2 
production, resulting in a reduced inﬂux of monocytes/macrophages.
??Type I interferons may also facilitate pneumococcal infections by skewing the T cell 
response through inhibition of the IL-23-IL-17 axis.
??Serum levels of glucocorticoid are increased following IAV infection, which may 
suppress the inﬂammatory response to secondary pneumococcal infections.
Role of pneumococcal colonization in viral infections
??Stimulation of PRRs with either bacterial lysates or with speciﬁc bacterial PAMPs 
suppresses subsequent infection with inﬂuenza virus.
??Colonization with S. pneumoniae induces the production of IFN-?, which is 
mediated through the pore-forming toxin pneumolysin (Ply), which results in innate 
cytosolic sensing of pneumococcal DNA and subsequent production of IL-1?.
??Gut-derived Gram-positive bacteria and bacteria in the nasopharynx are important 
for DC homeostasis and migration by providing activation signals for IL-1? 
production. Removal of these signals e.g. by antibiotic treatment can increase 
subsequent viral replication.
??High pneumococcal carriage may affect the clinical outcome of subsequent 
inﬂuenza virus infections
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ABSTRACT 
Otitis media (OM) affects >80% of children before the age of three. OM can arise 
following co-infection with inﬂuenza A virus (IAV) and the bacterium Streptococcus 
pneumoniae. We have previously shown that H3 IAV strains (such as Udorn/72) 
induced a higher rate of bacterial OM than H1 strains (such as PR8/34). This was 
associated with more efﬁcient replication of H3 strains in the middle ear. Here, we 
assess if the increased replication of IAV strains such as Udorn/72 in the middle ear 
is dependent upon the binding of the viral HA to ?2,6-linked sialic acid. Using murine 
and in vitro models, the present study shows that recognition of ?2,6-linked sialic 
acid was not required to facilitate bacterial OM. Taken together, these data suggest 
that other features of the HA mediate bacterial OM. 
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INTRODUCTION
Otitis media (OM) is the most frequently diagnosed illness in children under the age 
of ﬁve and can lead to permanent hearing loss 1. OM is a polymicrobial disease and 
can arise following co-infection with inﬂuenza A virus (IAV) and the bacterium 
Streptococcus pneumoniae (the pneumococcus) 1. We and others have demonstrated 
that infection with IAV facilitates the development of pneumococcal OM 2-4. Speciﬁcally, 
we showed that  H3 IAV strains, such as Udorn/72 (H3N2), induced a higher rate of 
pneumococcal OM in mice compared to H1 strains, such as PR8/34 (H1N1) 5. 
This was related to the ability of the H3 hemagglutinin (HA) to mediate increased 
viral replication in the middle ear.  H3 viruses also infected human middle ear 
epithelial cells (HMEECs) at a higher rate than H1 strains in vitro 5. Here, we investigate 
if the increased replication of H3 strains in the middle ear is related to the sialic 
acid preference of the HA.
The HA of IAV binds to terminal sialic acid residues on cell surface glycoproteins and 
glycolipids, facilitating virus internalisation 6. Human inﬂuenza viruses typically display 
a preference for sialic acid residues linked to cell surface glycans by an ?2-6 linkage 6. 
In humans, ?2-6 linkages are most prevalent in the upper respiratory tract, whilst both 
?2-3 and ?2-6 linkages are found in the lower respiratory tract 7. Interestingly, whilst 
pre-1977 H3N2 strains like Udorn/72 recognise both ?2,3- and ?2,6-linked sialic acid, 
later H3N2 strains have evolved to recognise only ?2,6-linked sialic acid 8, 9. In contrast 
to humans, ?2,3-linked sialic acid dominates the murine respiratory tract 10. 
Accordingly, virus strains adapted for murine infections (such as PR8/34) preferentially 
recognise ?2,3-linked sialic acid 9. Given that we have previously demonstrated that 
the Udorn/72 HA mediates efﬁcient viral replication in the middle ear (and thus 
triggers bacterial OM) whilst the PR8/34 HA does not 5, the recognition of ?2,6-linked 
sialic acid may facilitate increased viral replication in the middle ear. However, the 
sialic acid linkages present in the middle ears of infant C57BL/6 mice has, to the best 
of our knowledge, yet to be described. Here, we use a mouse model of OM and in 
vitro cultured HMEECs to show that increased replication of select H3 inﬂuenza virus 
strains in the middle ear is independent of tropism for ?2,6-linked sialic acid.
METHODS 
Viral and bacterial strains: The bioluminescent S. pneumoniae strain EF3030lux 
(type 19F) was used in all experiments 11. A/Udorn/307/72 (H3N2; Udorn72), A/Port 
Chalmers/1/73 (H3N2; Port Chalmers/73) and HKx31 (H3N2) were grown in 
embryonated eggs 4. Horse-serum resistant (HSR) mutants were selected by growing 
the parent virus in embryonated eggs in the presence of non-immune horse serum. 
Tropism of all HSR strains for only ?2,3-linked sialic acid was conﬁrmed by the desi-
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alyation-resialyation of red blood cells 9, and was consistent with previous publications 
with these strains 9. 
Infection of mice: Animal experiments were approved by the Animal Ethics Committee 
of The University of Melbourne. C57BL/6 mice were bred and housed under speciﬁc 
pathogen-free conditions. Five-day old C57BL/6 mice were colonised intranasally 
(i.n.) with 2×103 colony forming units (CFU) of S. pneumoniae EF3030Lux  or PBS in 3 
μLs. At 14-days of age, mice were infected i.n. with 20 (PR8/34) or 102.5 (all other virus 
strains) plaque forming units (PFU) of IAV in 3 μLs. Six days post-IAV infection, organs 
were collected for analysis. 
Enumeration of bacterial and viral load: Tissues used to quantify bacterial and viral 
load were collected and processed as described previously 11.
Infection and staining of HMEECs: HMEECs 12 were kindly donated by Prof. David 
Lim (House Ear Institute, CA) and were infected and stained as described previously 
5. The percentage of infected cells was calculated by counting a minimum of 80 cells 
per well, where each data point was the average of an experimental duplicate. 
Lectin staining: Middle ears were collected and sectioned for histology essentially 
as described previously 4.  Lectin staining on middle ear sections was performed 
using the DIG glycan differentiation kit (Roche Diagnostics, Germany). Brieﬂy, 
sections were incubated for 1 hour at 37oC in PBS or PBS supplemented with 400mU/
mL Vibrio cholerae sialidase (Sigma, USA). Sections were subsequently labelled with 
DIG-labelled Maackia amurensis agglutinin (MAA; ?2,3-linked sialic acid) or 
Sambucus nigra agglutinin (SNA; ?2,6-linked sialic acid) and stained with 
anti-DIG-FITC (Roche, USA). Autoﬂuorescence was quenched using 0.01% (w/v) 
Evans blue (Sigma).  
HMEECs were incubated with PBS supplemented with 4mM CaCl2 ± 500 mU/mL 
Vibrio cholerae sialidase (Sigma) for 120 minutes at 37 degrees. Cells were 
subsequently washed and stained with biotinylated Maackia amurensis Lectin (MAL) 
II (Vector Laboratories, USA), or with biotinylated Sambucus nigra lectin (SNA) I (EY 
Laboratories, USA). Cells were once again washed, incubated with streptavidin- 
conjugated APC (BD Biosciences, USA) and lectin binding was measured on a LSR 
II ﬂow cytometer (BD Biosciences, USA). Data was analysed with FlowJo version 
7.6.5 (TreeStar Inc, Ashland, OR).
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RESULTS & DISCUSSION 
OM is not associated with tropism of the viral HA for ?2,6-linked 
sialic acid 
To determine if recognition of ?2,6-linked sialic acid was important in the development 
of secondary bacterial OM, we assessed the ability of a horse serum-resistant mutant 
(HSR) of Udorn/72 to cause pneumococcal OM. This virus has a single amino acid 
substitution at residue 226 of the HA that changes its specify from dual recognition of 
?2,3- and ?2,6-linked sialic acid, to ?2,3-linked sialic acid only 9. Mice colonised with 
S. pneumoniae at 5-days old were then infected with wild-type Udorn/72 or HSR 
Udorn/72 at 14-days old. Pneumococcal OM was assessed by measuring bacterial 
titres in the middle ear six-days post-IAV infection. This time-point was selected as we 
have previously shown that six days after IAV infection is the peak of bacterial OM in 
infant mice 4. Mice infected with HSR Udorn/72 displayed no signiﬁcant difference in 
middle ear bacterial titres compared to mice infected with wild-type Udorn/72 (Figure 
1A; Mann-Whitney U-Test, p > 0.05). Accordingly, there was no difference in viral 
replication between wild-type and HSR Udorn/72 in the middle ear six-days post IAV 
infection (Figure 1B; One-Way ANOVA with a Bonferroni post-correction, p > 0.05). 
Like Udorn/72, the H3N2 viruses HKx31 and PC/73 also replicated efﬁciently in the 
middle ear and facilitated bacterial OM 5. As these viruses also display a dual-receptor 
speciﬁcity 9, 13, we used HSR mutants to assess if bacterial OM caused by HKx31 and 
PC/73 was also independent of tropism for ?2,6-linked sialic acid. HSR HKx31 and 
HSR PC/73 did not mediate differential bacterial replication in the middle ear relative 
to their wild-type parental strains (Figure 1A; Mann-Whitney U-Test, p > 0.05). 
Similarly, there were no signiﬁcant differences in the titres of these viruses in the 
middle ear relative to Udorn/72 (Figure IB; One-Way ANOVA with a Bonferroni 
post-correction, p > 0.05) and their replication was equivalent to relevant parental 
strains 5. These observations were supported by immunoﬂuorescent staining of 
middle ears of unifected mice, which demonstrated that this site is rich in ?2,3-linked 
sialic acid (Figure 1C). In contrast, only non-speciﬁc background staining was 
observed for ?2,6-linked sialic acid (Figure 1C). The middle ears of S. pneumoniae, 
IAV and co-infected mice were also rich in ?2,3-linked sialic acid (Supp. 1). 
Furthermore, we have previously demonstrated that secondary pneumococcal OM is 
independent of the viral NA and that the pneumococci in the ear localise to the lumen 
rather than the middle ear epithelium 4, 5. Thus, ?2,6-linked sialic acid recognition is not the 
critical determinant of virus replication in the middle ear or secondary bacterial OM.
Tropism for ?2,6-linked sialic acid does not determine the in vitro 
infection rate of human middle ear epithelial cells by Udorn/72
To assess the relevance of these ﬁndings to human infections, HMEECs were infected 
with Udorn/72 or HSR Udorn/72. HSR Udorn/72 was not signiﬁcantly reduced in its 
ability to infect HMEECs when compared to the wild-type Udorn/72 (Figure 2A; 
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Figure 1. ?2,6-linked sialic acid recognition does not affect the development of pneumo- 
coccal OM. A. Titres of S. pneumoniae EF3030lux in the middle ears of mice six-days after 
i.n. infection with wild-type or horse-serum resistant (HSR) IAV strains. Bacterial counts are 
represented as the average titre derived from the left and right ear of each mouse. Data is 
pooled from a minimum of two independent experiments. Statistical signiﬁcance was 
determined using a Mann-Whitney U-Test between the relevant wild-type or HSR strain. Dashed 
line indicates the detection limit of the assay. B. Titres of IAV in the middle ears of mice six-days 
after i.n. infection with wild-type or horse-serum resistant (HSR) IAV strains. Viral tires are 
represented as the average titre derived from the left and right ear of each mouse. Data is 
pooled from a minimum of two independent experiments. Statistical signiﬁcance was 
determined using a One-Way ANOVA with a Bonferroni post-correction and is denoted by an 
asterisk (p < 0.05). Dashed line indicates the detection limit of the assay. C. Sialic acid 
expression in the murine middle ear. Sections were labeled with Maackia amurensis agglutinin 
(MAA; ?2,3-linked sialic acid ) or Sambucus nigra agglutinin (SNA; ?2,6-linked sialic acid) with 
or without pre-treatment with a sialidase. Positive staining is shown by an arrow. MEE: Middle 
Ear Epithelium; MEC: Middle Ear Cavity.
A B
C
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Mann-Whitney U-Test, p > 0.05). This suggests that recognition of ?2,6-linked sialic 
acid on HMEECs by the Udorn/72 HA is not the major factor in determining the rate 
of infection. Consistent with this hypothesis, HMEECs expressed both ?2,6- and 
?2,3-linked sialic acid on the cell surface (Figure 2B).  The speciﬁcity of this binding 
was conﬁrmed by the reduced number of ﬂuorescent cells observed following 
sialidase treatment of HMEECs  (Figure 2B). 
In summary, we have previously demonstrated that H3 viruses (such as Udorn/72) 
with dual speciﬁcity for ?2,6- and ?2,3-linked sialic acid facilitate bacterial OM. In 
contrast, H1 viruses (such as PR8/34) which only recognise ?2,3-linked sialic acid, 
do not facilitate bacterial OM. We therefore reasoned that recognition of ?2,6-linked 
sialic acid may promote increased viral replication in the middle ear and thus bacterial OM. 
Figure 2. ?2,6-linked sialic acid recognition does not affect infection of human middle ear 
epithelial cells (HMEECs). A. Percentage of HMEECs infected by wild-type Udorn/72 or horse 
serum resistant (HSR) Udorn/72 eight hours post-infection at an MOI of 1. Statistical signiﬁcance 
was determined using a Mann-Whitney U-Test. Data represents mean ± SEM.  B. Percentage 
of HMEECs expressing ?2,3- or ?2,6-linked sialic acid. HMEECs were incubated with PBS 
containing 1% BSA (unstained), biotinylated MAL II (to detect ?2,3-linked sialic acid), biotinylated 
SNA I (to detect ?2,6-linked sialic acid) or biotinylated MAL II or SNA I following sialidase 
treatment (sialidase treated). Cells were subsequently stained with streptavidin-conjugated 
APC and measured by ﬂow cytometry. The percentage of positive cells is deﬁned as the 
percentage of single cells which were APC positive. Data is pooled from two independent 
experiments where each experiment was performed in duplicate. Statistical signiﬁcance was 
determined using a One-Way ANOVA with a Bonferroni post-correction and is denoted by one 
asterisk (p < 0.05) or three asterisks (p < 0.001).
A B
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 66
66
Chapter 3
However, H3 viruses with a speciﬁcity for only ?2,3-linked sialic acid were still effective 
at inducing bacterial OM, replicating in the middle ear and infecting HMEECs. 
At present, it remains unclear what alternative feature of the H3 HA mediates increased 
viral replication in the middle ear and thus bacterial OM. Following sialic acid-mediated 
viral attachment, the H3 HA may promote more effective interactions with secondary 
receptors required for virus entry and replication 14. Alternatively, H3 HAs may display 
increased membrane fusion with epithelial cells in the middle ear, thereby promoting 
more efﬁcient viral replication 15. Thus, whilst OM is independent of tropism for 
?2,6-linked sialic acid, the other features of the HA which may mediate secondary 
bacterial disease remain an area of ongoing research. 
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Figure S1. Sialic acid expression in the murine middle ear following infection with Strepto- 
coccus pneumoniae (Sp) and/or the IAV strain Udorn/72. Sections were labeled with Maackia 
amurensis agglutinin (MAA; ?2,3-linked sialic acid), Sambucus nigra agglutinin (SNA; ?2,6-linked 
sialic acid) or unlabelled. Positive staining is shown by an arrow. MEE: Middle Ear Epithelium; 
MEC: Middle Ear Cavity.
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ABSTRACT
Widespread vaccination against Streptococcus pneumoniae (the pneumococcus) 
has signiﬁcantly reduced pneumococcal disease caused by vaccine serotypes. 
Despite vaccination, overall pneumococcal colonization rates in children have not 
reduced and otitis media (OM) by non-vaccine serotypes remains one of the most 
common childhood infections. Pneumococcal surface protein A (PspA) has been 
shown to be a promising protein antigen to induce broad protection against 
pneumococcal colonization. However, its ability to protect against OM remains 
unclear. Using our previously established mouse model of inﬂuenza-virus induced 
pneumococcal OM, we here show that intranasal vaccination of mice with PspA 
together with the mucosal adjuvant CTB results in a decrease in pneumococcal load 
in the middle ears. This decrease correlated with the induction of PspA-speciﬁc IgA, 
a balanced IgG1:IgG2a antibody response and the induction of a mucosal Th17 
response. Our data suggests that the IL-17 response to PspA is more important for 
protection against OM, whilst the presence of antibodies may be less important, as 
determined in mice deﬁcient in IL-17 signaling or antibody production. Together, these 
results suggest that mucosal vaccination with PspA may not only protect against 
colonization, but also against the development of virus-induced pneumococcal OM.
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INTRODUCTION 
Otitis media (OM) is one of the most common childhood infections and is a major 
contributor to hearing loss 1, 2. Even though pneumococcal conjugate vaccines (PCV) 
have been widely introduced in infant immunization schedules, Streptococcus 
pneumoniae is still a major cause of acute OM 3, 4. The efﬁcacy of PCVs against acute 
pneumococcal OM in infants is only 20-52% 5, probably owing largely to the 
replacement in pneumococcal carriage with non-vaccine serotypes 6.
Before PCVs were introduced, pneumococcal carriage rates typically declined after the 
age of 3 7. This is thought to be caused by repeated colonization events with S. 
pneumoniae, resulting in the establishment of broad natural immunity to conserved 
pneumococcal proteins and capsular antigens 8-10. Murine models of infection have 
suggested that protection against pneumococcal colonization is predominately 
mediated by a CD4+ T cell-dependent immune response, with accelerated clearance 
of pneumococci due to the production of IL-17 8, 11. Similarly, human colonization of the 
nasopharynx has also been shown to result in an increase in antigen-speciﬁc CD4+ 
IL-17 producing cells 12. The introduction of PCVs has also resulted in strong reduction 
of pneumococcal vaccine serotype strains in carriage, which has been suggested to 
be due to the presence of agglutinating antibodies that prevent the establishment of 
colonization 13. At present, it is not clear if these immune responses are also effective 
against the development of pneumococcal OM. Otitis-prone children have a reduced 
T helper memory response, including Th17 cells, suggesting that a functional Th17 
response is also important to protect against OM. At the same time, a reduced IgG 
response has also been identiﬁed as a risk factor for pneumococcal OM 14, suggesting 
that speciﬁc antibodies may also confer protection against OM.
Intranasal vaccination with recombinant PspA has been shown to induce protection 
against systemic infection, pneumonia and nasopharyngeal colonization in mice 15-17. 
However, to the best of our knowledge the ability of PspA to protect against OM has 
not yet been demonstrated. Using our previously-established model of inﬂuenza- 
induced pneumococcal OM 18, 19, we sought to determine whether mucosal vaccination 
with the model antigen PspA is able to induce protection against pneumococcal OM 
in a context of viral co-infection. 
METHODS
Viral and bacterial strains
The preparation and storage of S. pneumoniae for infection of mice has been 
described previously 20. Strain BHN100 (also known as ST162 21, belonging to 
serotype 19F) was used in all animal experiments. Inﬂuenza virus strain A/
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Udorn/307/72 (H3N2) (hereafter referred to as IAV) was prepared in the allantoic ﬂuid 
of embryonated chicken eggs and the virus titer was determined by three independent 
plaque assays performed on Madin-Darby canine kidney (MDCK) cells 22. 
PspA
N-terminally His-tagged recombinant PspA (rPspA) from the reference S. pneumoniae 
strain TIGR4 (SP0117) was provided by Intercell AG (Vienna, Austria) and was produced 
and puriﬁed using a similar strategy as described by Gieﬁng et al. (2008) 23. 
Vaccination and challenge
Animal experiments were approved by the Radboud university medical center 
Committee for Animal Ethics and conducted in accordance with the relevant Dutch 
legislation. All mice were housed under speciﬁc-pathogen-free (SPF) conditions at 
the Central Animal Facility at the Radboud university medical center. For vaccination 
experiments, BALB/c mice were obtained from Harlan (the Netherlands). C57BL/6 
(B6) and B6.μMT−/− mice were obtained from the Jackson Laboratories through 
Charles River Laboratories International. B6.IL17RA−/− mice 24, were bred at the 
Central Animal Facility at the Radboud university medical center. 
For immunization, naïve female 6-8 week old mice were vaccinated three times at two 
week intervals under isoﬂurane inhalation anesthesia by intranasal administration of 
5 μg of recombinant PspA, either with or without 4 μg cholera toxin subunit B (CTB, 
Sigma Aldrich) in a total volume of 10 μl PBS. Alternatively, mice were mock-treated 
with an equivalent volume of PBS.
For challenge experiments, mice were infected with 104.5 plaque forming units of IAV 
in 10 μl of PBS three weeks after the last vaccination, as described previously  Three 
days later, mice were challenged with 104 colony forming units (CFU) of BHN100 in 10 
μl of PBS. Three days after pneumococcal infection, mice were sacriﬁced and nasal 
lavages and middle ear homogenates were collected as described previously 25. 
Pneumococcal load was then quantiﬁed in the nasal lavage and in middle ear 
homogenates by plating out serial dilutions on blood agar plates containing 5 μg/ml 
of gentamicin. Following plating, nasal lavage and bulla homogenate samples were 
centrifuged for 10 min at 4 °C and 3200 x g and supernatants were stored at -20 °C 
until further analysis. Serum was obtained prior to vaccination, two weeks after the 
ﬁnal vaccination and at the conclusion of the experiment. 
Cellular immunity
For analysis of cellular responses, naïve 6-8 week old female BALB/c mice were 
vaccinated as described above. One week after the ﬁnal vaccination, mice were 
anesthetized by isoﬂurane inhalation and perfused by intracardiac injection with PBS. 
Single cell suspensions were then prepared of the spleen by meshing through a 70 
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μM sterile sieve. Lungs were collected, minced into small pieces and incubated for 1h 
at 37 °C in 1 ml of RPMI with 5% FCS, 1 mg/ml collagenase type 2 (Worthington) and 
0.02 mg/ml DNase I (Roche). Single cell suspensions were then prepared by meshing 
through a 70 μM cell strainer (BD Falcon). Following red blood cell lysis, cells were 
resuspended in RPMI + 5% FCS and 2×106 cells were transferred to U-bottom 
96-wells plates. GolgiPlug (BD Biosciences, 1 μl/ml) was added and cells were 
incubated for 3h at 37 °C and 5% CO2. Following incubation, cells were washed and 
incubated with anti-CD16/CD32 (Fc-block, BD Biosciences), followed by incubation 
with anti-CD3e-APC, anti-CD8-PE-Cy7and anti-CD4-APC-Cy7 (all BD Biosciences). 
Intracellular staining was then performed with anti-IL-17-PE (BD Biosciences) in BD 
Perm/Wash buffer according to the manufacturer’s instructions. Cells were then 
analyzed on a BD LSR-II ﬂow cytometer (BD Biosciences). FACS data was analysed 
using FlowJo software version 7.
ELISA
The IL-17 cytokine concentration in middle ear homogenates was measured using 
the mouse IL-17 ELISA MAX Standard (Biolegend), according to the manufacturer’s 
instructions.
IgA and IgG antibodies against rPspA were measured by ELISA in serum, middle ear 
homogenates and nasal lavages. Brieﬂy, 96 well Maxisorp plates (Nunc, USA) were 
coated overnight at 4 ºC with 0.6 μg/ml rPspA in PBS. For the standard curve, wells 
were plated with rat-anti-mouse Ig, ? light (Becton Dickinson, cat no. 559749). Wells 
were washed and then blocked with 1% bovine serum albumin (BSA) (Ultrapure, 
Sigma), after which samples were added in serial dilutions. To generate a standard 
curve, serial dilutions of known amounts of mouse IgA (Southern Biotech) or IgG1 
(Sigma) were included on each plate. After incubation and washing, mouse-anti-IgG-
AP (Sigma, cat no. A7434) or mouse-anti-IgA-AP (Southern Biotech, cat no. 1165-04) 
antibodies were added. Bound antibody was detected using p-Nitrophenyl Phosphate 
Disodium Salt (pnpp) (Calbiochem) substrate (pnpp tablets were dissolved in 10 mM 
diethanolamine, 0.5 mM MgCl2, adjusted to pH 9.5). 
Absorbance was measured at 405 nm with a Tecan plate reader, and data was 
analysed using Magellan software (Tecan). 
Statistical analysis
Statistical analysis was performed with a Kruskal-Wallis test accompanied by a 
Dunn’s multiple comparison posttest, or with a Mann Whitney t-test. A p value of ? 
0.05 was considered signiﬁcant. Statistical analyses were performed using GraphPad 
Prism 5.0 for Windows (GraphPad Software).
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RESULTS
Intranasal vaccination with PspA and CTB reduces pneumococcal 
load in both the nasal cavity as well as the middle ear
To investigate if mucosal vaccination with PspA induces protection against OM, mice 
were vaccinated intranasally three times at two-week intervals with PspA and CTB, 
PspA alone, CTB alone or with PBS. Three weeks after the last vaccination, mice were 
infected with IAV to facilitate secondary pneumococcal OM, similar to the strategy we 
used for IAV-induced bacterial OM by non-typeable Haemophilus inﬂuenza 25. Three 
days after IAV infection, mice were infected with S. pneumoniae BHN100 (serotype 
19F), followed by enumeration of viable S. pneumoniae in the middle ears and the 
nasal cavity three days later. We found that intranasal vaccination with PspA in the 
presence of CTB signiﬁcantly reduced the number of S. pneumoniae in both nasal 
cavity and middle ear by 78 and 18-fold respectively, as compared to the response 
to PBS alone. This reduction in bacterial load was not observed in mice vaccinated 
with either PspA or CTB alone (Figure 1A).
Vaccination with PspA and CTB induces both IgG1 and IgG2a 
antibodies to PspA
To evaluate the antibody response, PspA-speciﬁc IgA and IgG were analyzed by 
ELISA in post-vaccination, pre-challenge serum samples. Additionally, post-challenge 
nasal lavage and middle ear homogenates were analyzed for the presence of 
PspA-speciﬁc antibodies. Mice vaccinated with a combination of PspA and CTB 
showed a signiﬁcant 49-fold increase in serum PspA-speciﬁc IgA levels three weeks 
after vaccination compared to mice vaccinated with CTB or PBS (Figure 1B). A similar 
pattern was observed for the nasal lavage and the middle ear. A comparable increase 
in PspA-speciﬁc IgG was observed in the serum, nasal lavage and middle ear 
homogenates of mice vaccinated with PspA and CTB together. Surprisingly, an 
increase in PspA-speciﬁc IgG was also observed in mice vaccinated with PspA alone 
(Figure 1C).
Although immunization with PspA alone was sufﬁcient to induce anti-PspA IgG in the 
absence of co-administered adjuvant, this did not result in a reduction in 
pneumococcal load in the nasal cavity or the middle ear cavity (see Figure 1A). CTB 
has previously been shown to polarize T helper cell differentiation 26, 27 and thus may 
lead to a shift in PspA-speciﬁc IgG subtypes. To test whether different IgG subtypes 
were induced, we measured the amount of serum IgG1 and IgG2a speciﬁc for PspA 
after the ﬁnal vaccination and compared the ratio of these antibody subtypes. Figure 
1D shows that vaccination with PspA and CTB induced high amounts of both 
PspA-speciﬁc IgG1 and IgG2a, whilst vaccination with PspA alone predominately 
induced IgG1 but virtually no IgG2a.
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Vaccination with PspA and CTB induces a mucosal CD4+IL17+  
T cell response
Next, we analyzed whether mucosal vaccination with PspA resulted in the induction 
of mucosal CD4+ IL17-producing T cells, which have previously been shown to be 
associated with protection against pneumococcal colonization 11. For these 
experiments, we used an identical vaccination setup as described above. However, 
instead of challenging with IAV and S. pneumoniae, one week after the third 
vaccination we analyzed the mucosal and systemic cellular response. Flow cytometry 
analyses of the lungs and spleen showed a signiﬁcant increase in pulmonary 
CD3+CD4+IL17+ cells in mice vaccinated with PspA and CTB compared to mice 
vaccinated with CTB or PBS. In contrast, we found that mucosal vaccination did not 
result in the induction of CD3+CD4+CD8-IL17+ cells in the spleen (Figure 2). 
IL-17 signaling is associated with protection to OM 
To determine the role of IL-17 and antibodies in the observed reduction of the 
pneumococcal load, wildtype C57BL/6(B6) mice, B6 mice deﬁcient in IL-17 signaling 
(B6.IL-17RA-/-) 24 and B6 mice deﬁcient in antibody production (B6.μMT-/-) 28 were 
vaccinated with PspA and CTB and challenged with IAV and S. pneumoniae, as 
described above. Three days after challenge a signiﬁcant increase in pneumococcal 
load in the nasal cavity of IL-17 receptor A deﬁcient mice was observed compared to 
wildtype B6 mice (Figure 3A). A similar trend was observed for the pneumococcal 
load in the ears, although this did not reach statistical signiﬁcance (p>0.05, Figure 3A). 
No reduction in pneumococcal load was observed in the μMT-/- mice compared to 
B6 mice, although there was a trend towards increased CFUs in the nose and a 
reduction of CFUs in the ears. 
Next, we measured the IL-17 levels in the middle ears of the μMT mice versus the 
wild-type mice. Although the difference was small, we observed that the μMT mice 
had signiﬁcantly lower levels of IL-17 (p=0.04) in their middle ears as compared to 
wild-type mice (Figure 3B).
We then analyzed the amount of PspA-speciﬁc IgG and IgA in post-vaccination, 
pre-challenge serum samples, and in post-challenge nasal lavage and middle ear 
homogenates. Antibody levels of the μMT-/- mice were below detection, as expected 
(data not shown). No difference was observed for the IgG antibody levels of the IL17 
RA knockout mice as compared to the wild-type mice (Figure 3C). Surprisingly, the 
IgA antibody levels for the IL17 RA knockout mice were signiﬁcantly higher than in the 
wild-type mice in serum and middle ear homogenates, but not in the nose lavages 
(Figure 3D). 
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Figure 3. Vaccination of IL-17 receptor knockout mice abrogates protection against S. 
pneumoniae in both ears and nose, in contrast to μMT-/- mice. Wildtype C57BL/6, B6.
IL-17RA-/- and B6.μMT-/- mice were vaccinated with PspA and CTB and challenged with IAV and 
S. pneumoniae as described above. A. Mice were sacriﬁced three days after challenge and the 
pneumococcal load was determined in post-challenge middle ear homogenates and nasal 
lavage. Statistics was performed using a Kruskal Wallis test accompanied by a Dunn’s multiple 
comparison posttest (p<0.05). Statistical signiﬁcance is denoted by one or two asterisks 
(p<0.05 and p<0.01, respectively). Only the statistically signiﬁcant comparisons are shown. 
Horizontal lines indicate the geometric mean of the group values. B. IL-17 levels were measured 
by ELISA in post-challenge middle ear homogenates. Statistics was performed using a 
Mann-Whitney t-test. Statistical signiﬁcance is denoted by one asterisk (p<0.05). C&D. ELISA 
was used to determine PspA-speciﬁc IgG (C) and IgA (D) in post-vaccination, pre-challenge 
serum samples, as well as in clariﬁed post-challenge nasal lavage and middle ear homogenates. 
A Mann Whitney t-test was performed to test for statistical signiﬁcance. Statistical signiﬁcance 
is denoted by three asterisks (p<0.001).
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DISCUSSION
Even though the incidence of bacterial OM under children remains enormous in both 
underdeveloped and developed countries, there is still no vaccine that effectively 
reduces bacterial OM. Importantly, 28-70% of all OM cases are induced by a bacterial- 
viral co-infection 2. We have previously shown that inﬂuenza-induced secondary 
pneumococcal OM in mice shows many similarities with the clinical course of acute 
OM in humans, including the induction of local inﬂammation and hearing loss 18, 19. 
Inﬂuenza A virus is well-known to modulate the host immune response. Since an 
effective OM vaccine should also provide protection under these conditions, we 
studied mucosal vaccination in this context. Mucosal vaccination studies against S. 
pneumoniae almost exclusively focus on nasopharyngeal colonization or clearance 
of the airways as the critical endpoint 15, 16, 29, 30. Using a clinically relevant model, we 
show that intranasal vaccination of mice with the pneumococcal antigen PspA and 
the mucosal adjuvant CTB resulted in protection against inﬂuenza virus-induced 
pneumococcal OM.
We found that vaccination with PspA and CTB, but not with either PspA or CTB alone, 
conferred heterologous protection against a challenge infection with pneumococcal 
strain BHN100 in both the nasal cavity and the middle ear. Although both the TIGR4 
strain and the BHN100 strain belong to the same PspA clade (clade 3), they differ 
approximately 70% in their amino acid sequence and it is likely that protection will be 
further enhanced in the case of a homologous challenge. 
Vaccination with PspA and CTB resulted in a reduction in pneumococcal load in the 
middle ears of more than 1 log, as compared to vaccination with CTB alone (p<0.05). 
Although mucosal vaccination with PspA and CTB did not induce complete clearance, 
it should be noted that several clinical studies have recently found a strong correlation 
between a modestly increased nasopharyngeal pneumococcal density (0.9 log) and 
Figure 3. Continued. 
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the development of a more severe clinical outcome 31, 32. This may imply that restriction 
of the pneumococcal density may favor a better clinical outcome. Moreover, we used 
an experimental challenge dose that is likely to be much higher than during natural 
exposure in humans. The observed reduction in bacterial load was accompanied by an 
increase in PspA-speciﬁc IgA and IgG in the middle ear, suggesting that antibodies were 
involved in protection. Interestingly, similar to what was observed in other studies 15, 16, 
we found that PspA by itself also induced speciﬁc mucosal and systemic IgG, 
suggesting intrinsic adjuvant-activity of this antigen. Nevertheless, protection against 
pneumococcal OM was only observed when PspA was administered together with 
CTB.
Analysis of IgG subtype distribution showed that vaccination with PspA resulted in 
signiﬁcantly lower total amounts of IgG2a. A low and balanced PspA-speciﬁc 
IgG1:IgG2a ratio, as induced by CTB and PspA together, has previously been shown 
to be important for protection 16, 33 Different IgG subclasses differ in their afﬁnity to 
bind to the different Fc? receptors 34, which could have a subsequent effect on the 
phagocytic capacity, and thereby the ability to kill the opsonized bacteria. Additionally, 
IgG subclasses are known to differ in their ability to activate complement by binding 
of C1q to the Fc domain. In mice, IgG subclass IgG2a and IgG2b activate complement, 
while IgG1 does not 35. In addition, several studies indicated that complement might 
play an important role in protection against bacterial OM 25, 36. The induction of com-
plement-binding PspA-speciﬁc IgG2a might therefore be important in the protection 
against OM.
Although the induction of a balanced IgG response was associated with protection in 
wildtype mice, no difference in protection was observed in antibody-deﬁcient B6.
μMT-/- mice. Indeed, middle ear bacterial load was even slightly reduced in the 
absence of antibodies, which is in accordance with our previous study 37 in which we 
showed that the presence of non-speciﬁc antibodies can actually enhance 
pneumococcal OM in unvaccinated mice by inducing NET formation in the middle 
ear. In contrast, an opposite trend towards increased bacterial load was observed in 
the nasal cavity of vaccinated B6.μMT-/-, highlighting the complex and niche-speciﬁc 
roles of antibodies in the interaction with S. pneumoniae. Clinical studies show that 
otitis-prone children have lower serum levels of IgG to S. pneumoniae 14, 38 and 
anti-capsular IgG antibodies have been implicated in herd-immunity against vaccine 
serotypes 13. Thus, antibodies may be able to prevent the acquisition of pneumococcal 
colonization, but once colonization has been established it is possible that their 
protective effects against pneumococcal OM are limited. 
Vaccination of wildtype mice with PspA and CTB resulted in the induction of a 
mucosal Th17 response. Further experiments in B6.IL-17RA-/- mice demonstrated that 
IL-17 signaling is not only essential in protection against colonization, as shown 
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previously by the group of Malley 11, but also against pneumococcal OM. We also 
observed a small but signiﬁcant difference in the IL-17 levels in the middle ears of the 
μMT mice as compared to wild-type mice. Although it is unclear what the biological 
signiﬁcance of the differences between the mouse strains is, these observations 
demonstrate that IL-17 is also produced in the middle ear cavity in response to 
infection and that it is likely involved in protection against inﬂuenza-virus induced 
pneumococcal OM. This is supported by the study of Rosch et al., who showed that 
protection against OM in mice vaccinated with live attenuated pneumococci was 
correlated with a speciﬁc IgG2a, IgG2b and IgA response and that CD4+ T cells were 
essential in this protection 39. In addition, our data indicates that abrogation of IL-17 
receptor signaling can also inﬂuence PspA-speciﬁc IgA antibody levels, which could 
also play a role in the observed increase in CFUs. Finally, it should be noted that no 
littermate controls were used in this study, which could potentially have inﬂuenced the 
outcome.
Taken together, our data points to an important role for IL-17 in the protection against 
inﬂuenza-virus induced pneumococcal OM. Our data further suggest a role for IgG2a 
antibodies in limiting bacterial load in the middle ears, possibly through activation of 
the complement pathway. Following establishment of colonization, we hypothesize 
that the IL-17 response is the most important factor in protection against OM. 
Considering that bacterial OM remains one of the most common reasons for children 
to visit a physician and receive antibiotic treatment, the development of an effective, 
safe, cross-protective vaccine against pneumococcal OM would be a major step 
forward. 
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ABSTRACT
Despite the availability of effective vaccines, the respiratory pathogen Streptococcus 
pneumoniae is still a major problem. Early clearance of pneumococci from the lungs 
is thought to occur through opsonophagocytosis by resident alveolar macrophages. 
Here, we studied whether pre-existing antibodies may have indirect effects on the 
early clearance of pneumococcal pneumonia by affecting the inﬂammatory response. 
Using an in vitro model of PBMCs and alveolar macrophages from healthy human 
volunteers, we demonstrate that alveolar macrophages conditioned with supernatant 
of PBMCs stimulated with IgG-opsonized pneumococci are less able to kill 
pneumococci compared to macrophages conditioned with supernatant of PBMCs 
stimulated with S. pneumoniae alone (p<0.0001). Analysis of cytokine production 
showed a strong IgG-dependent skewing from IL-17 towards IFN? production 
(p<0.0004) and an early shift towards a pro-inﬂammatory environment, i.e. an 
increase in IL-1? (p<0.0004) and a decrease in IL-10 production (p<0.0004). Further 
analysis by ﬂow cytometry analysis identiﬁed a strong increase in proliferating and 
IFN?-producing NK cells (p<0.0004). Inhibition of actin-dependent phagocytosis 
nearly completely blocked the IgG-dependent enhancement of IFN? production 
(p<0.0004), suggesting that active uptake is required. To summarize, our data 
provides novel insights into how antibodies may modulate the inﬂammatory response 
to S. pneumoniae infection and subsequent clearance by phagocytes.
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INTRODUCTION
Despite the availability of effective vaccines, the respiratory pathogen Streptococcus 
pneumoniae (the pneumococcus) still causes 0.7 million deaths each year, worldwide 1. 
The ﬁrst step towards the development of pneumococcal disease is colonization of 
the nasopharynx, after which dissemination to the middle ear, lungs, blood and/or the 
brain can occur. Early clearance of pneumococci from the lungs is thought to occur 
through opsonophagocytosis by resident alveolar macrophages 2-5. Here, we studied 
whether pre-existing speciﬁc antibodies may have indirect effects on early clearance 
of pneumococcal pneumonia by affecting the inﬂammatory response.
Alveolar macrophages (AM) are resident phagocytes in the lungs that have an 
important function in the recognition and clearance of invading pneumococci, in 
particular during subclinical infection. In this setting, invading bacteria are cleared 
without the subsequent emergence of clinical features of pneumonia 3, 4. Besides 
AMs there are also other local and recruited immune cells that are known to play a 
role in pneumococcal clearance, including T cells, neutrophils and B cells. For 
instance, IL-17-producing CD4+ T cells have been suggested to play an important 
role in the clearance of colonizing S. pneumoniae, by activating epithelial cell 
responses. IL-17 has further been shown to enhance killing of internalized bacteria by 
resident and recruited phagocytes, such as macrophages and neutrophils 6-9. 
Because most people will have experienced multiple episodes of pneumococcal 
colonization by the age of ﬁve 10, 11, early clearance of pneumococci by alveolar 
macrophages can also occur in the presence of pre-existing anti-pneumococcal 
antibodies. In sufﬁcient quantities, opsonizing antibodies can directly prevent the 
pathogen from attachment to the respiratory epithelium 12. Antibodies may also 
enhance the uptake and killing of pneumococci by phagocytes 5, 13-15. Similarly, the 
production of IL-17 by pneumococcus-speciﬁc CD4+ T cells has also been shown to 
facilitate pneumococcal internalization and killing 9. 
Although there is a wealth of data concerning the direct effects of antibodies on 
S. pneumoniae, little is known of the potential indirect effects of pneumococcus- 
speciﬁc antibodies on the inﬂammatory response to pneumococcal infection and 
bacterial clearance. For instance, opsonizing IgG antibodies can also signal to 
various Fc? receptors on immune cells and thereby affect the subsequent 
inﬂammatory response 16. To study these effects, we established an in vitro model 
using immune cells from human volunteers that had been experimentally challenged 
with S. pneumoniae and who had cleared the infection. AMs conditioned with culture 
medium from PBMCs that were stimulated with IgG-opsonized pneumococci showed 
a reduced killing capacity as compared to stimulation with non-opsonized bacteria. 
Further stimulation experiments showed that IgG strongly skews the immune 
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response from IL-17 production towards a pro-inﬂammatory response and IFN? 
production by NK cells. 
METHODS
Bacterial strains
S. pneumoniae TIGR4 (obtained from Prof. H. Tettelin 35) was cultured in Todd Hewitt 
Broth (Becton Dickinson, New Jersey, USA) supplemented with 0.5% yeast extract 
(Becton Dickinson) (THY medium), to an OD660 of 0.3. Bacteria were then cooled on 
ice, washed three times with PBS (Lonza, Basel, Switzerland), killed by heat-inactiva-
tion for 30 min at 65ºC and stored at -80ºC. 
S. pneumoniae strain 6B (BHN418) was cultured in Vegitone infusion broth (Fluka 
41860, Sigma-Aldrich, Missouri, USA) for human intranasal inoculation or in THY for 
the alveolar macrophage killing assay. Bacteria were cultured at 37˚C with 5% CO2 
until early log phase and were stored at -80°C.
For all experiments heat-inactivated S. pneumoniae was used, with the exception of 
the macrophage killing assay, for which live S. pneumoniae strain 6B (BHN418) was 
used.
AM conditioning and killing assay
Blood samples and bronchoalveolar lavages (BAL) were collected from volunteers 
enrolled in one of the Experimental Human Pneumococcal Carriage studies 2. Ethical 
approval was given by the National Health Service Research Ethics Committee (REC 
Ref 12/NW/0873). Blood samples were collected 21 days after nasal inoculation with 
live S. pneumoniae strain 6B. PBMCs were isolated and stimulated for 5 days with 
medium, IgG, heat-killed Sp (strain 6B) and heat-killed Sp opsonized with IgG, as 
described below. PBMC-stimulated supernatant of 6 donors was pooled together for 
each condition, which was used for ﬁve of the killing assays. For the remaining killing 
assays supernatant of single PBMC stimulations was used. BAL was obtained three 
months after pneumococcal inoculation as previously described 9. AMs were pelleted 
(440g for 10 min at 4˚C), resuspended in RPMI 1640 (Gibco, Thermo Fisher Scientiﬁc) 
containing 10% FBS (Heat-inactivated, Gibco) and 1% antibiotics (Penicillin, 
Neomycin and Streptomycin, Sigma-Aldrich) (hereafter referred to as complete 
RPMI) and 5×105 AM/well were added  to 24-well ﬂat bottom plates (Greiner Bio-One, 
Kremsmünster, Austria). After 4 hr adherence the AM were washed with complete 
RPMI, following overnight incubation at 37˚C with 5% CO2. AMs were then washed 
once with complete RMPI and conditioned with 50 μl of culture supernatant from 
PBMCs stimulated with either Sp alone or IgG-opsonized Sp for 5 hours, after which 
the cells were used in an opsonophagocytic killing assay (OPKA), as previously 
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 93
93
IgG skews immunity to NK-derived IFN-gamma
5
described 9, 36, with minor modiﬁcations. Brieﬂy, live pneumococci were opsonized in 
a 1:16 dilution of intravenous immunoglobulin (IVIG, Gamunex, Grifols Inc, Spain) in 
HBSS +/+ (with Ca2+ Mg2+). AMs were washed twice with RPMI without antibiotics, 
and incubated for 1hr with the opsonized pneumococci in HBSS +/+ with 0.9% gelatin, 
4.5% FBS and 10% complement (baby rabbit complement, Mast Group) at 37˚C on 
a shaking rotor. Multiplicity of infection used was 1 pneumococcus to 100 AM. 10 μl 
of the suspension was plated onto blood agar plates (Columbia blood agar, Oxoid, 
Thermo Scientiﬁc) in triplicates and the plates were incubated overnight at 37ºC and 
5% CO2. The following day the killing index was determined using the equation: “ 
Killing index (%) = 100 – [(100*Condition)/Control] “, where ‘Condition’ represents the 
average of colony forming units (CFUs) recovered from each experimental condition 
and ‘Control’ represents the average CFU recovered from the bacterial dose (received 
only bacteria, no cells).
Isolation of PBMCs and stimulation assays
For further stimulation experiments, blood was drawn from healthy volunteers upon 
written informed consent in Monoject EDTA tubes (Covidien Ltd, Dublin, Ireland). The 
PBMC fraction was isolated by density gradient centrifugation using Lymphoprep 
(Axis-Shield Diagnostics, Dundee, UK). Blood was diluted using an equivalent 
volume of PBS (Lonza), added on top of the Lymphoprep and centrifuged at 750g 
without using the brake. PBMCs were harvested, washed three times with PBS and 
resuspended in serum free culture medium (X-VIVO 15, Lonza) with 1% Penicillin/ 
Streptomycin (P/S) (Gibco, Thermo Fisher Scientiﬁc, Waltham, USA). 
A total of 5×105 cells/well were added to round bottom 96-well plates (Nunc cell 
culture treated, Thermo Fisher Scientiﬁc). Heat-killed S. pneumoniae (Sp) (multiplicity 
of infection of 10 for each cell) was resuspended in X-VIVO 15 medium (Lonza) + 1% 
P/S. IgG (Nanogam, Sanquin, Amsterdam, Netherlands) was dialysed against PBS 
using a Pierce Slide-A-Lyzer Dialysis Cassette (Thermo Fisher Scientiﬁc), added to 
the Sp at a concentration of 10 mg/mL and incubated for 1 hr at 37ºC before PMBCs 
were added. After 24 hr and after 7 days, plates were centrifuged at 450g for 10 min, 
and supernatants were harvested and stored at -20ºC for subsequent cytokine 
measurements. For inhibition of actin-dependent phagocytosis, PBMCs were 
incubated with 2 μg/mL cytochalasin D (Sigma-Aldrich) for 1 hour at 37ºC, before 
stimuli were added to the cells. 
Antibody opsonization of S. pneumoniae
Following incubation of S. pneumoniae with IgG, surface binding of IgG was determined 
by ﬂow cytometry. IgG-opsonized bacteria were washed and incubated with 1:100 
goat anti-human IgG (? chain speciﬁc)-FITC (F0132, Becton Dickinson), after which 
opsonization was measured on a LSR-II ﬂow cytometer (Becton Dickinson).
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ELISA
Cytokine concentrations were measured in the cell supernatants by commercial 
ELISA kits. TNF?, IL-1?, IFN?, and IL-10 kits were obtained from Pelikine Compact 
(Sanquin). The IL-17 ELISA kit was obtained from R&D Systems (Minneapolis, USA). 
A HydroSpeed plate washer (Tecan, Männedorf, Switzerland) was used and Magellan 
software (Tecan) was used to analyse the data.
Flow cytometry analysis of cellular responses
For ﬂow cytometry analysis of cellular responses, PBMCs were stimulated as 
described above. After 7 days, PBMCs were re-stimulated with 12.5 ng/mL PMA 
(Sigma-Aldrich), 5 μg/mL Brefeldin A (Sigma-Aldrich) and 500 ng/mL ionomycin 
(Sigma-Aldrich) for 4 hours at 37ºC and 5% CO2. Cells were then stained with ﬁxable 
viability dye-eF-780 (FVD, eBioscience, Thermo Fischer Scientiﬁc) for 30 min, followed 
by surface staining, ﬁxation/permeabilization (Intracellular Fixation & Permeabiliza-
tion Buffer Set, eBioscience, Thermo Fischer Scientiﬁc) and intracellular staining. The 
following antibodies were used: a-CD3-Paciﬁc Blue, a-CD4-PC5.5, a-CD8-APC-
AF700, a-CD56-ECD, KI67-AF488 (all Beckman-Coulter, Brea, California, USA) and 
a-IFN?-PE-Cy7 (eBioscience, Thermo Fischer Scientiﬁc). Cells were analyzed on a 
Beckman Coulter Navios ﬂow cytometer (Beckman-Coulter) and ﬂow cytometry data 
were analyzed using Kaluza software (version 1.5a, Beckman-Coulter). Cells were 
ﬁrst gated on singlets, then on viability and subsequently a lymphocyte gate was set 
in the SSC vs FSC plot after which NK cells (CD3-CD56+), CD4+ cells (CD3+CD4+CD8-) 
and CD8+ cells (CD3+CD4-CD8+) were gated.
Statistical methods
The data of Figure 1 was analyzed using a paired t-test. Statistics was performed 
using Graphpad (V5). Data of Figure 2, 3 and 4 were analyzed using a three way 
ANOVA after logarithmic transformation. Statistical analysis on this data was 
performed on LN-transformed values. For the graphs, all values were transferred 
back to the original scale of measurement, giving geometric means and 95% 
conﬁdence intervals. Pair wise comparisons were performed by comparing all groups 
with each other. Statistical signiﬁcance is denoted with one (p<0.05), two (p<0.01) or 
three asterisks (p<0.001) and is only shown (if signiﬁcant) for the comparisons 
[mock] versus [IgG] or [Sp], [Sp] versus [Sp + IgG] and [IgG] versus [Sp + IgG] in 
ﬁgure 2 and 3. For ﬁgure 4 the statistical signiﬁcance is shown for the comparisons 
[mock] versus [IgG] or [cytD] or [IgG + cytD] and [Sp] versus [Sp + IgG] or [Sp + 
cytD] or [Sp + cytD + IgG]. Statistics was performed using SPSS (V22), graphs were 
made using Graphpad (V5) and Adobe Illustrator (CS6). 
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RESULTS
Attenuation of pneumococcal killing by alveolar macrophages
Both local and recruited phagocytes play an important role in the mucosal clearance 
of S. pneumoniae 17. In order to examine whether the presence of pre-existing IgG 
could affect the inﬂammatory response to S. pneumoniae and the subsequent killing 
capacity of alveolar macrophages, we used PBMCs and AMs from human volunteers 
enrolled in an experimental pneumococcal carriage model 2. PBMCs were isolated 
from human volunteers 21 days after they were challenged by intranasal pneumococcal 
inoculation. AMs were isolated from the BAL up to 3 months after challenge. 
To mimic the inﬂammatory response PBMCs were stimulated in vitro with heat killed 
S. pneumoniae alone or heat-killed S. pneumoniae that was pre-incuabated with IgG 
for 1 hr. After 5 days, PBMC culture medium was harvested and pooled according to 
each stimulation condition. These culture supernatants were then used to condition 
AMs, followed by a pneumococcal killing assay. We found that AMs primed with the 
culture supernatant of PBMCs that were stimulated with IgG-opsonized Sp had a 
signiﬁcantly reduced capacity to kill pneumococci, as compared to the supernatant 
of PBMCs stimulated with Sp alone (p<0.0001) (Figure 1). 
Figure 1. Conditioning of alveolar macrophages with the supernatant of PBMCs stimulated 
with IgG-opsonized S. pneumoniae attenuates their capacity to kill S. pneumoniae. Percent of 
S. pneumoniae killed by alveolar macrophages conditioned with the supernatant of PBMCs that 
were stimulated with IgG-opsonized S. pneumoniae in comparison to S. pneumoniae alone (n=12). 
Statistics was performed using a paired t-test.
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IgG skews the inflammatory response to S. pneumoniae towards 
IFN? production
Next, we examined which factors in the PBMC supernatant could be responsible for 
the observed IgG-dependent attenuation in the killing capacity of alveolar macro - 
phages. PBMCs that were obtained from healthy volunteers were stimulated for 
seven days as described previously, after which IL-17, IFN? and IL-10 levels were 
measured by ELISA. Pneumococcal opsonization was validated by ﬂow cytometry 
(supplemental ﬁgure S1). IL-10 levels were near detection limit concentrations (data 
not shown). Stimulation with S. pneumoniae in the absence of antibodies resulted in 
IL-17 production, as described previously 7, 18. Unexpectedly, we found complete 
suppression of IL-17 production (p<0.0004) in response to pneumococcal stimulation 
in the presence of IgG (Figure 2A). This suppression was accompanied by a 
signiﬁcant 24-fold increase (p<0.0004) in IFN? production (Figure 2B). 
Co-stimulation with IgG induces an early pro-inflammatory response
To determine whether the presence of IgG also affected the inﬂammatory response 
to S. pneumoniae, we repeated the PBMC stimulation described above. After 24 hr, 
ELISA was performed on cell supernatants to detect the production of IL-1?, TNF?, 
IL-6 and IL-10. No differences were observed for IL-6 production in the presence of 
antibodies (Figure 2F). Although stimulation with IgG alone resulted in the induction 
of TNF? (p=0.048) compared to medium (Figure 2D), none of the other cytokines 
showed a response to stimulation with IgG alone. In contrast, we found that the 
production of IL-1? was increased 5-fold (p<0.0004) following co-stimulation of 
PBMCs with S. pneumoniae and IgG, as compared to stimulation with Sp alone 
(Figure 2C). This IgG-dependent increase of the pro-inﬂammatory cytokine IL-1? was 
accompanied by a 5-fold lower production of the anti-inﬂammatory cytokine IL-10 
(p<0.0004) (Figure 2E). Together, these results point to the induction of a pro- 
inﬂammatory response. 
Immunoglobulins activate natural killer cells to proliferate  
and produce IFN? 
To identify the source of the IgG-dependent increase in IFN? production, we 
stimulated PBMCs as described above and performed ﬂow cytometry analysis. 
Following 7 days incubation, PBMCs were re-stimulated with PMA and ionomycin for 
4 hr in the presence of brefeldin A to allow accumulation and detection of intracellular 
cytokines. Cells were then stained and analyzed by ﬂow cytometry. Stimulation of 
PBMCs with Sp in the presence of IgG resulted in a signiﬁcant increase in IFN?+ CD3- 
CD56+ NK cells (GM of 30% IFN?+ of CD3-CD56+ cells) as compared to stimulation 
with Sp alone (GM of 0.9% IFN?+ of CD3-CD56+cells) (p<0.0004) (Figure 3A, 3B). A 
small but signiﬁcant increase in IFN?+ CD4+ cells was also observed following 
co-stimulation with Sp and IgG as compared to Sp alone (p=0.016); however, this 
was still lower than the mock-treated PBMCs, suggesting this ﬁnding is not biologically 
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Figure 2. Stimulation of PBMCs with Sp in the presence of IgG increases IFN? and 
suppresses IL-17 production, and induces a pro-inﬂammatory response. PBMCs were 
stimulated with medium, IgG, heat killed S. pneumoniae (Sp) or Sp with IgG. After seven days 
IL-17 (A) and IFN? (B) concentrations were determined in the supernatant by ELISA (n=5-16 
individual donors), while after 24 hr the concentration of IL-1? (C), TNF? (D), IL-10 (E) and IL-6 
(F) was measured in the supernatant by ELISA (n=5-11 individual donors). Bars show the 
geometric mean value of each treatment group with 95% conﬁdence intervals. Statistical 
signiﬁcance was analyzed using a three way ANOVA after logarithmic transformation. * 
indicates p<0.05, ** indicate p<0.01 and *** indicate p<0.001. The dashed line indicates the 
lower detection limit of the assay.
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relevant. A similar pattern was observed for IFN?+ CD8+ T cells, where the GM for the 
mock-treated PBMCs was also higher than the IgG, Sp or IgG with Sp stimulated cells.
Figure 3.  Stimulation of PBMCs with S. pneumoniae in the presence of IgG increases NK 
cell proliferation and IFN? production. Flow cytometry of Ki-67 versus IFN? staining of NK 
(CD56+), CD4+ and CD8+ T cells at seven days after PBMC stimulation with medium, IgG, heat 
killed S. pneumoniae (Sp) or Sp with IgG, following restimulation with PMA and ionomycin in the 
presence of Brefeldin A. (A) Representative FACS plots of one donor for NK cells (CD56+ CD3-), 
CD4 T cells (CD3+CD4+CD8-) and CD8 T cells (CD3+CD4-CD8+). Numbers in top right 
quadrants indicate percent IFN?+ Ki-67+ dividing cells (B) Cumulative data showing the 
percent IFN?+ cells of NK, CD4+ and CD8+ cells (n=5-11 individual donors). (C) Cumulative 
data of the percent IFN?+ Ki-67+ NK, IFN?+ Ki-67+ CD4+ and IFN?+ Ki-67+ CD8+ cells of the 
total lymphocytes (n=5-11 individual donors). Statistical signiﬁcance was determined using a 
three way ANOVA after logarithmic transformation. Shown are the geometric means of the 
group values with 95% conﬁdence intervals. p<0.05, ** indicate p<0.01 and *** indicate 
p<0.001.
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Co-stimulation with Sp and IgG increased the percentage of proliferating IFN?+ NK 
cells (CD3-CD56+ IFN?+ KI67+) by 36-fold as compared to stimulation with Sp alone 
(p<0.0004) (Figure 3C). Whilst proliferation of IFN?+ CD4+ and CD8+ T cells was also 
observed after co-stimulation with Sp and IgG, this effect was much more pronounced 
for NK cells (GM of 1.02% IFN?+ KI67+ NK cells, 0.15% IFN?+ KI67+ CD4+ cells and 
0.05% IFN?+ KI67+ CD8+ cells of total lymphocytes). To summarize, the presence of 
IgG strongly induced the percentage of proliferating IFN? positive NK cells in 
response to stimulation with S. pneumoniae.
The IgG-dependent polarization towards IFN? production is 
dependent on phagocytosis
To determine if phagocytosis played a role in the skewing towards IFN?, PBMCs were 
stimulated as described above, with the exception that cytochalasin D (cytD) was 
added prior to stimulation to inhibit actin-dependent phagocytosis. To rule out any 
effects of cytD on surface-signaling, IL-1?, TNF?, IL-10 and IL-6 were measured in the 
supernatant after 24 hr incubation, while IFN? and IL-17 were measured after seven 
days incubation. 
Treatment with cytochalasin D did not affect the production of TNF? and IL-6 to heat 
killed S. pneumoniae after 24 hr and marginally reduced IL-1? and IL-10 production 
(fold changes of -1.8 and -2.1 respectively). This suggests that the early production of 
these cytokines is largely independent of phagocytosis (Figure 4A). Similarly, cytD 
treatment of PBMCs did not result in major differences in early cytokine production 
when cells were stimulated with S. pneumoniae in the presence of IgG (1.9 fold 
increase for IL-10), with the exception of IL-6 (4.1-fold increase, p=0.005).
IL-17 production to S. pneumoniae after 7 days was completely suppressed in the 
presence of cytD (Figure 4B) (fold change -6.0, p<0.0004), suggesting that this 
process, as expected, is dependent on phagocytosis and subsequent antigen 
presentation. IFN? production after stimulation with S. pneumoniae alone was very 
Figure 3.  Continued.
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low and not affected by cytD. Conversely, the increased production of IFN? that was 
seen following co-stimulation with IgG and S. pneumoniae was almost completely 
suppressed in the presence of cytD (fold change -5.8, p<0.0004), suggesting that 
the IgG-dependent polarization towards IFN? production is dependent on 
phagocytosis.
Figure 4. The IgG-dependent increase in IFN? production is dependent on phagocytosis. 
PBMCs were incubated for 1 hr with medium or cytochalasin D (cytD), followed by stimulation 
for 24 hr or 7 days with medium, IgG, heat killed S. pneumoniae (Sp) or Sp with IgG (n=5 
individual donors). At 24 hr after stimulation, IL-1?, TNF?, IL-10 and IL-6 were measured by 
ELISA in the supernatant (A). IL-17 and IFN? were measured by ELISA in the supernatant after 
7 days incubation. (B). Shown are the geometric means of the group values with 95% conﬁdence 
intervals. Statistical signiﬁcance was analyzed using a three way ANOVA after logarithmic 
transformation. * indicates p<0.05, ** indicate p<0.01 and *** indicate p<0.001. The dashed 
line indicates the lower detection limit of the assay.
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DISCUSSION
Alveolar macrophages are thought to play an essential role in the clearance of 
pneumococci from the lung during early pneumococcal infection 3, 4. Our data 
suggests that the presence of pre-existing IgG can affect the inﬂammatory response 
and attenuate clearance by AMs, at least in vitro. We show that in the presence of IgG, 
the immune response to S. pneumoniae is skewed from a more IL-17-biased response 
towards a more pro-inﬂammatory IFN? NK-cell response. These results demonstrate 
that there is signiﬁcant interaction between the humoral and cellular parts of 
the immune response to S. pneumoniae, which may have an impact on in vivo 
pneumococcal clearance. 
Although further studies are required to validate whether these ﬁndings can be 
extrapolated to an in vivo setting, there is evidence from previous studies that 
supports a role for IFN? in attenuating pneumococcal clearance. In a murine 
model of pneumococcal meningitis, treatment with anti-IFN? antibody increased 
survival of infected mice 19 and IFN?-/- mice were protected from severe pneumococcal 
meningitis 20. Similarly, IFN? receptor deﬁcient mice had signiﬁcantly fewer pneumococci 
in their lungs compared to wt mice 21.   Additionally, high production of IFN? has also 
been shown to reduce phagocytosis and killing of S. pneumoniae by alveolar 
macrophages 22, 23. In contrast, there is also some evidence suggesting that the 
production of IFN? can also be beneﬁcial. Deﬁciency of the NK cell activating receptor 
NCR-1 in mice resulted in decreased lung IFN? production and increased 
pneumococcal load in the lungs 24, while deﬁciency of the NK cell transcriptional 
regulator FHL2 in mice, lead to a decrease in IFNy production and decreased survival 
after pneumococcal infection 25. It is possible that the exact contribution of NK cells 
and IFN? to pneumococcal clearance differs based on the site of infection as well as 
the presence or absence of pre-existing immunity in the form of antibodies or T cells. 
Whereas high IFN? concentrations may reduce bacterial uptake and killing, IL-17 
plays an opposite role in that it can facilitate phagocytosis in human macrophages 26. 
It is therefore likely that the combined effect of high IFN? and low IL-17 levels are 
responsible for the observed reduced killing capacity of alveolar macrophages. 
Flow-cytometry showed strong proliferation of IFN?-producing NK cells in response 
to stimulation with IgG-opsonized pneumococci, an effect that was also observed in 
CD4+ and CD8+ T cell subsets but to a much lower extent. Although NK cells have not 
frequently been studied in the context of pneumococcal infection, there is increasing 
evidence that NK cells and IFN? may attenuate the clearance of S. pneumoniae. For 
instance, depletion of NK cells in mice prolonged their survival due to reduced 
pneumococcal replication in the lungs 27. 
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Stimulation of PBMCs with S. pneumoniae in the presence of IgG also increased 
production of IL-1? and suppressed IL-10, suggestive of a pro-inﬂammatory response. 
IL-10 is known to suppress NK cell stimulation and IFN? production 28 and can inhibit 
TNF? and IL-1? production 29. The decrease in IL-10 may therefore explain the 
increased production of IL-1? in the presence of both IgG and S. pneumoniae and the 
skewing towards IFN?-production, although it is also possible that these events occur 
independent from each other through an alternate mechanism. Although IL-1? is 
typically also associated with the induction of a Th17 response 30, 31, this was not the 
case in our setting. A previous study using co-cultures of monocyte-derived dendritic 
cells and CD4+ T cells also found increased IL-1? production following co-stimulation 
with IgG and S. pneumoniae 32. However, in contrast to our ﬁndings, Den Dunnen and 
colleagues found that this led to increased IL-17 production. Interestingly, a major 
difference in experimental design is the presence of NK cells in our study, which can 
be an important source of IFN?. NK cells represent roughly 10% of all lymphocytes in 
healthy lungs 33 and it is therefore likely that activation of these cells in an antibody- 
dependent manner can modulate the local response. Since the IgG-dependent 
production of IFN? was already observed 24 hours after stimulation (data not shown), 
it is likely that this may inhibit IL-17 production.
In order to study the involvement of actin-dependent uptake and subsequent anti-
gen-presentation, PBMCs were treated with cytochalasin D prior to stimulation. The 
results from these experiments show that the IgG-dependent shift towards IFN? 
production by NK cells was dependent on phagocytosis. This may suggest that anti-
gen-presenting cells are involved in this process, potentially through cross-talk with 
NK cells. An alternative explanation is that IgG has a direct effect on the NK cells, e.g. 
through Fc? receptor CD16, possibly inducing phagocytosis or activation, mediated 
through polymerization of actin ﬁlaments. Although this has not yet been shown for S. 
pneumoniae, a recent study showed that activation of NK cells and uptake of the 
fungal pathogen Candida albicans was triggered by actin-dependent phagocytosis. 
In that study, secretion of granulocyte-macrophage colony-stimulating factor, IFN? 
and TNF? was observed, resulting in enhanced neutrophil antifungal activity 34. 
Preliminary data (not shown) from our laboratory shows that direct stimulation of NK 
cells with Sp together with IgG is sufﬁcient to increase the production of IFN?, 
suggesting that there indeed may be a direct effect of IgG on the NK cells.
The in vitro nature of this study presents several limitations. First of all, in our 
experimental setup, the NK cells were physically separated from the alveolar 
macrophages, since we only investigated the inﬂuence of the secreted factors of the 
PBMCs. A study by Elhaik-Goldman showed that macrophage-NK cell crosstalk also 
can contribute to early clearance of S. pneumoniae 24. Secondly, there remain many 
other factors that are absent from our in vitro model but which may play a role during 
infection, such as mucosal IgA or IgM, complement and secreted factors from 
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mucosal endothelial or epithelial cells. The dynamic changes in the local environment 
and the complex interactions are difﬁcult to recapitulate in an in vitro model, so it is 
important to validate the ﬁndings presented in this study. 
To summarize, we show that anti-pneumococcal IgG antibodies can reduce the 
ability of alveolar macrophages to kill opsonized pneumococci, which may play an 
important role in early mucosal clearance of pneumococci. At the same time, the 
cellular response to S. pneumoniae was skewed from IL-17 production towards an 
NK-cell-dependent IFN? response. These results indicate that there is signiﬁcant 
interaction between the humoral and cellular parts of the immune response to S. 
pneumoniae, which may have an impact on pneumococcal clearance. Although the 
introduction of pneumococcal conjugate polysaccharide vaccines (PCVs) have 
clearly demonstrated that PCV-induced IgG antibodies play an important role in the 
prevention of pneumococcal disease, future research should further explore the 
indirect effects of antibodies on the immune response to S. pneumoniae and 
ultimately, the clinical outcome. 
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Figure S1. Determination of the percentage of IgG-opsonized S. pneumoniae. S. pneumoniae 
was incubated with PBS (Sp) or IgG (Sp + IgG) for 1 hour at 37 ˚C, washed with PBS and 
incubated with anti-human IgG-FITC. Analysis by ﬂow cytometry showed that all pneumococci 
were IgG-opsonized.
SP
SP + IgG
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ABSTRACT
The respiratory pathogen Streptococcus pneumoniae is a major cause of diseases 
such as otitis media, pneumonia, sepsis and meningitis. The ﬁrst step towards 
infection is colonization of the nasopharynx. Recently, it was shown that agglutinating 
antibodies play an important role in the prevention of mucosal colonization with 
S. pneumoniae. Here, we present a novel method to quantify antibody-dependent 
pneumococcal agglutination in a high-throughput manner using ﬂow cytometry. 
We found that the concentration of agglutinating antibodies against pneumococcal 
capsule are directly correlated with changes in the size and complexity of bacterial 
aggregates, as measured by ﬂow cytometry and conﬁrmed by light microscopy. 
Using the increase in size, we determined the agglutination index. The cutoff value 
was set by measuring a series of non-agglutinating antibodies. With this method, we 
show that not only anti-polysaccharide capsule antibodies are able to induce 
agglutination but that also anti-PspA protein antibodies have agglutinating 
capabilities. In conclusion, we have described and validated a novel method to 
quantify pneumococcal agglutination, which can be used to screen sera from murine 
or human vaccination studies, in a high-throughput manner.
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INTRODUCTION
Nasopharyngeal colonization with the respiratory pathogen Streptococcus pneumoniae 
is a prerequisite for the development of pneumococcal disease. Following dissemination 
of bacteria to the ear, lung, bloodstream or brain, otitis media, pneumonia, sepsis or 
meningitis may develop, respectively. Several mucosal defense mechanisms, such 
as antibody-mediated opsonization and opsonophagocytosis by phagocytes, have 
been suggested to be important in the reduction or complete prevention of 
colonization 1, 2. Recently, Roche et al. (2015) showed that the presence of agglutinating 
antibodies on the mucosal surface plays an important role in the prevention of 
pneumococcal colonization in a mouse model of colonization and transmission 3. 
The agglutinating properties of antibodies raised against novel vaccine candidates 
might therefore be predictive for protective efﬁcacy, and would be an important 
parameter to include in clinical trials.
The agglutinating properties of antibodies against S. pneumoniae have long been 
known. In 1902 Neufeld described agglutination of pneumococci with speciﬁc 
antisera, visible as capsular swelling and clumping of bacteria, which became known 
as the quellung reaction 4. Classiﬁcation of pneumococci by speciﬁc serological 
reactions was described in 1913 5, 6, and the identiﬁcation of new serotypes followed 
over the years, leading to the description of 80 distinct serotypes in 1960 7. Since then, 
the quellung reaction using polyclonal rabbit antisera has been the ‘gold standard’ 
for serotyping. Capsular swelling, which is usually accompanied by agglutination, 
is typically visualized microscopically or macroscopically with e.g. latex beads or 
slide-agglutination 8, 9. While the determination of an agglutination titer for serum 
against several bacteria has been described using a tube or well agglutination test, 
where a titer is determined using serially diluted serum that is mixed with a constant 
quantity of bacteria 10, variability in individual interpretation of results makes it difﬁcult 
to standardize this method. In addition, this method is relatively time consuming and 
therefore not very suitable for high-throughput use. 
Mucosal protection against colonization by agglutinating capsule-speciﬁc antibodies 
is thought to be mediated predominately by immunoglobulin G. Although IgA1 
antibodies, which represent the most abundant immunoglobulin subclass present on 
the airway mucosa, can also induce bacterial aggregates, the expression of IgA1 
protease by S. pneumoniae has been shown to negate this effect 3. The pneumococcal 
conjugate vaccines (PCVs) induce high amounts of systemic IgG against several 
different types of capsular polysaccharides. Due to active transport to the mucosal 
surface via the neonatal Fc receptor, these antibodies also provide protection against 
pneumococcal colonization 11, 12. A recent study has shown that agglutination by anti- 
pneumococcal IgG antibodies contributes to protection against pneumococcal 
colonization 3, 13.
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Since the agglutinating effect of antibodies has shown to be an important factor in the 
protection against pneumococcal colonization, there is a clear need for adequate 
methods to assess and quantify this antibody functionality. However, to date, there is 
no standardized method to measure pneumococcal agglutination. Here, we 
developed a high-throughput method to screen serum samples for their agglutinating 
potential of various pneumococcal strains, using ﬂow cytometry. Using this novel 
method, we assessed the agglutinating potential of both capsule-speciﬁc antibodies 
and antibodies generated against the pneumococcal surface protein A (PspA). 
METHODS
Pneumococcal strains
The Streptococcus pneumoniae serotype 4 strain TIGR4 14 and the serotype 19F 
strain EF3030 15 were used in agglutination experiments with anti-capsular antibodies. 
Non-encapsulated strains were used in experiments with anti-PspA antisera. The non- 
encapsulated derivative of TIGR4 (PspA clade 3) and G54 (PspA clade 4) and 
construction of these mutants were described before 16. Other non-encapsulated 
strains differing in PspA clades 17 and used in agglutination with anti-PspA sera were 
constructed with primer pair FI4 and PE21 18 as described before 16. These capsule 
locus deletion mutants were constructed of strains EF3030 (clade 1; 15), PBCN0226 
(clade 2; 19), BHN100 (clade 3; 20), and PBCN0117 (clade 5; 19). A PspA deletion mutant 
of the non-encapsulated TIGR4 strain was constructed by allelic exchange using a 
spectinomycin resistance cassette. Overlap extension PCR was applied to insert the 
spectinomycin resistance cassette between the ﬂanking regions of the pspA gene. 
The two ﬂanking regions and the spectinomycin resistance cassette of plasmid 
pR412 21 were PCR-ampliﬁed with the CvdG_SP_0117-pspA_L1/L2 (GCAAGTTGTTG-
CATCGTAGC/ CCACTAGTTCTAGAGCGGCTGAGACGTAACAAAACC), CvdG_SP_0117- 
PspA R1/R2 (CTCATGGTAAGTCTCCCATC/ GCGTCAATTCGAGGGGTATCAATGC-
CAATGGTGAATGGG) and (GCCGCTCTAGAACTAGTGG/ GATACCCCTCGAATT-
GACGC) primer pairs. The overlap extension PCR product was transformed in the 
unencapsulated TIGR4 strain, directed mutants were selected by selective plating 
with 150 μg/ml spectinomycin and correct integration was conﬁrmed by PCR with 
primer CvdG_SP_0117-pspA_C (CAACAAGCGCCACATCATTC). The bacteria were 
grown in Todd Hewith Broth (Becton Dickinson), supplemented with 5% Yeast extract 
(Becton Dickinson) (THY medium) to mid-log phase and stored at -80°C in THY 
medium supplemented with 15% glycerol. The number of viable bacteria in frozen 
stocks was enumerated by three times independent plating on blood agar plates 
(Becton Dickinson). 
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Sera
Polyclonal rabbit serum against serotype 4, serotype 14 and serotype 19F (factor 
serum 19b) were used (Statens Serum Institute, Denmark). Polyclonal sera against 
PspA were used from an animal study in which 8 week old BALB/C mice (Charles 
River Laboratories, Germany) were immunized intranasally with PspA adjuvanted 
with Cholera Toxin subunit B (CTB). Mice were immunized intranasally under inhalation 
anesthesia (isoﬂurane) with 10 μg His-tagged PspA from TIGR4 (kindly provided by 
Mucosis B.V., Groningen, The Netherlands), 4 μg CTB (Sigma) and PBS in a 10 μl 
volume three times, with 2 week intervals. The mice in this vaccination study were 
challenged with 106 CFU TIGR4 in PBS in a 10 μl volume divided over both nares of 
anesthetized mice. Four days post inoculation euthanasia was performed by terminal 
bleeding under inhalation anesthesia (isoﬂurane), followed by cervical dislocation. 
Blood was centrifuged at 7000 x g and serum was stored at -20 °C. Serum from mice 
immunized with CTB alone in PBS was used as negative control (mock). The animal 
experiment was approved by the Radboud university medical center Committee for 
Animal Ethics (approval number RU-DEC 2012-175) and conducted in accordance 
with the relevant Dutch legislation.
Agglutination assay
Pneumococci were diluted in THY from -80 °C stocks. Experiments were performed 
using non-coated V-bottom 96-well plates (Falcon). For each reaction, 105 colony 
forming units (CFU) were incubated in duplicate with various serum dilutions for 1 
hour in a total volume of 50 μl for anti-polysaccharide agglutination and 10 μl for 
anti-PspA agglutination, at 37°C and 5% CO2. Bacteria were then gently ﬁxed by 
adding paraformaldehyde to a ﬁnal concentration of 1%. After ﬁxation the samples 
were either analysed by phase contrast microscopy or diluted with PBS (Lonza) for 
direct analysis by ﬂow cytometry.
Analysis of agglutination by flow cytometry
Bacteria were measured on a BD LSRII Flow Cytometer (BD Biosciences) and BD 
FacsDiva Software 6.1 (BD Biosciences, San Jose, CA, USA). Pneumococci were 
gated and a dot-plot was generated by forward scattering (FSC-A) on the x-axis and 
side scattering (SSC-A) on the y-axis. To enable reproducible measurements, PMT 
voltages and threshold were adjusted gated on negative control bacteria, and the 
speed of the ﬂow was set at 0.5 μl/ sec for all measurements. The cutoff value for FSC 
positive agglutination was set using the negative control without serum. All samples 
were analyzed in duplicate and between 5000 - 100000 events were acquired for 
each measurement. Results were analysed by FlowJo version vX.07 (FlowJo, 
TreeStar, Inc, Ashland, U.S.A.).
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Phase contrast microscopy
Bacterial aggregates were visualized by phase contrast microscopy. Bacterial 
samples were transferred to glass slides, sealed with nailpolish and incubated 
overnight at room temperature before microscopic imaging. Images were acquired at 
a magniﬁcation of 6300x using a Leica DM600 B microscope.
RESULTS
Quantification of capsular antibody-dependent pneumococcal 
agglutination by flow cytometry
To determine if agglutination can be measured by ﬂow cytometry, we compared 
agglutinated with non-agglutinated pneumococci. S. pneumoniae TIGR4 was 
incubated with agglutinating serotype 4-speciﬁc (ST4) polyclonal rabbit antiserum as 
well as with a non-agglutinating heterologous control antiserum against serotype 14 
(ST14). Following ﬂow cytometry analysis, we found that a large proportion of the 
bacteria incubated with ST4-speciﬁc serum had increased on both the FSC and SSC 
axis, as compared to the bacteria incubated with ST14-speciﬁc serum (Figure 1A & B). 
In addition, the number of events measured in the FSC channel, which is representative of 
the number of particles detected by the ﬂow cytometer, was reduced in the presence 
of agglutinating antibodies. This suggests the formation of bacterial aggregates, which 
was conﬁrmed by phase contrast microscopy analysis (Figure 1C). 
In order to quantify pneumococcal agglutination, we incubated S. pneumoniae TIGR4 
(serotype 4) or S. pneumoniae EF3030 (serotype 19F) with serial dilutions of serotype- 
speciﬁc anti-capsular antibodies, i.e. anti-ST4 and anti-ST19F, or with heterologous 
anti-serotype 14 serum. Flow cytometry analysis showed a clear increase for both 
TIGR4 and EF3030 in the percentage of FSC-positive cells with increasing 
concentrations of serotype-speciﬁc antibodies (Figure 2A). This was accompanied 
by a decrease in the number of events in the FSC channel (Figure 2B).  Neither TIGR4 
nor EF3030 showed an increase in FSC following incubation with anti-serotype 14 
serum (Figure 2C). The FSC values of these control samples always remained below 
5 %, which was therefore used as the cutoff for positivity. We termed the percentage 
of FSC-positive bacteria the agglutination index. For both TIGR4 and EF3030, a clear 
increase in the agglutination index could be observed in the presence of increasing 
concentrations of type-speciﬁc serum (Figure 2C). Samples were treated with para-
formaldehyde before measurement on the ﬂow cytometer, which did not affect the 
agglutination index. 
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Figure 1. Agglutination of S. pneumoniae by anti-capsule antibodies can be detected by 
ﬂow cytometry. S. pneumoniae TIGR4 were incubated with a serotype speciﬁc polyclonal 
rabbit antiserum (serotype 4; ?-ST4; right panel) and with rabbit antiserum against a 
heterologous serotype (serotype 14; ?-ST14; left panel). Agglutination was assessed by ﬂow 
cytometry and is represented as dot plots of the FSC-A vs the SSC-A (A) and histograms of the 
FSC-A signal (B) and by phase contrast microscopy (C).
A
B
C
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Figure 3. Antibodies against the pneumococcal protein PspA are capable of inducing 
agglutination. An S. pneumoniae TIGR4 capsule mutant strain was incubated with increasing 
amounts of serum from mice that had been mock-vaccinated (control serum) or that had been 
vaccinated with PspA (?-PspA serum) (performed in duplicate). Agglutination was visualized by 
ﬂow cytometry as dot plots of the FSC-A and SSC-A signal (A), as histogram of the FSC-A 
signal (B) or with phase contrast microscopy (C). Flow cytometry data is summarized in a 
single graph for both the anti-PspA serum and the control serum (D). Nonencapsulated 
pneumococcal strains with PspA sequences from clades 1-5 (EF3030: clade 1, PBCN0226: 
clade 2, TIGR4: clade 3, BHN100: clade 3, G54: clade 4, PBCN0117: clade 5), as well as a PspA 
mutant strain (TIGR4?cps?pspA) were incubated with increasing amounts of mouse anti-PspA 
serum (E). The dashed line represents the agglutination cutoff value.
A
B
C
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Antibodies against the pneumococcal protein PspA are capable  
of inducing agglutination
Next, we sought to investigate if antibodies generated against a pneumococcal 
protein antigen known to confer mucosal protection, would also be capable of 
inducing agglutination. To do so, we made use of antiserum against pneumococcal 
surface protein A (PspA) from a mouse vaccination study. An S. pneumoniae TIGR4 
capsule mutant strain (TIGR4?cps) was incubated with serial dilutions of anti-PspA 
or control mouse serum. Samples were then analysed by ﬂow cytometry. Similar to 
the anti-capsular serum used before, anti-PspA antibodies also induced a shift in the 
FSC and SSC of the bacterial population (Figure 3A and 3B). Analysis of the samples 
by phase contrast microscopy conﬁrmed that incubation of pneumococci with 
PspA-speciﬁc serum induced the formation of aggregates, which did not occur in the 
presence of control serum (Figure 3C). Incubation with different concentrations of 
anti-PspA serum showed that the agglutination index reached a plateau when more 
than 1 μl of serum was added per 105 bacteria (Figure 3D).The anti-PspA serum was 
obtained from mice vaccinated with recombinant PspA representative of PspA clade 
3 14. To determine if serum against this PspA type was also able to induce agglutination 
of pneumococcal strains with PspA sequences representing different PspA clades, 
Figure 3. Continued. 
D
E
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non-encapsulated pneumococcal strains with PspA sequences from clade 1, 2, 3, 4 
and 5 were incubated with increasing amounts of anti-PspA serum. As a negative 
control, a PspA mutant strain (TIGR4?cps?pspA) was used. Figure 3E shows that 
the anti-PspA serum induces agglutination for pneumococcal strains with PspA 
sequences from all the different clades. Nevertheless, major differences were 
observed between the agglutination index of pneumococcal strains belonging to 
different PspA clades, with clade 1 showing the highest agglutination index, and the 
BHN100 strains with a PspA from clade 3 having the lowest agglutination index. As 
expected, the control PspA mutant strain did not agglutinate. 
DISCUSSION
Antibody-mediated agglutination of pneumococci has recently been shown to be an 
important factor in the prevention of pneumococcal colonization 3. While bacterial 
agglutination may be analyzed using methods such as light microscopy, they are 
generally not very suitable for quantiﬁcation and/or high-throughput analysis. Thus, 
we present a novel ﬂow cytometry-based assay to quantify the pneumococcal 
agglutinating capacity of serum. This assay can be easily adapted to incorporate 
other strains and/or other bacterial species and allows screening of serum samples 
in a high-throughput manner. Finally, we show that both anti-capsule and anti-protein 
antibodies are able to induce agglutination. 
In this manuscript, we show that antibody-induced agglutination correlated with a 
shift in the FSC and SSC properties of the bacterial particles, as measured by ﬂow 
cytometry. These ﬁndings were validated by light microscopy. The shift in FSC 
represented the agglutination index, i.e. the percentage of bacteria with a positive 
FSC signal. The actual percentage of agglutinating bacteria is probably higher, since 
agglutinates might have fallen apart due to the shearing force that is exerted in the 
FACS capillaries. In addition, bacterial aggregates are detected as single particles by 
the ﬂow cytometer, whilst in reality they consist of multiple bacteria clumped together. 
The latter is also reﬂected in the number of events that were measured in the FSC 
channel, the total of which was much lower for the agglutinated samples as compared 
to the non-agglutinated samples. The agglutination index is therefore inﬂuenced by 
several factors; the actual number of agglutinating bacteria, the afﬁnity of the 
antibodies, and the concentration of antibodies relative to the bacteria. Measurement 
of the absolute number of bacteria with for example a DNA stain, could provide more 
insight in the actual percentage of agglutinating pneumococci. 
When comparing the agglutination index of different samples, we suggest to use a 
ﬁxed amount of serum. However, it is also possible to use other methods such as the 
determination of an endpoint titer. The cutoff value for positive agglutination was set 
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at 5 %, which is based on data obtained with non-heterologous serotype speciﬁc 
serum. The cutoff value at which agglutination leads to protection against colonization 
remains to be studied. The current method has been further validated on human 
samples in a larger study, where post-vaccination nasal washes from a human 
pneumococcal challenge model mediated increased pneumococcal agglutination 
as compared to nasal washes collected before vaccination 13. 
All sera that were used in this study are likely to contain not only IgG, but also IgA 
(primarily IgA1). However, it has been shown that IgA1 has no agglutinating effects in 
IgA1 protease-producing pneumococcal strains 3. In addition, since all sera used in 
this study were raised by multiple booster vaccinations during a period of at least 9 
weeks, class switching will have taken place, which means that levels of IgM are 
negligibly low and will therefore likely not play a role in the observed agglutination. 
Before the introduction of PCVs, pneumococcal carriage rates typically declined after 
the age of 3 2, which is thought to be caused by the establishment of broad natural 
immunity to conserved pneumococcal proteins and capsular antigens 22-25. The high 
amounts of systemic IgG that are induced by PCVs are indeed correlated to protection 
against colonization 11, 12 and agglutination has recently been suggested to be the 
main mechanism for this protection. However, the role of antibodies targeting 
pneumococcal proteins is not yet clear 3, 13. We and others have shown that intranasal 
vaccination with the pneumococcal surface protein A can protect mice, not only 
against systemic infection and pneumonia, but also against nasopharyngeal 
colonization 26-28. This vaccine-induced protection has frequently been attributed to 
PspA-speciﬁc cellular immunity. Conversely, the contribution of antibody-dependent 
agglutination has, to the best of our knowledge, not been investigated before. Our 
ﬁndings show that murine antibodies against PspA have the ability to agglutinate a 
range of pneumococcal strains belonging to different PspA clades. Our rationale for 
using non-encapsulated strains was because pneumococci are known to 
downregulate their capsule expression during nasopharyngeal colonization 29, 30. 
Using strains without capsule allowed us to evaluate the agglutinating capacity of 
anti-PspA antibodies in an in vitro setting, whilst the presence of a capsule is known 
to interfere with the ability to bind to PspA molecules. Further experiments are needed 
to conﬁrm the in vivo protective effects of these anti-PspA antibodies against 
colonization with encapsulated S. pneumoniae. 
To summarize, this study demonstrates a novel quantitative, high-throughput 
technique to determine agglutination of S. pneumoniae. The protective efﬁcacy of the 
pneumococcal conjugate vaccines (PCVs) is correlated with antibody levels. In 
addition, opsonophagocytosis is often measured to characterize the functional 
antibody response 31. Recently, it was shown that antibody-mediated agglutination 
strongly contributes to protection 3, 13, which might explain the herd immunity observed 
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upon PCV vaccination 32, 33. However, more in-depth research is needed to conﬁrm a 
direct relation. The method presented here will allow high-throughput screening of 
serum samples to determine the level of agglutinating antibodies. Accordingly, this 
method is particularly useful to study the contribution of antibody-mediated 
agglutination to the protection of PCVs but also to evaluate novel vaccine candidates.
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ABSTRACT
Streptococcus pneumoniae is responsible for an estimated 1.6 million deaths 
worldwide every year. Whilst rapid detection and timely treatment with appropriate 
antibiotics is preferred, this is often difﬁcult due to the amount of time that detection 
with blood cultures takes. In this study, a novel quantitative PCR assay for the 
detection of S. pneumoniae was developed. To identify novel targets, we analyzed 
the pneumococcal genome for unique, repetitive DNA sequences. This approach 
identiﬁed comX, which is conserved and present in duplicate copies in S. pneumoniae, 
but not in other bacterial species. Comparison to lytA, the current gold standard for 
detection by quantitative PCR, demonstrated an analytic speciﬁcity of 100 % for both 
assays on a panel of 10 pneumococcal and 18 non-pneumococcal isolates, but a 
reduction of 3.5 Cq values (+/- 0.23 SEM) resulting in an increased analytical 
detection rate of comX. We validated our assay on DNA extracted from serum of 
30 bacteraemic patients that were blood culture positive for S. pneumoniae and 
51 serum samples that were culture positive for other bacteria. This resulted in a 
similar clinical sensitivity between the comX and lytA assay (47 %) and in a diagnostic 
speciﬁcity of 98.2 % and 100 % for the lytA and the comX assay respectively. 
In conclusion, we have developed a novel quantitative PCR assay with increased 
analytical sensitivity for the detection of S. pneumoniae, which may be used to 
develop a rapid bedside test for the direct detection of S. pneumoniae in clinical 
specimens.
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INTRODUCTION
Despite available vaccines, the bacterial pathogen Streptococcus pneumoniae 
causes an estimated 1.6 million deaths every year 1 and remains a major cause of 
invasive disease as well as non-invasive infections. As the mortality rate of sepsis 
increases rapidly with each hour of delay in the initiation of antimicrobial therapy 
(7.6 % per hour of delayed treatment) 2, broad spectrum antibiotic treatment is 
administered as soon as possible. Conversely, targeted antimicrobial treatment 
instead of broad-spectrum antibiotics increases the survival rate from pneumococcal 
septic shock more than two fold, from ~25 % to ~55 % 3 and it has been suggested 
that it might also increase the survival rate of patients with pneumococcal bacteraemia 4. 
In addition, focused treatment is preferred in order to prevent antibiotic resistance. 
The current ‘gold standard’ for diagnosis of pneumococcal bacteraemia and sepsis 
is blood culture. Unfortunately, blood cultures generally take between 24-48 hours to 
become positive, and antibiotic treatment is normally initiated before the results of 
blood cultures are known. Additionally, 55 - 65 % of blood cultures remain negative in 
septic shock cases 3, 5. It is thought that this low sensitivity of blood cultures might be 
caused by antibiotic use prior to specimen collection, and in the case of S. pneumoniae 
infections, possibly by the release of pneumococcal autolysin, resulting in cell death 6, 7. 
Taken together, there is a clear need for more rapid and sensitive molecular detection 
techniques. 
Alternative strategies that could be used in the clinic to diagnose invasive pneumococcal 
disease are the urine antigen test (e.g. Binax-Now (Alere)) or quantitative PCR (qPCR). 
Although the Binax-Now test is rapid, it has poor positive predictive value in population 
groups with high pneumococcal colonization rates, such as children, as carriage 
also leads to a positive test result 8, 9. In contrast, a recent study showed that 
pneumococcal DNA was not detected in peripheral blood of individuals colonized 
by S. pneumoniae 10. Moreover, qPCR detection of pneumococcal DNA in blood can 
give positive results within 2 hours, and can theoretically detect as little as one 
genome copy of DNA. It has been shown that at least one third of culture-negative 
clinical samples that were analyzed by 16S rDNA PCR analysis tested positive for 
pneumococcal DNA 11. Since bacterial numbers in the blood of a sepsis patient can 
be as low as 10 colony forming units (CFU) per ml of blood 12, 13, it is important that 
the PCR assay is highly sensitive, in order to detect the pathogen without a pre-culture 
step. Various studies have shown that qPCR has the potential to be a more sensitive 
detection method than traditional blood culture 6, 7, although the ability to detect the 
pathogen is also dependent on the stage of disease, antibiotic treatment 6 and the 
volume of blood that is used for culture or qPCR 7, 12, 14. 
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To date, several targets for qPCR-based detection of S. pneumoniae have been 
described, amplifying genes such as the autolysin gene lytA 15, the pneumolysin 
gene ply 16, pneumococcal surface adhesion A gene psaA 15, topoisomerase gene 
parE 17, the spn 9802 gene fragment 18 and the 16S ribosomal RNA gene 19. Of these 
targets, the lytA primer probe set designed by Carvalho et al. (2007) has been tested 
most extensively in clinical studies 7, 20. This target has been shown not to cross-react 
with the recently described species S. pseudopneumoniae 21, which is genetically 
very similar to S. pneumoniae and can be misidentiﬁed as a-typical pneumococci 
with traditional identiﬁcation methods 22, 23. Many of the other qPCR assays also give 
a positive result for S. pseudopneumoniae 15, and are therefore not speciﬁc for 
S. pneumoniae. Although it remains unclear what the exact clinical relevance of 
S. pseudo pneumoniae is as a cause of sepsis, pseudopneumococcal isolates do 
have a different antimicrobial resistance proﬁle as compared to S. pneumoniae 22, 24, 
25. Therefore, correct identiﬁcation of these two species is important for the appropriate 
administration of antibiotics.
All the targets described to date, with the exception of 16S rDNA, are present in the 
genome as a single copy. A multicopy target is likely to increase the sensitivity of 
detection. Although the 16S rDNA is also present in multiple copies, due to the high 
similarity of the 16S rDNA between S. pneumoniae and other closely related 
streptococcal species 26, it is difﬁcult to design probes and primers that speciﬁcally 
detect S. pneumoniae. In this study we have searched for a multi-copy, conserved 
and species-speciﬁc DNA region in S. pneumoniae. Subsequently, the speciﬁcity 
and sensitivity of this assay were evaluated and compared to the lytA assay described 
by Carvalho et al. (2007) 15. Finally, we evaluated our assay using clinical samples 
obtained from patients with bacteraemic pneumococcal or non-pneumococcal 
infections.
METHODS
Bacterial isolates. The panel of bacterial isolates to determine analytic intraspecies 
speciﬁcity consisted of 10 different serotypes (serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 14, 
19A) of S. pneumoniae that were obtained from patients with pneumococcal 
bacteraemia. The panel to determine interspecies speciﬁcity consisted of 
Enterococcus faecalis (CDC NY 5), Enterococcus faecium (clinical isolate), 
Staphylococcus aureus (MRSA mw2), Staphylococcus aureus (ATCC 29213), 
Staphylococcus epidermis (ATCC 14990T), Staphylococcus hominis (clinical isolate), 
Klebsiella oxytoca (ATCC 13182/DSM5175), Klebsiella pneumoniae (ATCC 13883), 
Pseudomonas aeruginosa  (ATCC 10145T), Escherichia coli (ATCC 11775T), 
Acinetobacter baumannii (ATCC 19606/DSM 6974), Acinetobacter calcoaceticus 
(ATCC 23055), Acinetobacter genomospecies 13TU (ATCC 17903), Acinetobacter 
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genomospecies 3 (ATCC 19004), Veillonella parvula (DSM 2008/ATCC 10790), 
Streptococcus oralis DSM 20627 (ATCC 35037), Streptococcus mitis DSM 12643 
(ATCC 49456) and Streptococcus pseudopneumoniae (ATCC BAA-960).
Clinical specimens
Two collections of serum samples were used for this study. The ﬁrst one consisted of 
sera from 30 patients, hospitalized at a Dutch hospital with a blood culture-proven 
pneumococcal bacteraemia, collected prior to antibiotics treatment. The second set 
consisted of sera from 51 patients, hospitalized at a Dutch hospital with bacteraemia 
caused by a non-pneumococcal pathogen (Table 2). Culturing of the blood was 
initiated at the same day as the collection of the sera. This study was approved by the 
Local Medical Ethics Committee of the Canisius-Wilhelmina Hospital.
DNA extraction for quantitative PCR analysis
DNA from S. pneumoniae, S. mitis, S. oralis and S. pseudopneumoniae was extracted 
using a modiﬁed protocol from the Qiagen DNA mini kit (Qiagen, Hilden, Germany). 
Bacterial pellets were incubated for 30 min at 37 °C in a chemical lysis buffer (20 mM 
Tris-Cl pH8.0, 2 mM sodium EDTA, 1.2 % Triton X-100) supplemented with 10 mg 
lysozyme ml-1 (Merck), followed by a 30 min incubation at 56 °C with 1.5 mg proteinase 
K ml-1  (Qiagen). The bacterial lysate was then processed according to the 
manufacturer’s instructions, eluted in 50 μl DNase free water (Sigma) and stored at 
-20 °C until further use. DNA concentrations were determined by measuring the 
absorbance at 260 nm using a Nanodrop instrument (Thermo Scientiﬁc). DNA from 
other species was isolated and quantiﬁed as described previously 27.
Total DNA of the clinical samples was extracted from 200 μl of thawed patient serum 
using the MagNA Pure 96 Instrument and the MagNA Pure 96 DNA and Viral NA 
Small Volume Kit (both Roche Diagnostics, Almere, The Netherlands). Extracted DNA 
was eluted in 100 μl elution buffer, which was stored at -20 °C until further use. A 
positive control for the extraction consisted of Phorcine Herpes virus (PhHV) 28 that 
was spiked into the samples prior to extraction and was assayed separately. 
Design of comX primers and probe
For the identiﬁcation of species-speciﬁc pneumococcal repeat regions, the online 
analysis tool MultiMPrimer was used (http://bioinfo.ut.ee/multimprimer3) 29. Seventeen 
pneumococcal strains (GenBank accession numbers FQ312030, FQ312029, 
FQ312027, FM211187, CP002176, CP002121, CP001993, CP001033, CP001015, 
CP000936, CP000921, CP000920, CP000919, CP000918, CP000410, AE007317, 
AE005672) of which the closed genome sequences were known, were screened for 
repetitive regions and compared to a non-target database. This strategy identiﬁed a 
repeat region, designated comX (Genbank accession number AE005672; SP_0014 
and SP_2006), which was then checked against the NCBI nucleotide database using 
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BLAST search (http://blast.ncbi.nlm.nih.gov) 30. For the pneumococcus-speciﬁc 
oligo nucleotide primers and a ﬂuorescent dye-labeled probe design, comX gene 
sequences of 25 S. pneumoniae strains, two S. pseudopneumoniae strains and two 
S. mitis strains were aligned with Clustal W (http://www.ebi.ac.uk). Primers and probe 
were designed according to Taqman guidelines. A whole genome shotgun BLAST 
search was performed on the NCBI website (http://blast.ncbi.nlm.nih.gov). All BLAST 
searches were performed on 27-01-2015. Primer efﬁciencies were calculated using 
the formula 10(-1/slope)-1)*100.
Quantitative PCR for comX and lytA
The oligonucleotide primers and ﬂuorescently labeled probes for the qPCR on lytA 
and comX are listed in Table 1. Primer and probe sequences for lytA were used as 
published previously 15. Amplicon lengths were 76 bp for lytA-CDC and 169 bp for 
comX. The PCR reaction was carried out in a ﬁnal 25 μl reaction volume and was 
performed in  PCR reaction buffer ((50 mM KCl (Sigma BioUltra), 10 mM Trizma base 
(Sigma BioUltra), 200 nM dNTPs (Roche), 5 mM MgCl2 (Sigma BioUltra), 0.5 mg BSA 
ml-1 (Sigma), 0.39 % Trehalose (Sigma), 1 U/ reaction FastStart Taq DNA polymerase 
(Roche)) with 10 μl template DNA. Primer and probe concentrations were 200 nM for 
both assays. In every run a no-template control and a positive control (S. pneumoniae 
TIGR4, obtained from Prof. H. Tettelin 31) were included. PCR was performed on the 
7500 Real Time PCR System (Applied Biosystems) with the following cycling 
parameters: 10 min at 95 °C, followed by 50 cycles of 95 °C for 15 sec and 60 °C for 
1 min. The data were analyzed using the 7500 Fast Systems Software (Applied 
Biosystems), with a threshold of 220436 for comX and 86559 for lytA.
Table 1   Real-time qPCR primers and probes. 
Oligonucleotide
name
Sequence (5’  3’) Nucleotide  
start position
lytA-CDC forward ACGCAATCTAGCAGATGAAGCA 1841014
lytA-CDC reverse TCGTGCGTTTTAATTCCAGCT 1840961 
lytA-CDC probe FAM-GCCGAAAACGCTTGATACAGGGAG-BHQ1 1840985
comX forward GGTCTCTGGCTAGATGATTATTATCTCTT 14747; 1914288
comX reverse ATAGTAAACTCCTTAAACACAATGCGTAA 14888; 1914147
comX probe FAM-CGCCCTCGAAATCGTTCATTGCTTAAGA-BHQ1 14841; 1914195
Nucleotide positions are given for S. pneumoniae strain TIGR4 (GenBank accession no. AE005672.3).
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Determination of analytical sensitivity and specificity
The MIQE guidelines for validation were followed 32. For determination of the analytical 
sensitivity and the lower limit of detection (LLOD) of the comX and lytA PCRs, 10-fold 
serial dilutions of genomic DNA of S. pneumoniae (TIGR4) in the range of 1 fg/
reaction to 100 pg/reaction were used, and performed in triplicate. In order to 
determine if the lower Cq values of comX resulted in a higher analytical detection rate, 
the PCR reaction containing 1 fg template DNA was repeated 40 times (in three 
independent runs). Determination of the analytical speciﬁcity was performed with 
DNA equivalent to 1000 CFU and with 10 pg/reaction for S. mitis, S. oralis and S. 
pseudopneumoniae, to maximize the chances of detecting any false-positive results 
with the most closely related bacterial species. To determine the intraspecies 
analytical speciﬁcity for different pneumococcal serotypes, 10 pg DNA /reaction was 
used. QPCR on the clinical specimens was performed using a single run of 5 μl of 
eluate from the DNA extraction.
Statistical analysis was performed using Graphpad Prism Software V.5.03. Paired 
T-tests were performed to determine the statistical signiﬁcance between two groups 
of samples with detectable Cq values. The statistical signiﬁcance threshold was set 
at 0.05.
RESULTS
ComX is a unique multicopy gene in Streptococcus pneumoniae
In order to develop a qPCR with increased sensitivity, we analyzed the pneumococcal 
genome for unique repetitive DNA sequences. Using the online web tool MultiM 
Primer, we identiﬁed competence regulator comX as a unique sequence for S. 
pneumoniae, of which two copies are present per pneumococcal genome. Oligonu-
cleotide primers and a ﬂuorescent-dye probe were designed and a BLAST search of 
the amplicon (170 bp) against all 27 published complete whole genome sequences 
on the NCBI database showed that all genomes contained the amplicon sequence 
in duplicate with a similarity of 99- 100  %, indicating that this potential target is highly 
conserved among S. pneumoniae. For comparison, we also performed the same 
BLAST search with the amplicon of the lytA assay as described by Carvalho et al. 
(2007) hereafter referred to as lytA-CDC, for which we also found a coverage of 100 %. 
To predict the speciﬁcity of our assay, we performed a BLAST search of the comX 
amplicon against the complete NCBI nucleotide database minus S. pneumoniae. 
This yielded only hits on S. pseudopneumoniae (93 % coverage) and S. mitis (92 % 
coverage). Since only one complete whole genome sequence was present in the 
NCBI database, we also performed a BLAST search on the six whole genome 
shotgun (wgs) sequences of S. pseudopneumoniae that were present in the database. 
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All six genomes contained a single copy sequence similar to the comX amplicon with 
a similarity of 90-93%. Further analysis showed that these sequences had at least 
two nucleotides difference within the comX forward primer binding site, three 
nucleotides difference with the comX probe and two nucleotides difference with the 
reverse primer. Similarly, for S. mitis the 38 wgs sequences showed 87-95 % sequence 
identity to the comX amplicon. All these strains differed in at least one nucleotide from 
the comX forward primer and two nucleotides from the comX probe.
In summary, in silico analysis showed that the comX target was present with two 
copies in all S. pneumoniae genome sequences present in the public domain. 
Although S. pseudopneumoniae and S. mitis also contained a single comX-like copy, 
nucleotide differences in the primer-probe binding regions for these two species 
suggested that the PCR would be speciﬁc. 
The comX qPCR assay detects S. pneumoniae with high  
analytical sensitivity 
To determine the LLOD of the novel assay comX and the reference assay lytA-CDC, 
we performed qPCR on serial dilutions of genomic DNA from S. pneumoniae TIGR4. 
Both lytA-CDC and comX showed high sensitivity with a LLOD at 10 fg template DNA/ 
reaction, equivalent to 4 genomic copies (calculated using the genomic weight of 
S. pneumoniae TIGR4). The comX PCR was more efﬁcient, detecting its target at a 
signiﬁcantly lower Cq value (3.46 Cq values difference, +/- 0.23 SEM) than the 
lytA-CDC PCR (Figure 1A)), whilst primer efﬁciencies were comparable (97 % and 103 
%, respectively). Both qPCR assays were performed using different commercial PCR 
buffers and different Magnesium concentrations, but the comX qPCR kept a lower Cq 
value compared to the lytA assay, indicating that buffer conditions were not playing a 
role (results not shown). 
To determine if the lower Cq values of the comX assay translated into an increased 
detection rate, we repeated the qPCR 40 times at a concentration 10x lower than the 
LLOD (1 fg/PCR). PCR analysis showed that in 54 % of cases (21 out of 40) comX was 
detected, whilst lytA-CDC was detected in 36 % of the repeat experiments (14 out of 
40). The mean of the difference in Cq value between the two assays at this 
concentration was 4.2 (p<0.0001) (Figure 1B). These results indicated that the lower 
Cq value at which the comX PCR detected its target indeed resulted in an increased 
analytical detection rate in comparison to the lytA qPCR.
The comX qPCR assay is specific for S. pneumoniae
To evaluate the analytical speciﬁcity of the comX assay, qPCR was performed on 
genomic DNA of 18 different non-pneumococcal species, including the most common 
causative agents of sepsis. The most closely related species S. mitis, S. oralis and 
S. pseudopneumoniae were also included. No ampliﬁcation was observed with any 
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of the species of this panel, as was predicted based on our in silico analysis 
(see above), resulting in an analytic speciﬁcity of 100 %. We also tested performance 
of the comX assay on a panel of 10 different pneumococcal serotype strains. 
Ampliﬁcation of genomic DNA from these strains showed that all serotypes gave 
similar Cq values (Figure 2). 
The comX qPCR assay detects S. pneumoniae with equivalent 
clinical sensitivity as the lytA assay
To evaluate the results of our new assay in a clinical setting, DNA was extracted from 
200 μl serum of 30 blood culture-positive pneumococcal bacteraemia patients that 
had not received antibiotics prior to sampling. qPCR was performed on the equivalent 
of 10 μl serum per PCR. Similar to our previous observations, the Cq values of the 
comX assay were signiﬁcantly lower than the lytA-CDC assay (p=0.0006) (Figure 3). 
Both with the comX and the lytA-CDC assay, 14 out of 30 culture positive patients had 
a positive qPCR result, indicating that the clinical sensitivity of both assays was the 
same. The comX assay detected three patients that tested negative with the lytA-CDC 
PCR. Vice versa, the lytA-CDC PCR also detected three patients that tested negative 
with the comX PCR. It is important to note that these patients all had Cq values >40 
for the comX PCR and >43 for the lytA-CDC PCR, indicating that this is most likely 
caused by the presence of very low copy numbers of pneumococcal DNA. Agarose 
Figure 1. The novel target comX has a higher analytical sensitivity than lytA-CDC and has 
a similar primer efﬁciency. (a) Standard curve of the primer efﬁciency on S. pneumoniae 
genomic DNA (n=3). The primer efﬁciency for lytA-CDC ( ) is 103 % and 97 % for comX ( ). 
comX detects pneumococcal DNA at mean Cq values 3.46 +/- 0.23 (SEM) lower than lytA-CDC. 
(b) Analytical detection rate at 1 fg S. pneumoniae TIGR4 genomic DNA/PCR compared to 
lytA-CDC (n=40). The dotted line indicates the detection limit (number of ampliﬁcation cycles 
of the PCR reaction). Statistics was performed with a paired t-test of samples that had detectable 
Cq values.
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gel electrophoresis of the products showed that all samples with a Cq value higher 
than 40 contained a product of the expected size, indicating that the detection for 
both assays is indeed speciﬁc (results not shown).
Figure 2. Intraspecies coverage of comX on clinical isolates. Coverage of comX and lytA- 
CDC of clinical isolates of different pneumococcal serotypes, using 10 pg template DNA 
per PCR.
Figure 3. Detection of pneumococccal DNA in sera of culture proven pneumococcal 
bacteraemia patients. DNA was isolated from serum of 30 patients, obtained prior to antibiotic 
treatment. Real-time PCR with the comX ( ) and lytA-CDC ( ) assays was performed with an 
input equivalent to 10 μl serum. Open triangles ( ) represent samples that were detected with 
comX but not with lytA-CDC, open circles ( ) represent samples that were detected with 
lytA-CDC but not with comX. The dotted line indicates the detection limit (number of ampliﬁcation 
cycles of the PCR reaction). Horizontal bars indicate the mean of samples with detectable Cq 
values, statistics was performed with a paired t-test.
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To determine the diagnostic speciﬁcity, the assay was also validated on a control 
group of sera from 51 patients that were blood culture positive for other bacteria 
(n=33 Gram positive; n=18 Gram negative) (Table 2). One serum sample (blood 
culture positive for E. coli) was positive for lytA (Cq value 43.9), while none of the 
control samples was positive for comX, resulting in a diagnostic speciﬁcity of 98.2 % 
and 100 % respectively,
Table 2   Clinical sera blood culture positive for non-pneumococcal strains. 
Species no of clinical samples tested
S. epidermidis 11
S. hominis 2
Staphylococcus species 2
S. aureus 5
E. faecalis 2
S. pyogenes 1
E. faecium 1
A. urinae 1
S. gordonii 2
S. mitis 3
S. mutans 1
S. oralis 2
S. salivarius 2
E. coli 8
A. lwofﬁi 1
K. pneumoniae 3
P. aeruginosa 2
K. oxytoca 1
Acinetobacter species 1
P. mirabilis 1
B. fragilis 1
A panel of 51 different clinical sera, which were blood culture positive for different non-pneumococcal 
strains were assayed for both comX and lytA-CDC. One serum sample (blood culture positive for E. coli) 
was positive for lytA-CDC, while none were positive for comX.
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DISCUSSION
In this study, we developed a novel qPCR assay for the detection of S. pneumoniae. 
The comX assay has a higher analytical and a comparable clinical sensitivity as 
compared to the current gold standard for qPCR detection of S. pneumoniae in the 
preclinical setting, i.e. the lytA assay described by Carvalho et al. (2007) 15. The 
current gold standard for detection of the causative agent in septic patients is blood 
culture. Typically, blood culture takes 24-48h, while targeted treatment within the ﬁrst 
few hours after admission to the ICU is preferred. In order to switch from blood culture 
to qPCR-based detection of pathogens without a pre-culture step, it is important to 
be able to detect the pathogen with high analytical sensitivity without compromising 
the speciﬁcity. This may be particularly useful to identify S. pneumoniae in the blood 
of patients with low pneumococcal load.  
The novel target comX encodes an alternative sigma factor that regulates a set of late 
competence genes 33. The comX gene is present in duplicate in all pneumococcal 
genomes that have been fully sequenced to date and is highly conserved, an 
important property of any target to identify pathogens. In addition, we performed the 
qPCR on 10 pneumococcal strains representing different serotypes, which all gave a 
positive PCR result. Although the serotypes that we examined in this study represent 
clinically relevant pneumococcal serotypes, it should be noted that in total more than 
90 different pneumococcal serotypes have been identiﬁed. Testing of multiple 
isolates belonging to all serotypes should be performed to fully establish analytical 
speciﬁcity of this target. We tested genomic DNA of 18 non-pneumococcal strains 
that are prevalent in sepsis. Some of these species were selected based on the 
BLAST search (S. pseudopneumoniae and S. mitis). Additionally, 51 sera of patients 
that were blood culture positive for in total 21 distinct non-pneumococcal bacterial 
species. Although none of these control samples returned a positive PCR result, for 
a more extensive future validation additional non-pneumococcal strains should be 
tested.
Since the comX gene has two copies per genome instead of a single copy for lytA, 
comX should theoretically have a 2-fold increased sensitivity, corresponding to 1 Cq. 
However, we found that the comX PCR detects S. pneumoniae at ~3.5 Cq lower than 
the lytA-CDC assay, i.e. more than expected. This cannot be attributed to differences 
in primer efﬁciency, as this was very similar between the two assays. The difference 
could also not be attributed to suboptimal magnesium concentrations or a suboptimal 
buffer conditions. However, we did notice that the threshold for the lytA qPCR had to 
be set much lower than for the comX qPCR. The lytA-CDC probe has been designed 
with a guanine nucleic acid at its 5?-end, which is not recommended in the TaqMan 
guidelines (Primer Express Software Version 3.0 Getting Started Guide, Applied 
Biosystems) and could possibly play a role in the lower performance of the lytA assay 
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in terms of Cq values. Another potential explanation for the unexpected Cq difference 
may be that one of the two copies of comX is located very close (14 kb distance) to 
the putative origin of replication, compared to a distance of 1729 kb for lytA-CDC. The 
presence of multiple replication forks in an actively growing cell 34, could result in a 
higher copy number at any given time of the genes that are close to the ori, compared 
to genes that are located more distantly from the ori. Preliminary data from our 
laboratory suggests that the difference between Ct values of the comX and lytA assay 
is predominately present in actively growing cells, and not in cells that are in stationary 
phase. 
We show that, in a clinical setting, our assay performs equally well as the lytA-CDC 
assay in terms of overall detection rates in blood-culture conﬁrmed S. pneumoniae 
infections, but at signiﬁcantly lower Cq values. Even though the template DNA was 
isolated from an equivalent of 10 μl serum per PCR reaction, we were still able to 
detect pneumococcal DNA in almost half of the samples that were blood culture 
positive for S. pneumoniae.  In comparison, the blood culture results were obtained 
using two sets of blood cultures that each required a volume of 10-15 ml of blood, 
while bacterial loads can be as low as 10 CFU/ml during sepsis. Increasing the 
amount of serum used for the PCR is therefore likely to improve detection rates. 
Differences between samples that had a positive signal with comX but not with 
lytA-CDC, and vice versa, were restricted to samples with high Cq values (>40), 
suggesting that these may represent patients with a low bacterial load at or below the 
LLOD. Increasing the input volume of blood from these patients is expected to 
improve the clinical sensitivity of the qPCR. Several papers have been published 
recently on increasing the input blood volume for PCR applications, up to an input 
volume of 5-10 ml of whole blood 12, 13. The development of these methodologies are 
key in the advancement of qPCR-based diagnostic assays. qPCR using comX on 
genomic DNA at the LLOD showed enhanced analytical sensitivity and detection 
rates of S. pneumoniae as compared to lytA-CDC, suggesting that comX may 
particularly have added value for the detection of S. pneumoniae in the blood of 
patients with a low bacterial load. The small sample size of the clinical cohort used in 
this study does not allow to draw solid conclusions on whether using comX as qPCR 
target would increase the detection rate. In follow-up studies, it may therefore be 
useful to increase the number of patient samples and the blood volume used in the 
PCR. This manuscript describes the development of a qPCR assay that only detects 
S. pneumoniae. However, the development of a qPCR assay that in addition to S. 
pneumoniae would also be able to detect multiple other bacterial and/or fungal 
causative agents of sepsis and/or bacteraemic pneumonia would have signiﬁcantly 
more clinical relevance. Ongoing research efforts in our laboratory therefore focus on 
the incorporation of this PCR assay in such a multiplex PCR assay.
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Although translation into diagnostic use requires further validation studies, in this 
study we have shown that comX represents an attractive novel multi-copy target for 
qPCR detection of S. pneumoniae. The development and inclusion of comX into a 
robust, automated test for rapid diagnosis of sepsis may facilitate a more targeted 
treatment and as such has the potential to improve patient outcome and reduce the 
use of broad spectrum antibiotics. 
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SUMMARIZING DISCUSSION
Pneumococcal disease is still a major problem worldwide. Even though PCVs have 
been very effective in reducing pneumococcal disease, they also have their limitations. 
Serotype replacement, a high production cost and production-related limitations in 
the number of serotypes that can be covered per vaccine, represent some of its 
shortcomings 1-4. A better vaccine would need to be affordable, offer broad sero-
type-independent protection to most pneumococcal strains, and would need to be 
equally effective in mediating protection against pneumococcal disease as compared 
to the PCVs. In order to develop and test the efﬁcacy of novel vaccines, it is important 
to understand the immunological mechanisms of protection and the mechanisms 
that lead to exacerbation of disease. The central focus of this thesis therefore is the 
immune recognition and clearance of S. pneumoniae. In the ﬁrst section of this thesis, 
we studied the mechanisms that are important in exacerbation of pneumococcal 
disease due to the inﬂuenza A virus. In the second section, we examined the role of 
cellular and humoral immunity in protection and clearance of pneumococcal 
infections. The main results of this thesis are:
• The speciﬁcity for ?2,6-linked sialic acids by IAV does not affect the development 
of pneumococcal OM
• IL-17 and IgG2a are important in PspA/CTB induced protection against inﬂuen-
za-virus induced pneumococcal OM
• Opsonizing IgG antibodies skew the immune response to S. pneumoniae from IL-17 
towards IFN-? production, increase the percentage of proliferating IFN-?+ NK cells and 
reduce the killing capacity of S. pneumoniae by human alveolar macrophages 
• IgG antibodies to the pneumococcal protein PspA are able to mediate pneumococcal 
agglutination 
Moreover, in the last section of this thesis we developed a novel real-time PCR assay 
for the detection of S. pneumoniae, as part of a larger project to develop a bedside 
test for the rapid detection of the causative agent of sepsis. 
The mechanisms of IAV-induced exacerbation of  
pneumococcal disease
Combined infections of inﬂuenza virus with S. pneumoniae are responsible for a 
signiﬁcant proportion of all infection-related deaths worldwide 5, 6. In chapter 2, we 
reviewed the literature on the immunological pathways that are activated in secondary 
pneumococcal disease as a result of inﬂuenza virus infection and studied the 
contribution of each of these two pathogens on the exacerbation of disease. IAV is 
able to modify the host immune response at multiple levels. For example, IAV infection 
can result in neutrophil-induced immunopathology, production of IFN-? by T cells, 
desensitization of macrophages for several TLRs, and synergistic stimulation of type 
I interferons that results in inhibition of the Th17 response and decrease of the 
macrophage attracting chemokine CCL2 7-11. All of these IAV-induced effects can 
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have consequences for the susceptibility to infection with S. pneumoniae. While it is 
clear that IAV can exacerbate secondary pneumococcal infection, we also explored 
the possibility that pneumococcal infection may exacerbate IAV disease, but did not 
ﬁnd any supporting evidence for this. In contrast, there is some evidence from murine 
studies suggesing that preceding colonization with S. pneumoniae may actually 
reduce the severity of IAV infection, although there is no direct evidence yet for this in 
humans 12, 13. This may be of particular interest when observing the difference between 
IAV infection in children, who are more likely to be pre-colonized by S. pneumoniae, 
as compared to adults, who more frequently will ﬁrst encounter IAV since they 
generally have lower pneumococcal colonization rates than children. In this light, the 
question arises if future vaccines should also prevent pneumococcal colonization, 
apart from invasive disease. In contrast, pneumococcal colonization in children has 
been associated with increased detection of RSV and rhinovirus infections 14. It 
should be noted that this study only looked at children with conﬁrmed CAP and it 
remains unknown whether children with asymptomatic pneumococcal colonization 
will show similar results. Finally, pneumococcal colonization is also a natural 
immunizing event, boosting immunity, which can prevent subsequent carriage 15. 
In children, inﬂuenza virus infection is a signiﬁcant risk factor particularly for the 
development of otitis media 16, 17. In chapter 3, we looked at the mechanism by which 
inﬂuenza virus facilitates the development of pneumococcal otitis media. IAV with the 
hemagglutinin H3 type has previously been associated with increased incidence of 
murine pneumococcal OM, and was replicating with higher efﬁciency in human 
middle ear epithelial cells as compared to H1 IAV viruses 18. The HA recognizes sialic 
acid residues on cell surface glycoproteins and glycolipids of epithelial cells, which 
facilitates internalization of the virus 19. Since H3 viruses have dual speciﬁcity for ?2,6- 
and ?2,3-linked sialic acid and H1 viruses only recognize ?2,3-linked sialic acid 20, 21, 
we hypothesized that the sialic acid preference of the HA may be implicated in the 
development of pneumococcal OM. Using a mutant of the H3-type IAV with a single 
amino acid substitution that limited its speciﬁcity to ?2,3-linked sialic acids only, we 
showed that these single-speciﬁcity H3 viruses were still effective at inducing bacterial 
OM, replicating in the middle ear and infecting human middle ear epithelial cells. 
These results indicated that the recognition of ?2,6-linked sialic acids does not affect 
the development of pneumococcal OM. Other features of the HA therefore likely 
inﬂuence the susceptibility to pneumococcal OM. Possibly, the H3 HA promotes 
more effective interactions with secondary receptors that are required for viral entry 
and replication 22, or the H3 HA might promote more efﬁcient membrane fusion with 
middle ear epithelial cells.
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The role of cellular and humoral immunity in protection  
against otitis media
In chapter 4, we studied the role of cellular and humoral immunity in IAV-induced 
OM. Mucosal vaccination studies against S. pneumoniae have almost exclusively 
focused on nasopharyngeal colonization or clearance of the airways as the critical 
endpoint 23-26. Importantly, these animal models rarely make use of (inﬂuenza) virus 
infections as a physiological trigger to induce pneumococcal disease, even though 
this would be much more clinically relevant. Apart from the fact that IAV-pneumococ-
cal co-infections occur very frequently in OM 16, 17, it is also important to evaluate 
protection in an IAV co-infection environment since it is known that IAV can modulate 
the immune response to pneumococcal infection (Chapter 2). 
Using a co-infection model, we show that intranasal vaccination of mice with the 
pneumococcal model antigen PspA together with the mucosal adjuvant CTB resulted 
in protection against inﬂuenza virus-induced pneumococcal OM. This correlated with 
the induction of PspA-speciﬁc IgA, a balanced IgG1:IgG2a antibody response and 
the induction of a mucosal Th17 response. Our data points to an important role for 
both IL-17 and IgG2a in the protection against inﬂuenza-virus induced pneumococcal 
OM. Vaccination with PspA alone, which was not protective against OM, resulted in 
signiﬁcantly lower total amounts of IgG2a. Different IgG subclasses differ in their 
afﬁnity to bind to different Fc? receptors 27, which could have an effect on the 
phagocytic capacity of different antibody subclasses, and thereby the ability of these 
antibodies to kill the opsonized bacteria. Additionally, in mice, IgG subclass IgG2a 
and IgG2b activate complement, while IgG1 does not 28. The membrane attack 
complex that is formed on the surface of an invading bacterial cell as a result of 
activation of the complement system, is unable to directly lyse Gram-positive bacteria, 
including S. pneumoniae. However, complement activation also leads to production 
of complement peptides such as C3a and C5a, which can cause increased 
inﬂammation and recruitment of phagocytes 29. PspA-speciﬁc IgG2a might therefore 
be important in the protection against pneumococcal OM. 
Conversely, we also show that antibody-deﬁcient B6.μMT-/- mice displayed equal 
levels of protection to OM compared to wild-type mice. Although this may indicate 
that antibodies and/or B cells do not play an important role in protection, it remains 
possible that any protective effect of the antibodies in the wildtype mice is already 
negated by the high challenge dose that is used in these mouse studies. In a previous 
study by our group 30, we showed that the presence of non-speciﬁc antibodies can 
also enhance pneumococcal OM in unvaccinated mice by inducing neutrophil 
extracellular trap (NET) formation in the middle ear. This is in contrast to the ﬁndings 
presented in this thesis, which only showed a trend towards increased bacterial load 
in the nasal cavity of vaccinated B6.μMT-/-. The role of antibodies in the interactions 
with S. pneumoniae may therefore be more complex than previously assumed or 
517489-L-bw-Habets
Processed on: 19-2-2018 PDF page: 148
148
Chapter 8
niche-speciﬁc. One possibility is that speciﬁc antibodies are able to prevent the 
acquisition of pneumococcal colonization, but that their protective effect against 
pneumococcal OM is limited once colonization has been established. This is also 
supported by the fact that the efﬁcacy of PCVs, which primarily induce an antibody-type 
response 31-34 against acute pneumococcal OM in infants is only 20-52% 35. It also 
remains possible that, once infection has been established, the cellular response 
may be a more important factor in protection against OM.
The effect of opsonizing IgG antibodies on cellular immunity and  
on clearance by alveolar macrophages
Next, we studied whether pre-existing immunity in the form of antibodies may have 
indirect effects on early clearance of pneumococcal pneumonia by affecting cellular 
responses (Chapter 5). This is particularly relevant in adults, who generally already 
have developed antibodies and memory T cells against S. pneumoniae. Alveolar 
macrophages, which are resident phagocytes in the lungs that have an important 
function in the recognition and clearance of invading pneumococci, are suggested to 
play an essential role in early clearance of pneumococcal pneumonia 36, 37. However, 
other immune cells that play a role in pneumococcal clearance, such as T cells and 
B cells, are also present at the same time. Additionally, natural killer (NK) cells 
represent roughly 10% of all lymphocytes in healthy lungs 38. 
Once pneumococci arrive in the lungs, it is likely that they will be immediately 
opsonized by speciﬁc antibodies if these are present. In addition, once infection is 
successful, immune cells from the blood will also be recruited to the site of infection. 
We used an in vitro model to simulate the interactions that may take place between 
these different cell types when pneumococcal infection occurs in the presence of 
pre-existing immunity. Alveolar macrophages and PBMCs were obtained from human 
volunteers who were experimentally colonized with S. pneumoniae. We demonstrated 
that alveolar macrophages primed with supernatant of PBMCs stimulated with 
IgG-opsonized pneumococci, had a reduced capacity to kill pneumococci, as 
compared to the supernatant of PBMCs stimulated with S. pneumoniae alone. 
Analysis of cytokine production showed an IgG-dependent skewing of the immune 
response from IL-17 towards IFN-? production, as well as an early increase in IL-1? 
and decreased IL-10 production. Moreover, ﬂow cytometry analysis showed a strong 
increase in IFN-?-producing NK cells and proliferating IFN-?+ NK cells.
Our data suggests that pre-existing IgG can skew immune responses by immune 
cells and attenuate subsequent clearance by AM. Even though we did not examine 
the direct effect of the increase in IFN-? on the killing capacity of AM, previous studies 
have shown that high production of IFN-? reduces phagocytosis and killing of S. 
pneumoniae by alveolar macrophages 8, 39, which is in line with the ﬁndings from our 
study. Moreover, there is evidence from previous studies supporting a role for IFN-? 
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in attenuating pneumococcal clearance 40-42. However, there have also been studies 
suggesting that the production of IFN-? can be beneﬁcial under certain conditions 43, 
44. It is thus possible that the exact contribution of NK cells and IFN-? to pneumococcal 
clearance differs based on location and the exact context of pre-existing immunity, as 
well as on certain threshold levels of IFN-?. 
When we blocked actin-dependent phagocytosis in the PBMCs before stimulation, 
we observed a near complete blockage of the IgG-dependent enhancement of IFN-? 
production. This suggests that antigen-presenting cells are involved in this process, 
potentially through cross-talk with NK cells. However, it is also possible that IgG has 
a direct effect on the NK cells, e.g. through Fc? receptor CD16, possibly inducing 
phagocytosis or activation, mediated through polymerization of actin ﬁlaments. 
Although this has not yet been shown for S. pneumoniae, a recent study showed that 
NK cells can respond to the fungal pathogen Candida albicans via actin-dependent 
phagocytosis. As a consequence, secretion of granulocyte-macrophage colo-
ny-stimulating factor, IFN-? and TNF? was upregulated, resulting in enhanced 
neutrophil antifungal activity 45. Preliminary unpublished data from our laboratory 
shows that direct stimulation of NK cells with S. pneumoniae together with IgG results 
in increase of IFN-?, suggesting that there might indeed be a direct effect of IgG on 
the NK cells.
The in vitro nature of this study resulted in several limitations. First of all, in our 
experimental setup, the NK cells were physically separated from the alveolar 
macrophages, since we only looked at the inﬂuence of the secreted factors of the 
PBMCs. A study by Elhaik-Goldman showed that macrophage-NK cell crosstalk also 
can contribute to early clearance of S. pneumoniae 44. Secondly, we only looked at 
the inﬂuence of pre-existing immunity due to IgG antibodies. Vaccination against S. 
pneumoniae not only induces mucosal IgG, but also mucosal IgA and IgM antibodies 
46, 47. In addition, active complement was not present in our experimental setup, while 
complement can also play an important role in pneumococcal clearance 48, 49. Also 
secreted factors from endothelial or epithelial cells, which form the lining of the 
mucosal surface, were not included in this study. Furthermore, apart from 
macrophages, several other phagocytic cells such as neutrophils and dendritic cells, 
can play a role in the clearance of S. pneumoniae from the lungs. Even though the 
focus of our study was the early clearance of subclinical pneumococcal lung 
infections, during which alveolar macrophages are believed to play a very important 
role 36, 37, it remains possible that the increased levels of IFN-? also inﬂuence other 
phagocytes that are present on the alveolar mucosal surface. Future research should 
therefore be focused on exploring the interaction between Fc? receptors, NK cells 
and IFN-? in an in vivo setting to validate the ﬁndings presented here.
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Pneumococcal antibody-mediated agglutination: a potential 
correlate of protection
One of the problems in the development of novel vaccines is the lack of well-deﬁned 
correlates of protection to evaluate the efﬁcacy of non-capsular vaccines against different 
serotypes. The only truly accepted correlate of protection against pneumococcal disease 
used for the approval of the capsular polysaccharide-based vaccines, is the opsono-
phagocytic capacity of anti-capsular antibodies, since this has been clinically 
evaluated 50-52. Many potential correlates of protection have been identiﬁed through 
in vitro and murine studies, such as IL-17 production and anti-protein antibodies, 
however these have not yet been validated in clinical studies (53, 54 and Chapter 4).
Recently, it was demonstrated that anti-capsular IgG can prevent new acquisition of 
colonizing S. pneumoniae through agglutination and subsequent removal by cilliary 
clearance 55. In chapter 6, we developed a novel quantitative ﬂow cytometry-based 
assay to screen serum samples in a high-throughput manner for their agglutinating 
potential. Since the agglutinating properties of antibodies raised against novel vaccine 
candidates may be associated with protection, a quantitative assay for agglutination 
may be an important immunological readout for clinical trials.
While bacterial agglutination may be analyzed using methods such as light micro- 
scopy, these methods have not been optimized for quantitative analysis and are 
generally laborious, which makes them less suitable for high-throughput analysis. 
We found that the concentration of antibodies against pneumococcal capsule was 
directly correlated with changes in the size and complexity of bacteria, as measured 
by ﬂow cytometry. Using light microscopy, we conﬁrmed that bacterial aggregates 
could be detected in the presence of serum antibodies. Using the increase in size as 
determined by ﬂow cytometry, we determined the so-called ‘agglutination index’. Our 
method was further tested on human samples in a separate larger study, where 
post-vaccination nasal washes from a human pneumococcal challenge model 
mediated increased pneumococcal agglutination as compared to nasal washes 
collected before vaccination 54. 
However, in order to become an accepted standardized quantitative method for use 
in clinical trials, this assay will still need to be validated extensively. 
In addition, in chapter 6 we also show that anti-PspA protein antibodies can also 
induce agglutination, similar to anti-polysaccharide antibodies. Intranasal vaccination 
with the pneumococcal surface protein A can protect mice, not only against systemic 
infection and pneumonia, but also against nasopharyngeal colonization and otitis 
media, as shown by several publications 24, 25, 56 as well as in chapter 4. Moreover, we 
show that these antibodies have the ability to agglutinate a range of pneumococcal 
strains belonging to different PspA clades, indicating the potential of cross-protection 
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to different pneumococcal strains. Although it has not yet been validated in an in vivo 
model whether these in vitro agglutinating anti-PspA antibodies can prevent 
pneumococcal colonization and/or transmission, to the best of our knowledge this 
thesis presents the ﬁrst evidence that anti-protein antibodies may also be able to 
mediate pneumococcal agglutination. 
In order to mediate agglutination, the concentration of antibodies on the mucosal 
surface needs to be sufﬁciently high, and target antigen on the bacterial surface 
needs to be expressed during infection and accessible for antibodies. It might be 
argued that since we used unencapsulated mutant strains for these experiments, we 
do not represent the natural situation where the pneumococcal capsule might inhibit 
PspA-mediated agglutation in vivo. However, during colonization in the nasopharynx, 
the capsule is less expressed to allow nutrient uptake and adhesion to the mucosal 
surface. A recent study by Kietzman even showed that S. pneumoniae is able to 
completely shed the capsule in order to expose surface receptors that can facilitate 
attachment to the mucosal surface 57. In addition, it is not known if the concentration 
of anti-PspA antibodies on the mucosal surface in vivo is indeed high enough to 
mediate agglutination. Moreover, we only studied agglutination mediated by 
anti-PspA IgG antibodies, while IgA and IgM antibodies have also been shown to 
play a role in protection against S. pneumoniae 46, 58, which potentially might also be 
involved in agglutination.  
Improving diagnostic methods for the detection of the causative 
agent of sepsis
Finally, in chapter 7 we developed a novel qPCR assay for the detection of S. 
pneumoniae. This study was part of a larger consortium (the Molecular Diagnosis 
and Risk Stratiﬁcation of Sepsis project, i.e. ‘MARS’, funded by CTMM) with the aim 
to develop a rapid bedside test that can simultaneously detect the most important 
causative agents of sepsis within several hours. The current gold standard for 
detection of the causative agent in septic patients is blood culture. Unfortunately, 
60-70% of patients with severe sepsis and septic shock have a negative blood culture 
59. Moreover, blood culture typically takes 24-48h and the clinical consequences of 
delaying immediate antibiotic treatment following clinical presentation are huge. 
Conversely, targeted and timely antibiotic treatment may also be beneﬁcial for 
reducing mortality 60 and the long-term negative impact on the host microbiome may 
be minimal. 
In order to switch from blood culture to a more rapid qPCR-based detection without 
a pre-culture step, it is important that the diagnostic test is able to detect the pathogen 
with high analytical sensitivity without compromising the speciﬁcity. With the aim to 
develop a qPCR with increased sensitivity, we analyzed the pneumococcal genome 
for unique repetitive DNA sequences. We identiﬁed the competence regulator comX 
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as a unique sequence for S. pneumoniae, of which two copies are present per 
pneumococcal genome, and designed primers and a qPCR probe for this target. Our 
data showed that the comX assay we developed performed equally well compared 
to the lytA-CDC assay, which is the current gold standard for qPCR detection of S. 
pneumoniae. Moreover, the comX assay had a higher analytic sensitivity as compared 
to lytA-CDC, although this did not translate to a higher clinical sensitivity. 
Our study did have several limitations.  First of all, our clinical validation was minimal 
with only 30 S. pneumoniae culture-positive patients tested. Moreover, the conditions 
for the PCR were not ideal since we were only able to use an equivalent of ~20 μl 
whole blood per qPCR reaction, which most likely explains why both the lytA and 
comX assays only tested positive in less than half of the blood culture positive 
samples. In comparison, for blood culture, results are obtained using two sets of 
blood cultures that each require a volume of 10–15 ml whole blood. This is also a 
general important issue with diagnostic PCRs for sepsis, since the bacterial load in 
whole blood can be as low as 10 CFU/mL during sepsis 61, 62. The development of a 
more sensitive assay to detect the causative pathogen in blood, therefore is not only 
dependent on the sensitivity of the qPCR assay. Equally important is the efﬁciency by 
which the bacterial DNA is extracted from the blood sample, as well as the input 
volume of the blood sample. Moreover, considering that the maximum PCR volume 
is in the order of 50-100 μl, this means that concentration methods are required for 
processing whole blood for input DNA. Several papers have been published on this 
subject recently and it is now possible to use puriﬁed DNA from an equivalent of 5-10 
ml of whole blood in one qPCR reaction 61, 62. The development of these methodologies 
are key in the advancement of qPCR-based diagnostic assays.
In addition, in the past decade, several other molecular detection platforms have also 
been developed, such as loop-mediated isothermal or helicase-dependent ampliﬁcations 
of molecular targets, and protein-based detection using MALDI-TOF 63. Moreover, 
PCR-based technologies, have also been coupled to endpoint melting curve 
analyses, sequencing, or mass spectrometry, microarray hybridisation, or new 
generation sequencing platforms 64. MALDI-TOF, which allows rapid and accurate 
identiﬁcation of bacteria and fungi on basis of the generation of unique mass spectral 
protein ﬁngerprint signatures, is currently already used for routine identiﬁcation of 
bacterial or fungal colonies on agar plates or broth media. Even though MALDI-TOF 
cannot be used on samples without a culturing step, its routine use to detect 
pathogens in blood cultures has been suggested to reduce the time to appropriate 
antibiotic therapy, the length of ICU stay, and the mortality of patients with bacteraemia 65. 
However, the major revolution for rapid detection of the causative agent of sepsis 
would be to eliminate the culture step, which currently would only be possible using 
a PCR-based technology. 
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Apart from the development of a qPCR-based detection platform for rapid diagnosis 
of the causative agent in sepsis patients, one of the other aims of the MARS project 
was to study the host response at admission on the ICU. Several novel diagnostic 
markers of the host response were identiﬁed in the MARS study, which might help 
predicting severity and could provide the physician with guidance for treatment 66-68. 
Diagnostic markers of the host might be used in the near future to distinguish between 
the causative infectious agent, or between groups of infectious agents, early 
indicators of sepsis, predictors of risk, severity, response to therapy, or outcome 63. 
FUTURE PERSPECTIVES
The limitations of PCVs that have surfaced in recent years, have resulted in a 
concerted global effort to develop novel vaccine candidates with the aim to provide 
serotype-independent protection against S. pneumoniae. However, since the PCVs 
have been able to reduce invasive pneumococcal disease dramatically, these 
successful vaccines will likely not be abandoned. Therefore, novel pneumococcal 
vaccines will probably initially be used in a formulation together with a PCV, or in 
addition to PCVs to speciﬁcally protect vulnerable populations. However, a novel and 
affordable vaccine will allow low-middle income countries, that do not receive GAVI 
support and therefore have been unable to implement PCVs, to protect their 
population against pneumococcal disease. 
A promising vaccine candidate may be a mucosal vaccine consisting of a combination 
of several conserved pneumococcal proteins. Such a vaccine may be able to provide 
serotype-independent protection and may ensure minimal risk on vaccine escape 
variants as long as the conserved proteins are essential for pneumococcal survival. 
Moreover, this could potentially result in total prevention of pneumococcal 
colonization. An important point for discussion is whether total prevention of 
pneumococcal colonization is in fact feasible and desirable. As we identiﬁed in our 
review on the immunomodulatory effects of IAV and S. pneumoniae co-infection 
(Chapter 2), asymptomatic colonization with S. pneumoniae may also provide 
beneﬁcial effects to the host by reducing the susceptibility to inﬂuenza A virus 
infection, although to date this has not been conﬁrmed in any human study. In 
addition, it is not clear if pneumococcal colonization also has an effect on infection 
rates, either positive or negative, with other viruses.
We potentially identiﬁed a role for NK cells in bridging the communication between 
the humoral and cellular response to S. pneumoniae (Chapter 5). NK cells are a 
highly prevalent cell type in the human lung. Despite this, very little is known about 
their functional role in pneumococcal colonization and disease. Similarly, little is 
known about the role of IFN-? in pneumococcal infections. Future work should 
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therefore be directed to the in vivo importance of these immune factors to further 
unravel the mechanisms of pneumococcal clearance and the correlates of protection 
against pneumococcal clearance and disease. 
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9.1  NEDERLANDSE SAMENVATTING VOOR LEKEN
Infecties veroorzaakt door de bacterie Streptococcus pneumoniae (de pneumokok) 
zijn wereldwijd een groot probleem. Ieder jaar overlijden ongeveer 735.000 kinderen 
aan pneumokkenziekte, wat overeenkomt met 11% van alle kindersterftegevallen in 
de leeftijd van 1-59 maanden. Ongeveer 90% van dit sterftecijfer vindt plaats in 
ontwikkelingslanden. De eerste stap in een pneumokokken infectie is kolonisatie van 
de neusholte. In de meeste gevallen verloopt dit zonder aantoonbare symptomen. 
Vanuit de neusholte kan de pneumokok zich vervolgens verspreiden naar het 
middenoor, de longen, de bloedbaan of de hersenen, waar het respectievelijk 
midden oorontsteking, longontsteking, bloedbaaninfectie of hersenvliesontsteking 
kan veroorzaken. 
Al een aantal jaar zijn er effectieve vaccins tegen pneumokokkenziekte beschikbaar, 
die ervoor hebben gezorgd dat het aantal pneumokokkenziekte-gerelateerde ster-
ftegevallen signiﬁcant naar beneden is gegaan. Desondanks hebben deze vaccins 
ook beperkingen. Zo beschermen de vaccins maar tegen een beperkt aantal types 
pneumokokken (serotypes) van de meer dan 90 serotypes die mensen kunnen 
infecteren. Als gevolg hiervan vindt er meer kolonisatie plaats door serotypes die niet 
in het vaccin zitten, en als gevolg daarvan uiteindelijk ook meer ziekte. Een andere 
beperking is dat de serotypes die ziekte veroorzaken in Westerse landen, waar de 
vaccins op zijn gebaseerd, niet altijd overeenkomen met de serotypes in ontwikkel-
ingslanden. Daarnaast hebben deze vaccins hoge productiekosten en zijn er pro-
ductie-gerelateerde beperkingen in het aantal pneumokokken serotypes wat in 1 
vaccin kan worden samengevoegd. Criteria voor nieuwe pneumokokken vaccins zijn 
dat dat deze bijvoorbeeld goedkoper moeten zijn, brede serotype-onafhankelijke 
bescherming moeten bieden tegen de meeste types pneumokken, en minstens even 
goede bescherming moeten bieden tegen pneumokokkenziekte als de huidige 
vaccins. Een nieuw vaccin zal waarschijnlijk geen vervanging zijn van de huidige 
vaccins, maar zal eerder een aanvulling hierop worden. Om nieuwe vaccins te kunnen 
ontwikkelen en de werkzaamheid hiervan te kunnen testen, is een beter begrip van 
de immunologische mechanismen van bescherming, alsmede de mechanismen 
waardoor kolonisatie kan overgaan in ziekte, erg belangrijk. Het centrale thema van 
dit proefschrift is daarom de herkenning van de pneumokok,  en het opruimen van de 
bacterie, door het immuunsysteem.
 
Mechanismen van influenza virus-geïnduceerde verergering  
van pneumokokkenziekte
Infectie met het inﬂuenza virus, ook wel het griepvirus genoemd, vormt een risicofactor 
voor het ontwikkelen van ernstige pneumokokkenziekte en is verantwoordelijk voor 
een groot deel van alle pneumokokkenziekte-gerelateerde sterfgevallen wereldwijd. 
Hoofdstuk 2 geeft een overzicht van de literatuur over de immunologische 
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mechanismen die een rol spelen bij pneumokokken infecties als gevolg van een 
primaire infectie met het inﬂuenza virus. Daarnaast is ook de interactie van deze 
pathogenen bestudeerd bij de verergering van ziekte. We hebben de mogelijkheid 
bestudeerd dat een primaire pneumokokkeninfectie een secondaire inﬂuenza virus 
infectie zou kunnen verergeren. Hiervoor hebben we echter geen bewijs kunnen 
vinden in de literatuur. Daarentegen zijn er wel enkele muizenstudies die laten zien 
dat kolonisatie met pneumokokken voorafgaand aan een inﬂuenza virus-infectie kan 
zorgen voor een minder ernstig beloop van de inﬂuenza virus infectie. De ontwikkeling 
van een vaccin wat complete bescherming biedt tegen alle serotypes, en ook 
kolonisatie voorkomt, zou dus potentieel ook een keerzijde kunnen hebben. Ook 
infecties met andere virussen dan het inﬂuenza virus zouden anders kunnen belopen 
door een voorafgaande pneumokokkenkolonisatie. Daarnaast zou het wegvallen van 
de pneumokokken niche in de neus ook kunnen leiden tot vervanging van deze niche 
met ander, potentieel ziekmakende, bacteriën. Meer onderzoek hiernaar is dus van 
belang om te weten wat de eventuele nadelen zijn van een vaccin wat kolonisatie in 
zijn geheel voorkomt.  
Vooral in kinderen is infectie met het inﬂuenza A virus een risicofactor op het 
ontwikkelen van middenoorontsteking. Ongeveer 80% van alle kinderen onder de 
drie jaar heeft wel eens een middenoorontsteking meegemaakt, en de pneumokok is 
een van de meest voorkomende oorzaken daarvan. In hoofdstuk 3 is bestudeerd 
hoe het inﬂuenza virus de ontwikkeling van middenoorontsteking door pneumokokken 
kan faciliteren. Aan de buitenkant van het inﬂuenza virus zitten verschillende 
oppervlakte eiwitten. Eén daarvan is het hemagglutinine (H) eiwit, waarmee het virus 
zich vast kan maken aan speciﬁeke siaalzuren op het oppervlak van de gastheercel. 
Een eerdere muizenstudie liet zien dat inﬂuenza virus met een bepaald type 
hemagglutinine (H3) een verhoogde kans op oorontsteking door pneumokokken 
gaf, vergeleken met inﬂuenza virus met een ander type hemagglutinine (H1). 
Onze hypothese was dat de siaalzuur-speciﬁciteit van het hemagglutinine van het 
inﬂuenza virus betrokken zou kunnen zijn bij de ontwikkeling van middenoor- 
ontsteking veroorzaakt door pneumokokken. Met behulp van inﬂuenza virussen die 
gemodiﬁceerd waren in de bindingseigenschappen van hun hemagglutinine eiwit, 
hebben we in muizen en in humane middenoorcellen laten zien dat de siaalzuur- 
speciﬁciteit van het hemagglutinine van het inﬂuenza virus geen rol lijkt te spelen bij de 
ontwikkeling van middenoorontsteking door pneumokokken. Het zijn dus waarschijnlijk 
andere eigenschappen dan de siaalzuur-speciﬁciteit van het hemagglutinine, 
die bijdragen aan de verhoogde vatbaarheid voor inﬂuenza-gemedieerde midden-
oorontsteking door pneumokokken.
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De rol van de cellulaire en humorale immuniteit in bescherming 
tegen middenoorontsteking
In het tweede deel van dit proefschrift, is de rol van de humorale en cellulaire 
immuniteit bestudeerd bij respectievelijk het voorkomen en het opruimen van 
pneumokokken infecties. De humorale immuniteit is de afweerreactie van het lichaam 
die plaatsvindt door middel van antistoffen. Antistoffen zijn moleculen die direct 
kunnen binden aan ziekteverwekkers en kunnen helpen bij het opruimen hiervan. 
Cellulaire immuniteit wordt bepaald door T-lymfocyten, dit zijn gespecialiseerde 
afweercellen die een belangrijke rol spelen in de aansturing van andere afweercellen, 
die er uiteindelijk voor moeten zorgen dat de ziekteverwekker opgeruimd wordt. 
De huidige pneumokokken vaccins geven slechts 20-50% bescherming tegen 
midden oorontsteking veroorzaakt door pneumokokken. Dit komt o.a. doordat de 
vaccins slechts gericht zijn tegen een beperkt aantal types pneumokokken. 
Daarnaast geven de  huidige vaccins vrijwel alleen bescherming door antistoffen die 
aan de pneumokok binden. Dit zorgt vervolgens dat bepaalde afweercellen de 
pneumokok kunnen herkennen en opruimen. Daarnaast kan het binden van 
antistoffen aan de pneumokok voorkomen dat deze aan de luchtwegen kunnen 
binden. De bescherming die de huidige pneumokokken vaccins geven tegen midde-
noorontsteking komt waarschijnlijk voornamelijk doordat kolonisatie van de neusholte 
door pneumokokken voorkomen wordt, met als gevolg dat deze zich niet meer via de 
buis van Eustachius kunnen verspreiden naar het middenoor. 
Een aantal recente onderzoeken hebben laten zien dat natuurlijke bescherming 
tegen kolonisatie door pneumokokken voornamelijk afhankelijk is van de cellulaire 
respons, via T-lymfocyten, in het neusslijmvlies. Er zijn veel verschillende soorten 
T-lymfocyten. De Th-17 lymfocyt, die de stof IL-17 kan produceren, is erg belangrijk bij 
pneumokokkeninfecties. IL-17 zorgt ervoor dat andere afweercellen, zoals neutroﬁelen 
en macrofagen, naar de plaats van infectie toekomen en geactiveerd worden om de 
ziekteverwekker op te ruimen. In hoofdstuk 4 is de rol bestudeerd van Th-17 cellen 
(cellulaire immuniteit) en van antistoffen (de humorale immuniteit) in de bescherming 
tegen inﬂuenza virus-geïnduceerde middenoorontsteking door pneumokokken. 
In deze studie hebben wij muizen gevaccineerd met het PspA eiwit, wat in alle 
pneumokken voorkomt. Alhoewel er, net zoals bij de suikerkapsels, ook meerdere 
types PspA bestaan die niet volledige kruisbescherming tegen elkaar geven, is het 
technisch mogelijk om met behulp van een beperkt aantal PspA types brede 
bescherming op te kunnen wekken tegen alle types pneumokokken. Een nieuwe 
generatie pneumokokken vaccins zal waarschijnlijk niet alleen op PspA gebaseerd 
zijn maar kan bijvoorbeeld aangevuld worden door andere eiwitten die bescherming 
kunnen opwekken. Om een cellulaire immuunrespons op te wekken hebben wij 
gevaccineerd via de mucosale route, ofwel vaccinatie toegediend via de neus. We 
laten zien dat deze manier van vaccineren zowel beschermt tegen kolonisatie van de 
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neusholte als het ontwikkelen van middenoorontsteking. Zowel een antilichaam 
respons als een Th-17 respons werden opgewekt. Met behulp van muizen die niet in 
staat waren om antilichamen te maken of een Th-17 respons te geven, hebben we 
laten we zien dat de bescherming die door vaccinatie met PspA werd opgewekt 
waarschijnlijk meer afhankelijk is van de Th-17 respons dan van antistoffen. Het is wel 
belangrijk om hierbij de kanttekening te plaatsen dat de gevaccineerde muizen in het 
gebruikte diermodel werden geinoculeerd met een relatief hoge hoeveelheid 
pneumokokken. De belangrijkste reden daarvoor is dat dit de kans vergroot dat 
inoculatie ook daadwerkelijk leidt tot infectie. Een nadeel van deze strategie is dat 
mogelijke beschermende aspecten van de antistoffen die er zijn kunnen worden 
gemaskeerd doordat de toegediende hoeveelheid bacteriën zo groot is dat er toch 
kolonisatie optreedt. In mensen is dit – in tegenstelling tot ons diermodel - een niet 
gecontroleerd proces. De verwachting is dat mensen in het algemeen aan een lagere 
hoeveelheid bacteriën worden blootgesteld. 
Het effect van antilichamen op de cellulaire immuniteit en op het 
opruimen van pneumokokken door alveolaire macrofagen
De pneumokok kan onder andere opgeruimd worden door middel van fagocytose, 
een proces waarbij de bacterie door afweercellen wordt opgegeten en gedood. Ons 
lichaam heeft meerdere soorten afweercellen die kunnen fagocyteren, één daarvan 
is de alveolaire macrofaag. Alveolaire macrofagen bevinden zich in de longen en 
spelen een essentiële rol bij het opruimen van pneumokokken in het beginstadium 
van een infectie. Dit kan helpen bij het voorkomen van ziekteverschijnselen. Daarnaast 
zijn er ook nog andere celtypes aanwezig in de longen die een rol kunnen spelen bij 
het opruimen van pneumokokken, zoals T-lymfocyten, neutroﬁelen (ook een 
fagocyterend celtype) en B cellen (cellen die antilichamen kunnen produceren). 
Pneumokok-speciﬁeke antilichamen, die zijn opgewekt door vaccinatie of door 
natuurlijke kolonisatie van de neusholte, kunnen ook een belangrijke rol spelen in het 
opruimen van de pneumokok. 
In hoofdstuk 5 hebben we gekeken naar de invloed van deze antilichamen op het 
opruimen van de pneumokok door alveolaire macrofagen, en op de cellulaire respons 
in het algemeen. Onze resultaten lieten zien dat de aanwezigheid van antilichamen 
tegen de pneumokok ervoor kan zorgen dat de pneumokok minder goed opgeruimd 
kan worden door alveolaire macrofagen. Verdere experimenten met bloed van 
gezonde vrijwilligers, waarbij we immuuncellen hebben blootgesteld aan 
pneumokokken met of zonder antilichamen, lieten zien dat de aanwezigheid van 
antilichamen zorgde voor een sterke toename van de stof Interferon gamma. 
Daarnaast lieten onze resultaten ook zien dat deze stof geproduceerd werd door 
Natural killer cellen (NK cellen). NK cellen zijn  afweercellen die een rol spelen bij het 
doden van ‘verkeerde’ cellen van ons eigen lichaam (bijvoorbeeld cellen geïnfecteerd 
met een virus, of tumorcellen). Ongeveer tien procent van de cellen in de longen 
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bestaat uit NK cellen. Er is echter weinig literatuur over de rol van dit celtype in 
pneumokokken infecties. De stof Interferon gamma is belangrijk voor het sturen van 
de immuunrespons en eerder onderzoek heeft laten zien dat Interferon gamma 
inderdaad kan zorgen voor verminderde opname van pneumokokken door 
macrofagen. Antilichamen tegen de pneumokok lijken de cellulaire immuunrespons 
dus wel degelijk te beïnvloeden, en NK cellen lijken een rol te spelen in de 
communicatie tussen de humorale en de cellulaire respons tegen de pneumokok. 
Verder onderzoek moet uitwijzen of dit in de natuurlijke situatie, vergeleken met de 
kweekcondities in het laboratorium, ook het geval is. 
Agglutinatie van pneumokokken door antilichamen: een potentiele 
beschermingsfactor
Een van de problemen bij het ontwikkelen van nieuwe vaccins is het gebrek aan goed 
gedeﬁnieerde factoren die een rol spelen in de bescherming tegen pneumokokken-
ziekte (correlaten van bescherming). De ontwikkeling van een nieuw vaccin kan vele 
jaren duren. Hoewel een nieuw vaccin altijd eerst in diermodellen wordt uitgetest 
voordat de klinische evaluatie in mensen kan beginnen, wil dit lang niet altijd zeggen 
dat het vaccin ook bescherming zal bieden in mensen. Meer kennis over de 
immunologische correlaten van bescherming tegen pneumokokkenziekte is 
belangrijk om te kunnen bepalen welke afweerreactie een vaccin moet opwekken om 
bescherming te kunnnen bieden in mensen. Dit is een zeer belangrijk aspect in de 
ontwikkelingscyclus van vaccins. De enige beschermingsfactor tegen pneumo-
kokkenziekte die algemeen is geaccepteerd en uitvoerig is geëvalueerd in klinische 
studies met mensen, is de capaciteit van antilichamen om aan de verschillende 
serotypes pneumokokken te binden. Antistoffen die goed binden aan de pneumokok 
zorgen voor bescherming tegen ziekte. Alhoewel veel andere mogelijke correlaten 
van bescherming zijn geïdentiﬁceerd uit laboratorium onderzoeken en muizenstudies, 
zoals IL-17 productie en anti-eiwit antistoffen (zie ook hoofdstuk 4), zijn deze (nog) 
niet gevalideerd in klinische studies. 
Recent is gebleken dat antistoffen tegen de verschillende pneumokokken serotypes 
er ook voor kunnen zorgen dat pneumokokken kunnen ‘klonteren’, ook wel 
agglutineren genoemd. Hierdoor kunnen de pneumokokken beter door trilharen op 
de luchtwegen worden afgevoerd, waardoor kolonisatie van de pneumokok in de 
neusholte zelfs voorkomen kan worden. Het agglutinerend vermogen van antistoffen 
die opgewekt worden door nieuwe vaccin kandidaten, kan mogelijk correleren met 
bescherming. In hoofdstuk 6 hebben we een nieuwe kwantitatieve test ontwikkeld 
om bloedmonsters te screenen op de aanwezigheid van antistoffen die kunnen 
leiden tot pneumokokken agglutinatie. Agglutinatie van pneumokokken door 
antistoffen kon al vastgesteld worden door middel van microscopie, echter zegt dit 
niets over de hoeveelheid agglutinerende antistoffen. Daarnaast vergt de methode 
met microscopie relatief veel tijd, waardoor de methode lastig te gebruiken is als 
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grote hoeveelheden samples moeten worden getest, wat vaak het geval is in klinische 
studies. De methode die wij hebben ontwikkeld maakt gebruik van ﬂowcytometrie, 
waarbij met behulp van een laserstraal individuele deeltjes in een vloeistof  kunnen 
worden waargenomen. De verstrooiing van het licht van de laser wat wordt opgevangen 
door verschillende detectoren, geeft informatie over de grootte en de interne structuur 
van de deeltjes. Op deze manier konden we een verschil zien tussen agglutinerende 
pneumokokken en individuele pneumokokken die niet waren geagglutineerd. Deze 
methode kan op veel bloedmonsters tegelijk worden uitgevoerd, en kost relatief 
weinig tijd om uit te voeren. 
In hoofdstuk 6 laten we verder ook zien dat de anti-eiwit antistof anti-PspA agglutinatie 
van pneumokokken kan veroorzaken. Dit is een interessant resultaat omdat dit tot nu 
toe alleen bekend was van antistoffen gericht tegen de suikers aan de buitenkant van 
pneumokok, deze verschillende suiker-types bepalen het serotype. Voor zover 
bekend is dit het eerste bewijs van agglutinatie van pneumokokken door anti-eiwit 
antistoffen. Vaccinatie met PspA resulteert in bescherming tegen pneumokokken-
ziekte in muizen (o.a. hoofdstuk 4), mogelijk speelt het agglutinerend vermogen van 
antistoffen hierbij dus ook een rol. 
Het verbeteren van diagnostiek voor de detectie van de 
veroorzakende pathogeen van bloedbaaninfecties
Tenslotte is in het laatste deel van dit proefschrift een nieuwe diagnostische test voor 
het detecteren van pneumokokken ontwikkeld. Dit onderzoek was onderdeel van een 
grotere klinische studie (de MARS studie) met meerdere onderzoekspartners om een 
‘Point-of-Care test’ te ontwikkelen voor de snelle detectie van ziekteverwekkers van 
bloedbaaninfecties (sepsis). Sepsis is een ernstige bloedbaaninfectie, waarvoor 
patiënten op de intensive care moeten worden opgenomen en waarbij ongeveer de 
helft van de patiënten overlijdt. 
Onderzoek heeft uitgewezen dat de overlevingskansen op sepsis groter zijn als de 
behandeling met antibiotica zo snel mogelijk gestart wordt. Met ieder uur dat de 
behandeling later gestart wordt, daalt de overlevingskans sterk. Daarnaast is de 
overlevingskans van patiënten met sepsis ook hoger als er direct met de juiste 
antibiotica gestart wordt. De huidige standaard test voor het vaststellen van de 
oorzaak van sepsis is de bloedkweek; een microbiologische kweek van het bloed. 
Een probleem van deze methode is dat het ongeveer 24-48 uur duurt voor de uitslag 
van een bloedkweek bekend is. Omdat daarnaast uiteindelijk meer dan de helft van 
de bloedkweken negatief blijft en voor een verhoogde overlevingskans zo snel 
mogelijk antibiotica moet worden toegediend, wacht de behandelende arts normaal 
gesproken niet op de uitslag van de bloedkweek bij het starten van antibioticum 
behandeling. 
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Het doel van de MARS studie was om een test te ontwikkelen die binnen twee uur na 
afname van het bloedmonster de uitslag geeft. De test die binnen MARS is ontwikkeld 
is gebaseerd op het gelijktijdig detecteren van genetisch materiaal (het DNA) van de 
belangrijkste bacteriën en schimmels die sepsis veroorzaken. Hoofdstuk 7 beschrijft 
de validatie van het onderdeel van deze diagnostische test dat door ons is ontwikkeld 
voor het detecteren van de pneumokok. Deze nieuwe test is vervolgens vergeleken 
met een al bestaande test voor het detecteren van pneumokokken DNA, waaruit 
bleek dat onze test iets gevoeliger was. We hebben vervolgens ook bloedmonsters 
getest van patiënten die bloedkweek-positief waren voor de pneumokok, en deze 
zowel met onze nieuwe test als met de al bestaande DNA test vergeleken. Hieruit 
bleek dat de klinische gevoeligheid van beide testen hetzelfde was: beide methodes 
detecteerden dezelfde hoeveelheid positieve monsters. Deze nieuwe test is inmiddels 
opgenomen in het patent voor de test voor de snelle detectie van de meest 
voorkomende pathogenen die sepsis kunnen veroorzaken.
Conclusies
De onderzoeken beschreven in dit proefschrift helpen met het beter begrijpen van de 
manier waarop ons lichaam de pneumokok opruimt, en waarop ons lichaam 
bescherming ontwikkelt tegen pneumokokkenziekte. Deze fundamentele kennis kan 
bijdragen aan het ontwikkelen van betere, effectievere vaccins. Daarnaast zijn in dit 
proefschrift ook twee testen ontwikkeld;  één die bij kan dragen aan de ontwikkeling 
van vaccins, en één die bij kan dragen aan snellere diagnostiek van pneumokokken-
sepsis. 
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